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Abstract 
 
A large research effort is currently underway to find an effective and affordable 
malaria vaccine. Tools that allow the evaluation of the host immune response are 
essential to vaccine development. This thesis focuses on an assay to evaluate 
antibody-mediated inhibition of sporozoite infection: the Inhibition of Sporozoite 
Invasion assay (ISI). ISI measures antibody capacity to prevent sporozoite infection in 
an in vitro system that reflects the actual infection context. This assay was first 
described in 1982 by Hollingdale et al., but the assay has been affected by many 
limitations, particularly time-consuming and subjective microscopy readouts. The 
recent development of transgenic parasites detectable by flow cytometry (due to the 
expression of reporter proteins such as GFP) provides a readout which highly 
increases the throughput of the technique.  The objective of this thesis is to further 
develop the ISI assay and adapt it to evaluate humoral responses in candidate 
screening and clinical studies. Chapter 1 describes the process to optimise a protocol 
for a flow cytometry based ISI assay. In Chapter 2, mouse, macaque, and human 
serum samples (obtained after vaccination with a viral vector vaccine expressing a P. 
falciparum antigen) were tested using P. berghei transgenic parasites expressing P. 
falciparum antigens. In studies with mouse samples, the assay proved to be useful 
comparing the functional capacity of antibodies generated against different antigens 
and with different vaccination strategies, such as the adjuvant or vaccination dose. A 
positive increase of antibody functionality after vaccination was shown for some 
mouse, macaque, and human volunteer samples, and interesting correlations were 
found for ISI assay data and other antibody assays and clinical data. 
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INTRODUCTION 
 
Malaria impact and control measures 
Malaria is a parasitic infectious disease which affects mainly tropical and 
subtropical regions of the world [FigureI.1], in particular Sub-Saharan Africa, India and 
Southeast Asia. According to the 2014 World Malaria report published by the WHO (1), 
around 198 million clinical episodes occurred in 2013 leading to 584000 deaths from 
malaria which took place mainly in African countries, affecting mostly children under 5 
years of age and pregnant women. Malaria mainly affects poor populations with limited 
access to health care and prevention measures. In addition to the high morbidity and 
mortality, malaria has extremely negative consequences on the economic growth of 
malaria endemic countries (2).  
 
Figure I1. Countries with ongoing malaria transmission. Taken from 2014 World 
Malaria report, WHO (1). 
 
Malaria is caused by a protozoa (unicellular eukaryotic parasite) of the genus 
Plasmodium and is transmitted from one person to the other by the bite of an infected 
female Anopheles mosquito. Plasmodium species belong to the phylum of the 
apicomplexans, which are obligate intracellular parasites. There are several 
Plasmodium species that differ in their host species and their ability to cause disease. 
Five species can infect humans Plasmodium falciparum, Plasmodium vivax, 
Plasmodium malariae, Plasmodium ovale and Plasmodium knowlesi, which is also a 
macaque monkey parasite. Plasmodium berghei, Plasmodium yoelii, and Plasmodium 
chabaudi parasitize rodents and are important models in malaria research. 
Plasmodium falciparum is responsible for up to 90% of human malaria infections (1) 
and for most of malarial deaths (3). Plasmodium vivax can also cause human deaths 
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(4), but presents a lower risk of infection (since it requires the presence of Duffy gene 
which is absent in many populations) and causes a more benign disease since infected 
red blood cells do not attach to the vascular endothelium (5,6). 
Control strategies to target this public health challenge have been very effective 
in recent years (7–9), in fact, according to the WHO, malaria mortality rates have 
decreased by 47% between 2000 and 2013 (1). These interventions target malaria 
patients, exposed individuals and the mosquito vector. Vector control strategies focus 
on reducing malaria transmission mainly through the use of insecticide-treated 
mosquito nets (ITNs) and indoor residual spraying (IRS). ITNs have been shown to 
reduce mortality rates (by around 55% in children in Sub-Saharan Africa (10), and to 
decrease in about 50% the number of malaria cases in various regions (11). IRS has 
been described to have a similar impact than ITNs reducing malaria incidence (12). 
Exposed individuals could also be protected through administration of a preventive 
drug treatment during periods of higher risk, which would particularly benefit pregnant 
women and children living in regions with seasonal malaria (13,14). Regarding infected 
individuals, early diagnosis (usually rapid diagnostic test or observation of a blood 
smear with a microscope) facilitates an appropriated and more effective treatment. 
Artemisin combination therapy (ACT) is the treatment for uncomplicated P. falciparum 
malaria recommended by WHO (15). Anti-malarial drugs from the artemisins family are 
very effective against blood stages and reduce malaria transmission (16–19). 
Chloroquine and sulphadoxine-pyrimethamine were employed previously as 
treatments, but parasites have developed resistance against these drugs. An important 
threat to malaria control is parasite resistance to chemotherapy, due to the large 
genetic plasticity of malaria parasites. In fact, resistance to artemisin has been reported 
in various countries (20–22). Important efforts need to be made to discover not only 
new anti-malarial drugs, but also new insecticides since mosquitoes also develop 
resistance (23). 
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Malaria life cycle and associated pathogenesis 
Plasmodium parasite presents a complex life cycle, which involves both 
vertebrate and mosquito hosts and transformation through multiple developmental 
stages with their own antigenic variety [FigureI.2]. The cycle is initiated when the 
vertebrate host is bitten by an infected Anopheles mosquito, which transfers 
sporozoites that grow asexually first in hepatocytes and later within erythrocytes. 
Gametocytes are formed in the vertebrate host and their fusion and further 
development and propagation occurs in the mosquito. 
 
Figure I.2. Malaria life cycle. Taken from The Carter Center (24). 
 
Pre-erythrocytic stages 
Plasmodium parasites are transmitted to the vertebrate host through the bite of 
an infected Anopheles mosquito. Sporozoites are released from the mosquito salivary 
glands and injected in the host skin (25,26) while the mosquito is taking a blood meal. 
Only female mosquitoes are vectors of the disease since they need a blood meal for 
laying their eggs. Sporozoites are able to reach capillaries in the skin entering the 
circulatory system and migrate to the liver, within the first 15 minutes to few hours of 
infection (27,28). In addition, a proportion of sporozoites are drained to a proximal 
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lymph node where most are degraded and some achieve a partial development into 
exo-erythrocytic forms (26). Those sporozoites which reach the liver can cross the 
sinusoidal barrier through either Kupffer cells (resident macrophages in the liver) or 
endothelial cells (29,30). Sporozoites pass through several hepatocytes and finally 
invade one, where a vacuole is formed around the sporozoite as a result of the 
hepatocyte plasma membrane invagination (31). 
Migration through tissues and invasion of host cells is possible due to a 
sporozoite form of locomotion known as gliding motility, which is powered by an actin-
myosin motor (32,33). TRAP is a protein essential for this movement, since it is a 
transmembrane protein with a cytoplasmic tail that is fixed to actin filaments and also 
counts with extracellular adhesive domains. The extracellular portion of TRAP binds to 
host proteins and TRAP is translocated to the posterior end on the sporozoite, enabling 
a forward parasite movement (34). Using their locomotion machinery, sporozoites are 
able of disrupting host cell membranes (cell traversal capacity has been described on 
macrophages, epithelial cells and hepatocytes (31,35)) or enter host cells surrounded 
by the host cell plasma membrane that becomes part of the parasitophorous vacuole 
(36,37). 
CSP is an abundant protein on the sporozoite surface, which binds to heparin 
sulfate proteoglycans present on hepatocytes providing an attachment to host target 
cells and activating sporozoites for host cell invasion (38–40). Parasites develop into 
exo-erythrocytic forms (EEFs) within the hepatocyte, undergoing asexual replication 
inside the parasite vacuole. This process lasts between 5 and 7 days for Plasmodium 
falciparum (human parasite) and 42 hours for Plasmodium berghei (rodent parasite), 
and ends with the release of 20000 to 30000 merozoites (41). Merozoites leave 
hepatocytes within hepatocyte-derived vesicles called merosomes (42).  
Malaria liver stage is an ideal target for vaccination and drug discovery since this 
stage is clinically silent and the number of parasites present in the vertebrate host is 
very low compared to blood-stages. 
 
Erythrocyte stages 
In the blood stream, individual merozoites invade red blood cells (RBCs) where 
they undergo asexual replication inside a parasitophorous vacuole. RBC invasion 
begins with the interaction between receptors on the host cell and proteins expressed 
on the merozoite surface (such as MSP1-9, AMA-1 or PfRH family), followed by 
proteolysis of some of these proteins (43–45). Once inside the RBC, the parasite loses 
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the apical complex (invasion organelles) and adopts a ring shape known as 
trophozoite, which then matures and grows forming an erythrocytic schizont. This 
process is completed within 48 hours for P. falciparum (between 24 and 72 hours, 
depending on the species) and results in the iRBC rupture and release of 
approximately 20 new merozoites ready to infect erythrocytes. Parasitaemia levels can 
be higher than 50000 infected RBCs per microliter of blood (46).  
This cycle of RBC invasion, multiplication and rupture causes malaria pathology. 
Symptoms such as fever, headaches, fatigue and vomiting, coincide with erythrocyte 
rupture, due to the inflammation caused by parasite products released upon iRBCs 
lysis. In addition parasites are able to export some proteins to the RBC membrane, for 
example PfEMP1 (47). This protein mediates infected RBCs sequestration in tissues by 
binding to molecules on endothelial cells (such as ICAM-1, upregulated during 
inflammation), and in this way parasites avoid entering the spleen where they could be 
destroyed (47) and complicate diagnosis since sequestrated iRBCs can not be 
detected in peripheral blood smears. Moreover, PfEMP1 is also involved in binding to 
other RBC causing rosetting (48,49), which make the symptoms associated to 
erythrocyte sequestration worse and has been associated with clinical forms of severe 
malaria (50,51). iRBCs are sequestrated in a variety of organs including liver, heart, 
kidney, lung, brain and placenta, impeding normal tissue perfusion which is aggravated 
by the destruction of RBCs that further limits oxygen delivery. Peripheral tissues (under 
hypoxia conditions) and parasites produce lactid acid, leading to metabolic acidosis 
and respiratory distress (hyperventilation to expel more carbon dioxide) (52). 
Sequestration of iRBCs in the placenta is associated with reduced birth weight, early 
delivery and increase mortality in the newborn and the mother (53). The worst outcome 
of iRBCs sequestration occurs when iRBCs adhere to the brain microcapillaries 
causing vascular occlusion, local hypoxia and damage of the blood-brain barrier (54). 
Other severe malaria manifestations are anaemia, coma and renal problems. P. 
falciparum is responsible for most clinical cases of severe malaria and malaria deaths. 
The main difference between P. falciparum and P. vivax, which also cause severe 
symptoms, is that P. falciparum is able to invade a larger number of RBCs and 
presents a higher cytoadherence capacity which causes parasite sequestration (55). 
 
Sexual stage 
Some merozoites differentiate into gamatocytes (male and female) which are 
ingested by a mosquito while taking up a blood meal. Male and female gametes fuse 
and fertilise in the mosquito midgut forming a zygote which transform into an ookinete 
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with motile capacity to cross the midgut epithelium and reach the basal lamina where 
the development into oocyst occurs. The oocyst grows and undergoes multiple nuclear 
divisions, becoming a mature oocyst, which eventually bursts and releases thousands 
of sporozoites. Finally, sporozoites migrate towards the salivary glands where they 
mature and are stored for 1 to 2 months ready to be injected in a vertebrate host during 
a mosquito bite. 
Gametocytes present in the vertebrate host blood have not been associated with 
malarial clinical symptoms.  
 
 
Immune response to malaria 
 
The knowledge of the immune response to malaria is essential in order to 
develop a protective vaccine and effective therapies to treat the disease. Animal 
models (56) and longitudinal studies following volunteers with natural or experimental 
malaria infection have provided insight in the host immune response to the malaria 
parasite. In endemic areas with seasonal malaria transmission, cohorts of volunteers 
can be monitored before, during and after malaria infection, allowing gene-expression 
analysis and antibody profiling which can be correlated with clinical and parasitology 
data (57). Controlled malaria infections have been performed to analyse immune 
responses and evaluate vaccine candidates. These infections are achieved by 
exposing volunteers to mosquito bites or to the injection of infected red blood cells, and 
can be treated with available drugs, such as chloroquine (58–60). 
Individuals living in endemic areas develop an immune response that prevents 
the appearance of severe malaria symptoms (61,62) but they still suffer parasite 
infections (63,64). However, sterilizing immunity has been achieved through the 
administration of radiation-attenuated sporozoites (which do not achieve complete 
development within the hepatocyte) in studies with mice (65), non-human primates (66) 
and humans (67). The same effect has been reproduced with sporozoite injections 
together chloroquine treatment (which kills blood-stages) (58) and using transgenic 
parasites (which have been modified to avoid progression to blood stages) (68). The 
weak natural immune response elicited by malaria could be related with the immune-
regulatory environment of skin and liver and the low numbers of injected sporozoites or 
to sporozoite mechanisms to avoid the immune system (46). In addition, the complex 
parasite life cycle with intracellular stages that facilitates hiding from the host immune 
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system and its high antigen variability (due to frequent mutations), also contributes to 
the challenge of mounting strong immune responses.  
Both innate and adaptive immune systems contribute to the host immune 
response to Plasmodium parasites. 
 
Innate immune response 
The innate immune system provides a first line of defence through soluble 
components (e.g. complement system) and cellular components such as epithelial 
barriers (with epithelial cells providing a physical barrier and producing antimicrobial 
substances; and including intraepithelial T lymphocytes), antigen presenting cells (DCs, 
Macrophages and B cells) or NK cells (able to kill infected cells and activate the killing 
of phagocytosed parasites). The most relevant innate immune response to malaria is 
the stimulation of adaptive immune responses and inflammation.  
Antigen presenting cells (DCs, B cells and macrophages) internalise parasite 
components, which are degraded and presented as peptides on MHC molecules on the 
cell surface. CD4+ and CD8+ T cells can recognize the pathogen peptide on MHC 
through their TCR and a co-receptor. DCs obtained from lymph nodes of malaria-
infected mice or cultivated in vitro in the presence of sporozoites have been shown to 
present parasites epitopes to T cells (69–71). Antigen presentated to T cells, together 
with cytokines released by APCs has can activate T cells responses. 
During the inflammatory response, leukocytes (mainly neutrophils and monocites) 
and plasma proteins (e.g. complement and antibodies) are recruited to control and 
clear the infection, although it can also lead to pathogenesis. Inflammation is induced 
by cytokines (e.g. IL-1, IL-2, IL-6, IL-12, IFN-ɣ, TNF-α) released by cells such as 
macrophages and DCs in response to parasite recognition, and stimulate the 
expression of endothelial adhesion molecules (e.g.ICAM-1, VCAM-1) leading to 
leukocytes infiltration in tissues. Pro-inflammatory cytokines play an important role 
stimulating adaptive responses and controlling parasite growth, but they are also 
associated with malaria symptoms such as fever and iRBC are sequestrated through 
binding to endothelial adhesion molecules (whose expression is stimulated by 
inflammatory cytokines). Inflammatory responses are curtailed by activation of T 
regulatory cells (72,73). DCs also release anti-inflammatory cytokines at later stages of 
infection (74). The balance between anti and pro-inflammatory cytokines determines 
the extent of infection and pathogenesis (75,76). The inflammatory response takes 
place against erythrocytic stages and appears to be absent in pre-erythrocytic malaria 
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stages, since both the skin and the liver present an immunoregulatory environment 
(with populations of macrophages and regulatory T cells producing anti-inflammatory 
cytokines, mainly IL-10 and TGF-β). 
Certain pathogen structures (pathogen-associated molecular patterns, PAMPs) 
and host molecules produced during damage (damage-associated molecular patterns, 
DAMPs) can be recognised by the innate immune system (through pattern recognition 
receptors, PRRs, such as TLRs or complement proteins). Several examples of 
Plasmodium parasite components have been described to be recognised by the innate 
immune system such as Plasmodium RNA from liver stage; and GPI, AT-rich DNA or 
PfEMP1 from blood stages. Liehl et al. found that Plasmodium RNA is recognised as a 
pathogen-associated molecular pattern (PAMP) by the cytosolic receptor Mda5 in 
hepatocytes, initiating a type I interferon response which can trigger myeloid cells 
resulting in a reduction of the parasite burden and a delay in the parasite release into 
the blood (77). GPI, a glycolipid which serves as an anchor for membrane proteins (e. 
g. merozoite surface protein-1, MSP1), is recognised by TLR2 and TLR4 on 
macrophages, stimulating the production of pro-inflammatory cytokines and nitric oxide 
(78,79). Parasitic protein-DNA complex is recognised by TLR9 on DCs, which in turn 
activate NK cells to produce IFN-γ (80). AT-rich DNA from P. falciparum has been 
shown to activate a type I interferon response (81). PfEMP1 (P. falciparum erythrocyte 
membrane protein) binds CD36 on DCs which respond by producing IL-10, IL-12 and 
IL-18 (82). On the contrary, it has been shown that parasite adherence through PfEMP 
to dendritic cells prevents dendritic cell maturation and the subsequent T cell activation 
(83), which would be a mechanism of immune evasion. 
Other example of the innate immune system action was described by Qingfeng et 
al who found that NK cells killed iRBCs in a contact-dependent manner, using 
humanised mouse models infected with Plasmodium falciparum (84). 
 
Adaptive immune response 
The adaptive immune system can provide long-lasting immune responses to a 
wider range of antigens than the innate immune system and is able to generate 
memory cells. There are two classes of adaptive immune responses: cellular immunity 
which is carried out by T cells (e.g. CD4+, CD8+, Tregs) and humoral immunity, 
generated by B cells producing antibodies. 
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a) Humoral responses 
Humoral immunity is generated by B cells producing antibodies. B cells are able 
to bind parasite antigens through the BCR expressed on their surface and internalize 
the pathogens components which are degraded within the cell (85). Resulting peptides 
are loaded on MHC II molecules ready to be recognised by CD4+ T cells, which are 
able to activate the B cell in a contact-dependent manner and through cytokine 
secretion (86). Activated B cells undergo clonal expansion and after secreting IgM 
antibodies the antibody isotype they produce switches to IgG, IgE or IgA. Firstly after 
antigen encounter short-lived plasma cells secrete antibodies, and afterwards, memory 
B-cells and long-lived plasma cells are the populations responsible for the antibody 
production (87,88). 
Antibodies have been shown to play an important role in the immune response to 
malaria. Passive transfer of purified antibodies from individuals with certain immunity to 
malaria to infected volunteers, has been shown to decrease parasitaemia (89–91). In 
addition, a positive correlation between protection and antibody titres has been 
observed in clinical studies where volunteers where challenged after immunisation with 
a CSP subunit vaccine or irradiated sporozoites (67,92–94). However, some of the 
protected individuals had low antibody titres, and not all the volunteers with high 
antibody titres were protected, indicating the presence of other mechanisms 
contributing to immunity. Mouse models have also provided evidence for the relevance 
of antibodies in the malaria response both neutralizing parasites and helping to 
eliminate them (95,96).  
The main limitation of humoral responses is that parasites are exposed to 
antibodies for a very short amount of time, since malaria parasites are predominately 
present as intracellular forms and parasites travel quickly between host cells. 
Inoculated sporozoites can reach the liver within a few minutes (although this migration 
can last hours) (97) and merozoites released from an infected red blood cell can infect 
other one in minutes or less (98). Therefore, high antibody concentration and avidity 
would be required to mount an effective immune response at the moment of infection. 
Antibodies prevent hepatocyte and merozoite invasion (99), facilitate parasite 
clearance enhancing phagocytosis and opsonize and agglutinate infected erythrocytes 
avoiding their sequestration in blood vessels. Antibodies carry out their function 
through several mechanisms, either acting on their own (e. g. neutralization, 
agglutination) or mediating a cellular function through opsonisation (which enhances 
phagocytosis) or antibody-dependent cellular cytotoxicity (ADCC). Neutralization avoids 
host cell invasion (100,101) due to the presence of antibodies impeding normal 
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function or the interaction of relevant parasite proteins with hepatocytes or red blood 
cells. For instance, antibodies targeting CSP on sporozoite surface have been 
described to inhibit cell traversal activity (102), antibodies against TRAP (protein 
located in sporozoite micronemes) inhibit sporozoite gliding motility (34) and antibodies 
specific for P. falciparum erythrocytic binding protein (EBA-175) block invasion (103). 
Antibodies bound to the parasite can recruit complement proteins leading to parasite 
lysis, for instance, antibodies present in human sera targeting MSP1 and MSP2 can 
trigger complement deposition on merozoites avoiding erythrocyte invasion (104). 
Antibody-dependant complement lysis has also been described to have an effect on 
sporozoites (105) and on gametes (106). Opsonisation occurs when antibodies cover 
sporozoite or merozoite surface facilitating uptake by macrophages and dendritic cells, 
leading to parasite clearance (107–109). Schwenk et al., in a study where volunteers 
were vaccinated with RTS,S and later infected, described a higher sporozoite endocytic 
activity in the sera of protected individuals than in volunteers susceptible to infection 
(110). Antibody-dependent cellular cytotoxicity has been described in malaria mainly 
with monocytes (111–113). Antibodies have also described to affect parasite 
development in pre-erythrocytic (114), erythrocytic (115) and sporogonic stages 
(116,117).  
Antibodies can be raised with specificity for antigens present in different parasite 
development stages, and also against parasite proteins present on the surface of 
iRBCs. CSP (circumsporozoite protein) has been extensively described as a sporozoite 
antigen targeted by humoral responses, in particular a region (NANP) which contains 
peptide repeats and is shared by all Plasmodium species (118). Later, studies in 
naturally infected humans have found antibodies against CSP with different specificities 
(119), and also against other pre-erythrocytic antigens such as LSA1 (liver-stage 
antigen 1) and TRAP (thrombospondin-related adhesive protein) (120). High antibody 
titres targeting these sporozoite proteins have shown a positive correlation with 
protection in endemic areas (120–122). 
Blood stage antigens are also targeted by antibodies, and humoral responses are 
particularly relevant in blood stages since iRBC can not express MHC class molecules 
(which can be recognized by TCR on the T cell surface). Antibodies against MSP2 
(merozoite surface protein-2) have been associated with protection in Papua New 
Guinea (123). PfEMP also has been described to be targeted by protective antibodies 
in endemic areas (109), antibodies against this protein on the iRBCs would opsonize 
and agglutinate infected erythrocytes avoiding the sequestration in blood vessels. 
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In addition to the antibody antigen specificity, the kind of antibody isotype has 
also been regarded as important for the immune response, with studies describing that 
IgG1 and IgG3 (which have high affinity for Fc receptors and fix complement proteins) 
are the antibody subclasses more relevant to achieve protection (124–126). 
 
b) Cellular responses           
T lymphocytes express on their surface a TCR receptor and either co-receptor 
CD4 or CD8. The TCR recognises a peptide presented in the context of an MHC 
molecule and initiates a signaling cascade with the aid of co-receptors. MHC class I 
molecules are expressed on the surface of all nucleated cells, while MHC class II 
molecules can be found on APCs (B cells, dedritic cells and macrophages). Peptides 
are generated through the degradation of endogenous or exogenous proteins 
(pathogen proteins that are inside the cell due to infection or because they have been 
internalised) and loaded on MHC molecules inside the cell forming complexes (MHC-
peptide) which are exported to the plasma membrane. This antigen presentation 
process provides a system to show signs of potential infection on the cell surface. 
CD4+ T cells recognise MHC class II molecules on APCs and CD8+ T cells recognise 
MHC class I molecules on all nucleated cells (127).  
CD4+ T cells act mainly by recruiting and activating other immune cells and can 
be divided into different subtypes according to phenotypic markers and functionality, for 
example Th1, Th2, Th17 and T regs. Th1 cells secrete cytokines such as IFN-ɣ and 
TNF-α which mediate pro-inflammatory responses. In addition, Th1 cells support B cell 
and CD8+ T cell responses through cytokines and contact-dependent interactions, 
which elicit activation, proliferation and isotype switching for B cells. Th1 cells can 
trigger apoptosis in infected cells through the interaction between their Fas ligand 
(CD178) and Fas (CD95) on a target cell. Th2 cells, which secrete mainly IL4, IL5 and 
IL13, play an important role in immunity against extracellular pathogens. T regs, which 
are identified by high levels of CD25 and transcription factor FoxP3, down-regulate the 
immune response secreting anti-inflammatory cytokines such as IL-10 and TGF-β. In 
malaria, T regs may act in preventing immunopathology, however they can also have a 
negative effect inhibiting a protective Th1 response (72). 
CD8+ T cells (cytotoxic lymphocytes, CTLs), upon recognition of a specific MHC 
class I-peptide (128,129), are able to act as effector cells eliciting apoptosis in target 
cells through cytokine and cytotoxic granules secretion or through interaction between 
Fas and Fas ligand. CD8+ T cells also secrete IFN-ɣ which can activate innate cells 
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(e.g. macrophages), up-regulate expression of components involved in antigen 
presentation (e. g. MHC molecules) and stimulate the production of effector molecules 
such as NO. 
 
Liver-stage 
The liver is an autonomous priming site where antigen presentation can take 
place without the infiltration of APCs. Numerous cell types such as liver-resident 
dendritic cells, Kupffer cells (liver-resident macrophages), hepatic stellate cells, liver 
sinusoidal endothelial cells (LSEC) and infected hepatocytes have been described to 
present antigens to T cells (130–133). T cells are abundant in the liver, particularly 
CD8+ T cells (134,135). Bertolino et al. showed that hepatocytes can activate naive 
CD8+ T cells (133). Nevertheless, the liver presents an immunoregulatory environment 
(136,137), for instance, Kupffer cells (138) and liver dendritic cells (139) have been 
reported to secrete IL-10, inducing T cell tolerance. Both CD8+ and CD4+ (mainly Th1) 
T cells produce IFN-ɣ which inhibits sporozoite development into merozoites inside 
hepatocytes (140). CD8+ and CD4+ T cells specific for pre-erythrocytic Plasmodium 
antigens can also kill parasites through direct cytolisis. Studies with mice immunised 
with irradiated sporozoites, have shown that CD4+ and CD8+ T cells play an important 
role in the immune response elicited (96,141–143). Protection from clinical malaria has 
been associated with T cell responses against pre-erythrocytic antigens, for example: 
lymphocyte proliferation responses to LSA1 in Gabonese children (144) and CD4+ T 
cell responses to CSP in The Gambia (145). 
 
Blood-stages 
Erythrocytes and free merozoites lack MHC expression; therefore, they can not 
activate T cells through interaction with TCR. However, Pombo et al. described that 
volunteers challenged with iRBCs and cured, developed proliferative cellular immune 
responses against subsequent challenges (146). In protected volunteers, they detected 
CD4+ and CD8+ IFN-ɣ-producing cells and high levels of nitric oxide synthase in 
PBMCs. In addition, Riley et al. found T cell proliferative responses against MSP1 
(blood-stage antigen) associated with protection from severe malaria in children living 
in West Africa (147). Moorman et al. also showed an association between IFN-ɣ 
responses to MSP1 and delayed time to reinfection in western Kenya (148). Carvalho 
et al. measured higher in vitro cellular responses to MSP1 in PBMCs from indivuals 
who have been more exposed to malaria in Brazil (149).  
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Vaccine development and current status 
 
A malaria vaccine would be the most cost-effective control measure against 
malaria. The feasibility of a malaria vaccine is supported on the knowledge that natural 
immunity is adquiered over the years after repeated malaria infections, and that it is 
possible to achieve sterile protection immunising with radiation-attenuated sporozoites 
(RAS) (67). However, in spite of the large research efforts in the last decades, a 
licensed vaccine is not still available. The leading malaria vaccine is RTS,S with an 
efficacy of 30-50% which decreases after one year (150–152). Once phase 3 clinical 
trials were completed, the EMA (European Medicines Agency) gave a positive scientific 
opinion to the vaccine on July 2015 (153) and WHO’s recommendations on RTS,S are 
expected by November 2015. Afterwards, countries where the vaccine will be used will 
decide on licensing the vaccine. The partial efficacy of RTS,S will prevent a large 
number of malaria cases, but research continues to search for a second generation 
malaria vaccine that will elicit higher protection, in addition to be safe, affordable and 
easy to transport and deliver in endemic countries. 
Malaria vaccine candidates target pre-erythrocytic, erythrocytic and mosquito 
stages. The pre-erythrocytic stage has been regarded as the ideal target for malaria 
vaccination since it is clinically silent and it is the first step of infection with low parasite 
numbers and a duration of about one week (for P. falciparum) allowing enough time for 
the immune system to fight the infection at an early stage. Pre-erythrocytic stage 
vaccines aim to avoid sporozoite invasion of hepatocytes through protective antibodies 
or to eliminate infected hepatocytes by inducing CD8+ and CD4+ effector T cells. Blood-
stages vaccines attempt to reduce parasite levels in the blood by inhibiting merozoite 
invasion of RBC through humoral responses and stimulating CD4+ T cell responses. 
Inducing the production of antibodies that prevent iRBC sequestration is also helpful to 
avoid severe malaria symptoms. Lastly, transmission-blocking vaccines target parasite 
proteins involved in the development within the mosquito gut, eliciting antibodies that 
block the Plasmodium cycle at the mosquito stage and avoid the subsequent 
transmission to other vertebrate host. Transmission-blocking vaccines do not provide a 
direct benefit to those vaccinated, but generate protection at a population level (herd 
immunity). 
According to their composition, potential vaccines can be classified into those 
using the whole parasite or a subunit strategy. Whole parasite vaccines are prepared 
with parasites whose development is arrested during liver stages avoiding the clinical 
symptoms, but exposing the parasite antigens to the immune system. Sterile immunity 
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has been achieved immunising with irradiated sporozoites in both rodents and 
volunteers (65,67,154,155). Irradiate sporozoites invade hepatocytes, but can not 
complete their development and progress further in the life cycle. An important 
limitation for these vaccination approach is the large number of bites required (using 
over 1000 infected mosquitoes) to achieve immunity, making vaccine delivery in 
endemic countries complicated, and there is a risk of a breakthrough infection. The 
biotechnology company Sanaria is testing a vaccine consisting on purified and 
cryopreserved irradiated P. falciparum sporozoites, which are administered 
intradermally, subcutaneously or intravenously, and protects 90% of vaccinated 
volunteers (156–159). Other approaches to immunise with sporozoites that can not 
complete their development in the vertebrate host are heat-killed sporozoites (which 
can not invade hepatocytes), genetically arrested parasites (GAPs, which lack an 
esential gene involved in host cell invasion or development) and administration of 
sporozoites under drug treatment (e.g. chloroquine, primaquine) (68,160). Whole 
parasite vaccines have been described to elicit immune responses mainly mediated by 
CD8+ T cells (161–164). 
Subunit vaccines, which deliver a component of the pathogen, are safer and 
easier to produce and administrate than whole parasite vaccines. Most efforts on 
subunit vaccines have been focused on the protein CSP which is abundant on the 
sporozoite surface, but other pre-erythrocytic antigens have also been targeted such as 
TRAP, LSA1 and Exp1. Blood stage subunit candidate vaccines have been prepared 
mainly against MSP1 and AMA1. Subunit vaccines can be based on a peptide, a 
protein or even a DNA sequence. When the vaccine is a protein, adjuvants (e.g. 
aluminum salts, liposomes) have an important role enhancing immune responses, 
mainly activating the innate immune system which subsequently stimulates the 
adaptive response. RTS,S, the most advanced malaria vaccine, is an example of 
subunit vaccine which comprises a region of P. falciparum CSP fused to the hepatitis B 
virus antigen administered with a liposomal adjuvant (AS01) (165). Adjuvant 
formulation in RTS,S has been optimised and shown to be essential to induce an 
immune response (94,166). RTS,S elicits protection mainly through antibodies against 
CSP which prevent sporozoite entry into hepatocytes (167). 
Instead of a protein, vaccines can be based on a DNA sequence, which upon 
injection enters the host cells where the DNA encoded protein is synthesized. The 
pathogen protein expressed in the host cells can be degraded into peptides which are 
loaded on MHC Class I molecules to present the pathogen peptide on the cell surface 
to CD8+ T cells. A method of DNA delivery described to elicit strong immune responses 
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are viral vectors, such as poxvirus or adenovirus, that can carry a foreign DNA 
sequence and also have an adjuvant effect themselves (168). The serum samples 
tested in this thesis were collected after vaccination with chimpanzee adenovirus 
serotype 63 (ChAd63) and MVA enconding various antigens. MVA  (Modified Vaccinia 
virus Ankara) is a Poxvirus vector that was obtained by serial passaging until it lost its 
replication capacity (169). Replication of adenoviruses can be avoided through the 
deletion of a region (named E3) in their genome. The vector ChAd63 is a simian 
adenovirus, which is used to avoid the possibility of interference with pre-existent 
immunity against human adenovirus (170). Combination of viral vectors can be 
administered as a heterologous prime-boost vaccination regimen, in particular, ChAd63 
prime followed 8 weeks later by MVA boost has been the strategy followed in the 
laboratory and has been shown to elicit high titre protective antibodies and strong T cell 
responses (171), and protection in endemic areas (172). The most advanced malaria 
vaccine targeting cellular immunity consist of ChAd63 and MVA vectors encoding ME-
TRAP, a string of multiple epitope (ME) fused to TRAP. Phase IIb field clinical studies 
recently conducted with Kenyan adults, have shown that the vaccine induces partial 
protection against P. falciparum which was associated with T cell responses to TRAP 
(173). RTS,S/AS01 and viral vector ME-TRAP vaccines are being administered in 
combination in an ongoing study (already in Phase I/IIa trials) with the objective of 
improving efficacy and durability (171). 
 
 
Tools in malaria research: mouse models, in vitro 
cultures and transgenic parasites. 
 
Plasmodium falciparum, the causative agent of most malaria deaths, only infects 
humans and some primates such as Aoutus monkeys (which are of great value for 
malaria research, particularly for evaluation of drugs and vaccines for human use) 
(174,175). For this reason, P. berghei and P. yoelii, have been widely used as models 
to study malaria, since their life cycle can be reproduced in a laboratory using mice as 
vertebrate host and Anopheles stephensi mosquitoes. These rodent species can 
induce a range of pathologies that can be cured spontaneouly or even cause death 
depending on the mouse strain (176,177).  
Research on liver-stages is particularly difficult, since sporozoites need to be 
freshly collected by dissection of mosquito salivary glands for mouse infections and in 
vitro cultures; and studies with volunteers are not possible due to obvious ethical 
  
 25 
reasons. The main tools to study pre-erythrocytic stages are animal models and cell 
cultures of primary hepatocytes or hepatoma cell lines. The establishement of 
hepatoma cell lines has supported in vitro studies of liver stage invasion using 
Plasmodium parasites. Common cell lines used are HepG2 and Huh7 which support 
complete liver-stage development of P. berghei; and HC04, where not only P. berghei 
but also P. falciparum can develop (178). On the contrary, blood stages can be 
obtained from frozen infected blood and from peripheral blood of volunteers, and in 
vitro cultures of P. falciparum erythrocytic stages using RBCs are widely used (179–
181). 
Mouse models have provided important knowledge about the biology of the 
parasite, the pathogenesis of the disease and the host immune response (56). In 
addition, they are essential in vaccine development and drug discovery, since they 
have given the possibility of screening pre-clinical malaria antigens, and gaining a 
better understanding on the immune responses elicited by vaccines.  
The development of transgenic parasites through targeting a particular gene or 
cloning a protein into the parasite genome is giving a new insight in parasite biology 
and an important tool in vaccination development. This technique has allowed the 
generation of parasites that express GFP (green fluorescent protein) (182,183) and can 
be tracked by flow cytometry, enabling the quantification of infected cells in a cell 
culture or blood sample (183–186). Genetic manipulation has also been used to obtain 
knock-out parasites in which a relevant protein has been deleted in order to study how 
its absence affects the behaviour of the parasite (187–189). In addition, transgenic 
parasites allow pre-clinical evaluation in mouse models of P. falciparum antigens that 
are absent in rodent parasites, since the falciparum protein can be expressed in 
transgenic parasites. In fact, transgenic parasites expressing falciparum antigens have 
been used to challenge vaccinated mice whose post-vaccination sera have been 
evaluated in this thesis (190). 
 
 
Evaluation of humoral responses:  
Inhibition of Sporozoite Invasion assay (ISI). 
 
Immune responses to malaria have been evaluated mainly by measuring levels 
of antibodies, cytokines and IFNɣ using ELISA (Enzyme-Linked Immunosorbent 
assay), ELISPOT (Enzyme-Linked ImmunoSpot assay) and ICS (intracellular cytokine 
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staining) techniques. A unique immune correlate of protection has not been identified in 
the context of malaria, probably due to the diversity of the immune responses elicited 
by different vaccination strategies and to the presence of several immune mechanisms 
providing protection. Therefore, gathering the maximum amount of information about 
the immune response measured with different assays is extremely helpful to gain a 
better knowledge on the host immune response induced through vaccination. 
As it has been previously described, antibody responses play an important role in 
pre-erythrocytic malaria stage, in fact, RTS,S elicits protection mainly through humoral 
responses (167). This thesis focuses on the evaluation of post-vaccination antibody 
responses using the ISI assay, which measures antibody capacity to inhibit sporozoite 
invasion. ISI uses and in vitro system where sporozoites are co-cultured with 
hepatocytes to reflect the actual infection context, with the objective of measuring 
functionality of antibody responses rather than antibody concentration. ISI assay has 
evolved from time-consuming microscopic readouts to flow cytometric measures that 
make it possible to incorportate this assay into a routine of vaccine candidate 
evaluation. The following lines review how this assay was firstly described and 
subsequently improved. 
In 1982, Hollingdale et al. described an assay to evaluate the capacity of 
antibodies to prevent P. berghei sporozoites infection in vitro (191). They used human 
embryonic lung cells (WI38), since in previous studies (36) they showed this cell line 
could support P. berghei sporozoite infection and development with releasing of 
merozoites. At different incubation times after the addition of sporozoites, the cells 
were fixed with methanol and stained with Giemsa or an immunofluorescent antibody, 
allowing detection of sporozoites by microscopy. In the immunofluorescent test, serum 
from mice that had been injected with sporozoites was used as a primary antibody and 
a goat anti-mouse antibody labeled with fluorescein, as secondary antibody. In this first 
description of the ISI assay (191), a monoclonal antibody against Pb44 (former name 
given to the sporzoite surface antigen CSP) and its Fab fragment were shown to 
prevent the entry of sporozoites in WI38 cells, while sporozoites non-treated with 
antibodies could be seen inside the cells eight hours after infection. These results were 
consistent with previous studies where mice that had received a passive transfer of the 
same monoclonal antibody were protected against sporozoite challenge (192). The fact 
that this assay was able to reflect a functional effect of an antibody against a sporozoite 
antigen already seen in vivo, supported the idea of using this in vitro assay to evaluate 
the effect of antibodies and drugs aimed to prevent the sporozoite infection.  
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Following on from this work, the in vitro culture system was improved by 
substituting the target cells for HepG2, a liver cell line, as it had been shown to support 
the complete development of P. berghei to the point of merozoite release (193). HepG2 
cells were isolated from a child with primary hepatoblastoma and hepatocellular 
carcinoma (194) and shown to have surface receptors similar to those present in 
primary hepatocytes (195). A higher rate of infected cells was observed when using 
HepG2 instead of WI38 (196) and, most importantly, this cell line provided the 
opportunity to study the interaction between sporozoites and hepatocytes (their natural 
host cells). An immunoperoxidase-based technique (197) was found to offer a better 
resolution to identify early stages of parasite development, when used for the staining. 
In this case, the secondary antibody was a rabbit anti-mouse conjugated with 
horseradish peroxidase whose substrate was 3,3’-Diaminobenzidine.  
Hollingdale et al. and Leland et al. extended their studies using other 
Plasmodium parasites: falciparum and vivax, which also invaded HepG2 cells in vitro; 
testing the inhibitory capacity of different monoclonal antibodies, human sera from 
endemic areas and sera from volunteers immunised with irradiated sporozoites 
(198,199). P. falciparum and P. vivax did not achieve a complete development within 
HepG2 cells (198). Mazier et al. showed that P. falciparum could accomplish complete 
development in primary hepatocytes (174) and they used this system to study the 
effect of sera from mice immunised with CSP peptides on the parasite invasion and 
intracellular development (200). 
In all the studies described so far, the cell cultures were analyzed with 
microscopy after staining with a primary antibody specific for parasite antigens and a 
secondary antibody (bound to a fluorescent dye -fluorescein- or conjugated with and 
enzyme -peroxidease- that processes a substrate), or with Giemsa which is a dye able 
to stain Plasmodium chromatin (201). Microscopy readouts were not only time-
consuming, but also associated to the subjectivity of the observer’s criteria assessing 
whether the parasites were outside or inside the cells, or which stage of development 
they had reached. With the aim of using a more objective method to quantify the 
outcome of these in vitro assays, Zavala proposed an immunoradiometric assay in 
1985 (202). The two-site immunoradiometric assay (IRMA) quantified the amount of 
CSP on hepatocytes as a measure of sporozoite infectivity and relied on the presence 
of at least two identical epitopes (binding sites) in each CSP molecule. An extract of 
infected cell culture was added on a well coated with monoclonal antibody (3D11) 
against P. berghei  CSP, after incubation and washing, the same monoclonal antibody 
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labelled with 125I was used in order to generate a signal in a gamma counter 
proportional to the amount of CSP antigen inside infected hepatocytes. 
As an improvement to the staining techniques for microscopy readouts, which 
allowed observing the location and development of the parasites (unlike the 
immunoradiometric assay), Rénia et al. described a double staining method in 1988 
(203).  With the aim of increasing the objectivity when distinguishing between 
intracellular and extracellular sporozoites (until then, this distinction had been made 
using morphological criteria), they proposed a two step protocol combining two staining 
techniques that had been commonly used in the ISI assay. Each step employed the 
same primary antibody (a monoclonal antibody against antigens on the sporozoite 
surface), but different secondary antibodies. First, the cell cultures were fixed with 
paraformaldehyde, which did not allow the entrance of antibodies into the cells. As a 
result, the primary antibody was bound only to extracellular sporozoites, identified with 
a secondary antibody conjugated to peroxidase (Immunoperoxidase antibody test, 
IPAT). Secondly, the cell cultures were treated with ethanol, so the intracellular 
parasites were accessible to the primary antibody. In this step, an anti-mouse 
immunoglobulin antibody labeled with fluorescein was used (Immunofluorescent 
antibody test, IFAT). 
In 1998, Sinnis et al. described a method to quantify sporozoite invasion 
combining a gamma-counter readout with two different kinds of fixation (204). Each 
sample was tested in duplicate, fixing with paraformaldehide after incubation and 
adding methanol in only one of the replicates. In samples where methanol had been 
added, monoclonal antibody against CSP (3D11, labeled with 125I) could access both 
intracellular and extracellular parasites, while when methanol was not added only 
extracellular parasites were detected. By substracting the amount of extracellular 
parasites from the total number of parasites, a measure of hepatocyte invasion was 
given. 
RT-PCR (which had been previously used to quantify malaria liver stages (205)) 
was introduced by Kumar et al. (206) in 2004 as a quantitative readout of a sporozoite 
neutralizing assay using P. berghei transgenic sporozoites expressing P. falciparum 
CSP repeats (207). RT-PCR was performed amplifying the P. berghei 18S rRNA, and, 
with normalization purposes, the HepG2 beta-actin gene. 
Natarajan et al. in 2001 and Tarun et al. in 2006 used FACS (Fluorescence-
activated cell sorting) to isolate hepatocytes infected with sporozoites (P. berghei and 
P. yoelii, respectively) expressing GFP (183,184). Prudencio et al. used flow cytometry 
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in 2008 to quantify sporozoite invasion of hepatocytes, and to obtain other information 
relevant for the malaria liver stage, such as cell traversal capacity of sporozoites or 
parasite development within liver cells (208). The assay was performed adding P. 
berghei GFP sporozoites to Huh7 cells and incubating the co-culture for 2 hours. GFP 
signal within infected hepatocytes was detected when acquiring the samples on a flow 
cytometer, allowing measuring the percentage of infected hepatocytes. It was found 
that the intensity of the GFP signal was higher at longer times of incubation (12-36h), 
and this increase correlated with the number of parasites copies found by PCR, 
indicating a possible method to measure parasite development within liver cells. In 
2012, Kaushansky et al. also described a flow cytometry method to evaluate sporozoite 
infection (209). This study used P. falciparum sporozoites and HC04 cells, which are 
susceptible to infection by this Plasmodium species. In order to detect infected cells, 90 
min after incubation cells were fixed, permeabilized and stained with anti-CSP sera and 
a secondary antibody conjugated with Alexa-fluor 488.  
Flow cytometry provides a readout method for sporozoite inhibition of invasion 
assays, which highly increases the throughput of the technique and overcomes the 
bias associated to the traditional microscopy quantifications. qRT-PCR can also 
provide a quantitative readout with higher throughput than traditionally microscopy 
techniques, but flow cytometry is even less expensive and time-consuming than PCR, 
and gives information at a single cell level. 
According to the time of incubation of sporozoites with host cells, the antibody 
inhibition assay has been named ISI (Inhibition of Sporozoite Invasion Assay) when 
incubation lasts 1 to 24 hours and ILSDA (Inhibition of Liver Stage Development Assay) 
when incubations are extended between 1 or 2 days up to 6 days (210,211). Although 
in this thesis the antibody inhibition assay has been referred as ISI, it is actually in the 
limit between ISI and ILSDA, since sporozoite incubations lasts around 24 hours, an 
endpoint which was selected to detect the maximum percentage of infected cells on the 
flow cytometer.  
Although these antibody inhibition assays have limitations, mainly the difficulty in 
obtaining fresh sporozoites and biological parasite variability, a flow cytometric readout 
enables larger numbers of samples to be analysed more easily. This assay can 
therefore be very helpful in evaluation of antibody responses in vaccine studies and in 
the development of drugs targeting sporozoites and liver-stage parasites.
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Thesis aims and outline 
 
A large research effort is currently underway to find an effective and affordable 
malaria vaccine. Tools that allow the evaluation of the host immune response are 
essential to vaccine development, since, together with challenge studies and clinical 
data, they provide a criteria to select the best vaccine candidates. In malaria, there is 
not clear correlate of immune protection; both humoral and cellular responses have 
been described to play a role in host immunity. Therefore, a complete description of the 
immune response elicited by vaccination requires various assays to measure antibody 
and effector cell responses. This thesis focuses on an assay to evaluate antibody-
mediated inhibition of malaria sporozoite infection: the Inhibition of Sporozoite Invasion 
assay (ISI). This assay measures antibody capacity to prevent sporozoite infection and 
was first described in 1982 by Hollingdale et al. Since then, different host cells, 
sporozoite species and readouts have been used, but the assay has not been 
systematically employed to test large numbers of samples. The recent development of 
transgenic parasites detectable by flow cytometry provides a readout which highly 
increases the throughput of the technique and overcomes the subjectivity of the person 
performing a microscopy readout. The assay still presents many limitations: the 
complication of working with live sporozoites (the variability of infectivity achieved by 
different batches of sporozoites and the requirement to obtain enough freshly dissected 
sporozoites to perform the assay), the non-specific inhibition effect of naive serum and 
lack of standardisation and reproducibility. In spite of the difficulties associated, the ISI 
assay provides an in vitro system that reflects the actual infection context. Therefore, 
the measure of antibody-mediated prevention of sporozoite invasion would be a better 
reflection of antibody functionality and protection in vivo than measures of antibody 
concentration such as ELISA. 
The objective of this thesis is to further develop the ISI assay and adapt it to test 
a large number of samples. This work has been developed in collaboration with the 
Jenner Institute where an important part of the research conducted consists on 
evaluation of pre-clinical and clinical malaria candidate vaccines. So far, humoral 
responses in vaccine studies have been evaluated mainly using ELISA. This project 
aims to support the incorporation of a new protocol to evaluate humoral responses in 
candidate screening and clinical studies. 
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Aims: 
-To find the conditions where the infectivity rates may be higher with the objective of 
making the best use of sporozoites, which are a limited resource. To accomplish this 
objective different hepatoma cell lines, cell culture media, incubation times and 
cell:sporozoite ratio will be tested. 
 
-To optimise the number of host cells and sporozoites to use in each replicate in order 
to obtain reliable data while testing a large number of samples. To find adequate 
controls to normalise background effect and variability in infectivity associated to 
different sporozoite batches. 
 
-To adapt the assay for the use of transgenic parasites currently available at the Jenner 
Institute. 
 
-To evaluate whether the reporter protein MFI (Mean Fluorescence Intensity) measured 
by flow cytometry could be an indicator of parasite development and, consequently, be 
a potential measure of antibody effect on sporozoite development inside hepatocytes. 
 
-To use the assay to evaluate serum samples from mouse and macaque pre-clinical 
studies and clinical trials, collected in studies performed at the Jenner Institute, in order 
to obtain relevant information about antibody responses to the candidate vaccines of 
interest and validate the optimised assay. 
 
-To find whether there are associations between the data obtained with the ISI assay 
and other clinical and immunological data available for the samples tested. 
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MATERIALS & METHODS 
 
Cell lines & Culture media 
Four different hepatocyte cell lines have been used as host cells for sporozoites: 
a mouse cell line (BNL) and three different human cell lines (HepG2, Huh7 and HC04). 
The HepG2 cell line was established from a liver biopsy of a 15-year-old caucasian 
male from Argentina who had a hepatocellular carcinoma (194,212). The Huh7 cell line 
was established from hepatocellular carcinoma tissue removed from a 57-year-old 
Japanese male (213). HC04 was obtained from normal liver tissue taken from a 
hepatoma patient in Thailand (214). In our laboratory, HC04 cell line obtained from 
ATCC is genetically identical to HepG2 but grows differently. These cell lines have 
morphology characteristics that resemble those of liver parenchyma cells.  
DMEM (Dulbecco’s Modified Eagle’s Medium) [Sigma Aldrich] and RPMI (RPMI-
1640, Roswell Park Memorial Institute medium) [Sigma Aldrich] were used as culture 
media with the addition of 10% heat inactivated FCS [Sigma Aldrich], 100U/ml 
penicillin, 100µg/ml streptomycin [Sigma Aldrich] and 2mM L-glutamine [Sigma 
Aldrich]. Cells were cultured at 37ºC and 5% CO2. TrypLE Express Enzyme [Life 
Technologies] was used to detach hepatocytes from culture plates or flasks.  
 
Chimeric parasites 
All the experiments were performed using chimeric P. berghei sporozoites 
expressing GFP as a reporter gene. Sporozoites expressing GFP or GFP-luciferase 
(both under eef1α promoter) were used in chapter 1 to find the optimal conditions to 
perform the ISI assay. In chapter 2, in order to evaluate the capacity of post-
vaccination serum samples to reduce hepatocyte invasion, chimeric P. berghei 
parasites expressing GFP-luciferase and the same P. falciparum antigen expressed in 
the vaccine. These chimeric P. berghei parasites provided the possibility of testing P. 
falciparum antigens without the hazard of working with P. falciparum parasites and 
could be produced at the laboratory insectary. 
These chimeric parasites, kindly provided by DPhil student Ahmed Salman, were 
generated through GIMO (‘Gene insertion/marker out’) transfection (215). Chimeric 
parasites contain a construct, inserted in the genomic silent locus 230p, which includes 
a P. falciparum gene under Pb UIS4 promoter and a GFP-luciferase cassette under the 
control of Pb eef1α promoter. 
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P. berghei  
chimeric parasite 
P. falciparum  
antigen  
P. berghei  
homologue 
antigen 
Reporter 
‘WT’ 
- - GFP 
- - GFP luciferase 
Replacement CS CSP CSP berghei deleted GFP luciferase 
Addition parasite 
including the  
P. falciparum 
antigen added 
CSP 
P. berghei 
homologue 
present in 
chimeric 
parasites 
GFP luciferase 
TRAP 
CelTOS 
UIS3 
Falstatin 
SPECT1 
SPECT2 
HT 
RP-L3 
ETRAMP5 
No P. berghei 
homologue 
LSA1 
LSA3 
LSAP1 
LSAP2 
 
Table 1. Chimeric Plasmodium berghei sporozoites used. Parasites were 
generated and kindly provided by Ahmed Salman (DPhil student). 
 
 
Chimeric parasites used included one of the P. falciparum antigens: CelTOS, 
LSA1, LSA3, LSAP1, LSAP2, UIS3, ETRAMP5, Falstatin, SPECT1, SPECT2, RP-L3, 
HT, CSP and TRAP [Table1]. CelTOS, UIS3, Falstatin, SPECT1, SPECT2, RP-L3, HT, 
CSP and TRAP are present both in P. falciparum and P. berghei, while the rest of the 
P. falciparum antigens tested do not have a P. berghei homologue. The P. falciparum 
antigen was expressed under UIS4 promoter as an additional copy (‘addition 
parasites’). This strategy allows the generation of transgenic parasites even when a P. 
berghei homologue is not present. In this work, some experiments were performed with 
CSP ‘replacement parasites’ in which P. berghei CSP had been deleted and P. 
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falciparum CSP is expressed under the control of the P. berghei CSP promoter. This 
chimeric parasite was generated through the GIMO method, replacing the P. berghei 
CSP by the P. falciparum CSP. Pf CSP replacement parasites express GFP-luciferase 
under Pb eef1α promoter in 230p, as ‘addition transgenic parasites’. 
Both the genotype and phenotype analysis of the transgenic parasites were 
performed by Ahmed Salman [Ahmed Salman, DPhil thesis]. The correct integration of 
the construct in the chimeric parasites was demonstrated through southern analysis 
and PCR. The expression of the P. falciparum antigen was probed by IFAT 
(Immunofluorescence antibody test) using monoclonal antibodies whenever available 
or sera collected from vaccinated animals. 
 
 
Serum samples & Monoclonal antibodies 
Serum samples used in this work were provided by various researchers at the 
Jenner Institute (Oxford University) and had been obtained in pre-clinical vaccine 
studies, performed with mice and macaques, and in clinical trials [Table 2].  
All serum samples collected counted with all the necessary ethical approvals for 
the study. Mice work was conducted in accordance with the UK Animals (Scientific 
Procedures) Act 1986 under the project license number 30/2414 granted by the UK 
Home Office. University of Wisconsin-Madison IACUC (Animal Care and Use 
Committee) granted ethical approval for use of male rhesus macaques. With regard to 
clinical trials, approvals for VAC045 (CS and TRAP samples) were granted by the 
United Kingdom National Research Ethics Service (reference 12/SC/0037) and the 
United Kingdom Medicines and Healthcare Products Regulatory Agency (reference 
21584/0293/001-0001). Clinical trial MAL034 (TRAP samples), was approved by the 
Oxfordshire Research Ethics Committee (OXREC A 09/HO604/9) and the Medicines 
and Healthcare products Reglatory Agency (EudraCT 2008-006804-46) . All volunteers 
gave informed consent prior to participation.  
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Species Antigens Vaccination regime 
Time of 
serum 
collection 
Year Samples provided by 
Mouse 
samples 
 
CSP 
TRAP 
1•108 Ad, 1•107 
MVA  
(8 weeks interval) 
8-14 days 
after MVA 2013 Alexandra Spencer 
Falstatin 
CelTOS 
UIS3 
LSAP1 
LSAP2 
LSA1 
LSA3 
ETRAMP5 
1•108 Ad, 1•106 
MVA  
(8 weeks interval) 
1•108 Ad, 1•107 
MVA  
(8 weeks interval) 
two weeks 
after MVA 2012 
Rhea Longley 
Ahmed Salman 
SPECT1 
SPECT2 
HT 
RP-L3 
1•108 Ad, 1•107 
MVA  
(8 weeks interval) 
8-14 days 
after MVA 2014 Ahmed Salman 
R21 
RTS,S 
0.5-5 μg R21 / 
RTS,S 
(Virus Like Particles) 
2 doses (8wk) 
3 doses (3wk) 
11-21 days  
after 
vaccination 
2013 
2014 Katharine Collins 
Macaque 
samples TRAP 
5•107 Ad, 8•107  
(8 weeks interval) 
one week 
after MVA 2012 Alexandra Spencer 
Clinical 
samples 
CSP 
5•1010 Ad, 2•108 
MVA 
(8 weeks interval) 
two weeks 
after MVA 2012 
Katie Ewer 
Georgina Bowyer 
TRAP 
5•1010 Ad, 2•108 
MVA 
(8 weeks interval) 
two-three 
weeks 
after MVA 
2009 
2012 
Katie Ewer 
Georgina Bowyer 
 
Table 2. Serum samples tested with ISI assay in chapter 2. Post-vaccination 
serum was obtained from mice, macaques and volunteers that had been 
vaccinated against a P. falciparum antigen.  
 
Two monoclonal antibodies have been used in the work described here, both of 
which target the repeat region of CSP protein: 3D11 (fab fragment) [mAb-PbCS], which 
is specific for P. berghei CSP and 2A10 [mAb-PfCS], specific for P. falciparum CSP. 
Both antibodies were available at the laboratory. 
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Mosquito dissection 
After being fed on an infected mouse, A. stephensi mosquitoes were kept at the 
Jenner Insectary at room temperature (to promote sporozoite growth, (216)) for three 
weeks. Just prior to dissection, infected pots of mosquitoes were chilled at 4ºC, to 
reduce mosquito movement, and they were transferred to a petri dish, which was kept 
on ice during mosquito dissection. To isolate the salivary glands, the heads of 
mosquitoes were removed with the aid of insulin syringes [Nu-care Products] and 
forceps and salivary glands teased from the body of the mosquito [Figure.1.B1]. Ideally 
six per mosquito were collected, transferred into a homogenizer and kept in cold media 
to preserve their infectivity (217). As illustrated in [Figure.1.A] the salivary glands 
collected [Figure1.B1] were disrupted using a homogeniser, in order to release the 
sporozoites. GFP signal from chimeric sporozoites could be detected in salivary glands 
[Figure.1.B2].  
 
 
 
Figure 1. A) Schematic representation of sporozoite dissection. Mosquitoes 
were dissected under a microscope, pulling out the head with insulin syringes, 
to obtain the salivary glands. B) Image of three salivary glands obtained in a 
LEICA DM1300B microscope: B1) bright field, B2) GFP+ signal. 
 
Infection of liver cell cultures 
Hepatocytes from the cell line BNL, HepG2, HC04 or Huh7 were seeded on a 96 
well-plate. The standard number of cells used per well was 30000. Cells were plated at 
least 6 hours prior to sporozoite addition. Once salivary glands had been homogenised 
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and sporozoites counted using a disposable counting slide [Immune systems], 
sporozoites were diluted in culture media. Sporozoites were mixed on ice with serum 
samples or monoclonal antibody diluted in media, or just media. Culture media was 
removed from hepatocyte cultures, and 100 µL of sporozoite preparation was added to 
each well. Usually, 15000 sporozoites were used per well (together with the amount of 
cells, these numbers varied in optimisation experiments in Chapter 1). Plates were 
centrifugated (at 1600 rpm, 5 min, 4ºC) to enhance sporozoite entry into hepatocytes 
(210,218,219) and placed in the incubator at 37ºC. 
 
Flow cytometry 
Cells were harvested after overnight incubation when using GFP P. berghei, but 
with GFP-luciferase P. berghei at least 20 hours of incubation were needed to obtain 
GFP signal, cells were acquired after 24 hours of incubation for optimal results.  
Culture media was removed from each well and 30 µL of trypsin [TrypLE Express 
Enzyme, Life Technologyies] added and incubated for 10-15 minutes, since hepatoma 
cells used were very resistant to this treatment. The liver cell lines used tend to 
aggregate which could block the flow cytometer, for this reason trypsin was not washed 
away from the cells. Trypsin not only detached hepatocytes from the plate, but also 
served to remove non-infectious sporozoites that may have attached to the hepatocyte 
surface avoiding potential false positives (208). Cells were resuspended in 1%BSA  
[PAA Laboratories] in PBS [Sigma Aldrich] and transferred to a FACS tube or to a 96-
well U bottom plate, to be acquired manually or using a plate reader, respectively. DAPI 
(1μg/ml final concentration added just prior to acquisition) [Sigma Aldrich] was used as 
a live-death staining, as it is excreted from live cells while remains in larger amounts in 
death cells. Samples were acquired with a LSR IITM flow cytometer [BD Biosciences] 
using FACSDIVATM software V 6.2 [BD Biosciences]. 
Hepatocyte population was selected using forward and side scatter, and then 
single and live cells were selected [Figure2. Gating strategy]. The population of infected 
cells (GFP+ cells) was selected in a diagram were the GFP signal recorded in the 
Alexa Fluor 488 channel was represented against the signal recorded in the PE-A 
channel. Hepatocytes show high autofluorescence, which could be confused with GFP 
signal. Cell autofluorescence was detected both in PE-A and Alexa Fluor 488 channels 
and single live hepatocytes can be shown forming a diagonal when PE-A signal is 
plotted against Alexa Fluor 488 signal. The population of infected cells was selected as 
those that presented a greater signal in Alexa Fluor 488, standing out of the diagonal. 
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Using this method, cells with high autofluorescence were not included as false 
positives.  
 
Figure 2. Gating strategy.  
A) Non-infected cells (negative control). B) Infected cells. 
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Immunofluorescence Antibody Test (IFAT) 
To prepare IFAT slides, 0.01% poly-lysine (20 µL) was added to each well of a 8-
well slide and left until dried (overnight incubation). 20000 sporozoites in RPMI media 
(20-50 µL) were added to each well of the poly-lysine coated slide, after 20 minutes on 
ice (to allow sporozoites enough time to reach the bottom of the slide and interact with 
the poly-lysine) the liquid was removed and samples were fixed using 4% PFA in PBS 
(50-60 µL) at room temperature for 20 minutes incubation. Afterwards, each well was 
washed twice with PBS and slides were stored at 4ºC in sterile PBS (two slides in a 50 
mL Falcon). 
With the purpose of detecting post-vaccination antibodies binding to sporozoites 
antigens, mouse sera (targeting a P. falciparum antigen) were used to stain IFAT 
slides. Each well containing fixed sporozoites was washed three times with PBS. 
Samples were blocked using PBS containing 1% BSA and 10% FCS (20 µL) which 
was incubated for 30 minutes at room temperature. After removing blocking media, the 
primary antibody was added (1:10 and 1:50 post-vaccination serum dilution in blocking 
media) and incubated for 1 to 2 hours at room temperature. After primary antibody 
removal and three washes with PBS, the secondary antibody: Alexa Fluor 488 goat 
anti-mouse IgG [Life Technologies], was added (1:800 dilution in blocking media), 
incubated at room temperature for 1 hour and washed three times with PBS. In order to 
stain sporozoite nuclei, Hoechst 1:50 [Cell Signaling Technology] was added and 
incubated for 10 minutes at room temperature before washing twice with PBS and 
leaving slides until the remaining liquid had almost dried. Finally, a drop of 
Fluorescence Mounting Medium [Dako] was placed on each well and a coverslip was 
laid over the 8-well slide. Once mounting medium was dry, images were taken using a 
DMI-300B Leica fluorescence microscope, recording green signal (GFP: antibody 
bound to sporozoite antigens) for 7 seconds, and blue signal (Hoechst: nuclei staining) 
for 3 or 4 seconds. The signal was recorded over the same exposure time for every 
image, in order to compare the levels of antibody binding. For the same reason, 
brightness and contrast were adjusted in the same proportion using ImageJ software. 
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Confocal microscopy 
Hepatocyte cultures infected with P. berghei sporozoites were incubated for 45 
hours at 37ºC. 24 well-plates were used, containing 60000 Huh7 cells seeded on 
circular coverslips (12mm) [neuVitro], laid on the bottom of each well, and 20000 
sporozoites added per well. After incubation, culture media was removed and each well 
washed three times with PBS (200 µL). Cells were fixed with 4% PFA + 4% sucrose in 
PBS (200 µL) for 30 minutes at room temperature. Fixed cells were washed twice with 
PBS (1 mL), and quenched with 50 mM NH4Cl in PBS (300 µL) for 15 minutes at room 
temperature before washing again with PBS (1 mL). Cells were permeabilised with 
0.1% Triton in PBS (300 µL) for 5 minutes at room temperature. After two washes with 
PBS (1 mL), cells were blocked using 1% BSA in PBS (300 µL) which was incubated 
for 15 minutes. Alexa Fluor 594 goat anti-mouse IgG [Invitrogen] diluted 1:200 in 1% 
BSA in PBS was added (100 µL per well) and incubated for 30 minutes at room 
temperature. Samples were washed two times with PBS and the hepatocyte nuclei 
stained by addition of DAPI 1:5000 (100 µL) for 5 minutes. Coverslips were mounted 
on microscope slides using Fluorescence Mounting Medium [Dako] and left to dry at 
4ºC. Images were acquired using a LSM 710 Carl Zeiss confocal microscope. 
 
Data management and statistical analysis 
Cytometer acquisitions files (.fcs) were analysed with FlowJo.V 9.7.6 [Tree Star]. 
Blocking values were calculated with the percentage of infected cells measured in the 
presence or absence of the serum or monoclonal antibody of interest [Figure 3].  
 
 
Figure 3. Gating strategy. % Infected cells and % Infection blocked formulae 
  
 
Graphs were plotted using GraphPad Prism 6.0, where statistical analyses were 
also performed. A potential correlation between two parameters was evaluated using a 
nonparametric Spearman correlation test (r value) and linear regression (R2; p-value  
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from F test: is the slope significantly different than zero?). 
When comparing the average blocking response between 
various groups, Kruskal-Wallis test with Dunn’s multiple 
comparisons test were used. With macaque and human 
samples, to evaluate whether there was an effect of 
vaccination, blocking values pre- and post-vaccination (paired 
data) were analysed with a Wilcoxon matched-pairs signed 
rank test (two tailed). P-values lower than 0.05 were 
considered to be significant. [Table 3] shows how the levels of 
statistical significance have been represented on graphs, 
where p-values over 0.05 and under 0.3 were stated. 
 
 
  
Symbol p-value 
* ≤0.05 
** ≤0.01 
*** ≤0.001 
**** ≤0.0001 
[Table 3]. Symbols 
for statistical 
significance on 
figures. 
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Chapter 1:  
Optimising a flow cytometry based  
Inhibition of Sporozoite Invasion assay 
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CHAPTER 1: Optimising a flow cytometry based 
Inhibition of Sporozoite Invasion assay 
 
 
1.1. Introduction 
Sporozoite neutralisation assays are relevant techniques to determine the 
functionality of antibodies in their ability to inhibit parasite invasion and/or impede the 
development of malaria liver stages. As described in the introduction, these assays 
have been typically performed using microscopy as the readout method, causing the 
technique to be time-consuming and associated to the bias of the person analysing the 
sample. More recently, new approaches to measure the percentage of infected cells 
through PCR (206), and by flow cytometry (183,208) have made it suitable for the 
analysis of a high quantity of samples. 
 
Figure 1.0. Schematic representation of the Inhibition of Sporozoite Invasion (ISI) 
assay. GFP expressing P. berghei sporozoites enter into a hepatocyte and 
develop within it. Infected cells can be detected by flow cytometry as cells with 
positive GFP signal. The blocking capacity of an antibody is calculated knowing 
the percentage of infected cells measured in the absence and presence of the 
antibody. 
 
  
 44 
This chapter describes a series of experiments that were performed to optimise a 
flow cytometry based Inhibition of Sporozoite Invasion (ISI) assay. The protocol has 
been developed to make it suitable for the study of post-vaccination serum from 
vaccine pre-clinical and clinical studies, at a research centre with a limited capacity of 
sporozoite production and the need to test a large number of samples. The most 
limiting factor in these experiments was sporozoite availability. Therefore, one of the 
main objectives was to use the minimum amount of sporozoites to test each serum 
sample. A number of experiments described in this chapter were performed to find the 
conditions (e.g. host cell line, sporozoite:cell ratio, cell culture media, temperature of 
the first hour of incubation and time of incubation) where the infection rates were higher 
and where the antibodies could best show their blocking capacity (e.g. serum 
concentration and pre-incubation with sporozoites). 
Four different cell lines were tested in this chapter as potential hosts for 
sporozoites: a mouse cell line (BNL) and three human cell lines (HepG2, HuH-7 and 
HC-04). HepG2 is a cell line established from a liver biopsy of a 15-year-old caucasian 
male from Argentina with hepatocellular carcinoma (194,220). HuH-7 cell line was 
established from hepatoma tissue with hepatocellular carcinoma removed from a 57-
year-old Japanese male (213). HC-04 was obtained from normal liver tissue obtained 
from a hematoma patient in Thailand (214). These cell lines have morphology 
characteristics that resemble those of liver parenchyma cells. 
Two monoclonal antibodies were used in this work: 2A10 and 3D11. Both 
antibodies recognize the repeat region of CSP, either of P. falciparum (2A10) (221) or 
P. berghei (3D11) (222). 2A10 antibody has been described to inhibit P. falciparum 
sporozoite invasion of HepG2 cells (198). Similarly, 3D11 (previously described as anti-
Pb44) antibody and its Fab fragments prevented P. berghei entry into WI38 cells (191). 
P. berghei chimeric parasites expressing GFP or GFP-luciferase (both under 
eef1α promoter) were used to find the optimal conditions to perform the assay. In 
addition P. berghei parasites expressing both GFP-luciferase and P. falciparum CSP 
were used to test 2A10, the monoclonal antibody against P. falciparum CSP (mAb-
PfCS). This experiment was performed initially with ‘addition parasites’ that express P. 
falciparum CSP (under UIS4 promoter) as an additional copy. Afterwards, ‘replacement 
parasites’ expressing P. falciparum CSP (under P. berghei CSP promoter) in which P. 
berghei CSP had been deleted, were also tested. Ahmed Salman (DPhil student) 
generated all the chimeric parasites through GIMO (‘Gene insertion/marker out’ (215)). 
Eventually, the chimeric sporozoites used to evaluate efficacy in pre-clinical studies 
(described in chapter 2) were P. berghei sporozoites expressing a P. falciparum 
  
 45 
antigen of interest and GFP-luciferase, which was taken into account when optimising 
the time of readout in this chapter. GFP-luciferase was chosen over GFP as a reporter 
since the fused protein allows not only flow cytometry detection (GFP signal) and but 
also live-imaging microscopy (luciferase signal).  All the transgenic parasites used 
presented the same behaviour in the ISI assay (no differences where found in their 
infectivity capacity). 
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1.2 Results 
 
1.2.1. Adenovirus infection of HepG2 cells and BNL cells 
 
To determine whether small changes in the number of cells expressing GFP 
could be detected by flow cytometry, a preliminary experiment was carried out whereby 
liver cell lines were infected with adenovirus expressing GFP in combination with post-
vaccination serum (from mice that have been vaccinated with the same adenovirus).  
Two lines of liver cell lines, HepG2 cells (human derived) and BNL (mouse 
derived), were infected with different concentrations of adenovirus expressing GFP 
(AdC63 cmvLP eGFP). A range of dilutions of post-vaccination serum were also mixed 
with the adenovirus preparations and incubated for one hour at 37ºC. The different 
samples were added to each well (containing 50000 cells, in a 96 well-plate) and cells 
cultured overnight, prior to harvesting and acquisition on a flow cytometer to measure 
the proportion of cells expressing GFP (infected cells).  
When 5x105 ifu of adenovirus were added to the cells, 19% of HepG2 cells 
[Figure 1.1.A1] and 13% of BNL cells [Figure 1.1.B1] were infected. 5x104 ifu generated 
3% of infected HepG2 [Figure 1.1.A1] and 2% of infected BNL [Figure 1.1.B1]. The 
presence of serum was found to block the infection in a concentration-dependent 
manner [Figure 1.1.A2, B2].  
For HepG2 cells, serum dilutions from 1:200 to 1:3200 prevented 80% to 50% of 
the infection [Figure 1.1.A2]. The percentage of infection blocked by the addition of 
serum appeared to be slightly lower when a higher concentration of virus was used and 
could be related to a limitation of antibody availability. Similar blocking curves were 
observed for HepG2 infected with 5x103 ifu, 5x104 ifu and 5x105 ifu [Figure 1.1.A2], 
although the variation of the data was larger for 5x103 ifu as the percentages of 
infected cells ranged from 0 to 0.6% and the error associated with the experiment 
represents an important part of the measure. The amount of infection blocked was 
lower for BNL cells (60% to 0%) [Figure 1.1.B2] and the percentage of blocking 
observed when adding 5x105 ifu of virus, was approximately three times smaller than 
observed with 5x104 ifu of virus. This decrease in the percentage of the blocking 
associated with the use of a higher virus concentration, was hardly present in HepG2.  
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In general, higher concentrations of serum were needed for BNL cells to achieve a 
similar reduction in infection than observed for HepG2 cells with less serum. As HepG2 
cells are more permissive to infection, it could be expected that they would require a 
higher concentration of serum to prevent the infection. However, this was not observed, 
and the fact that BNL cells require higher amounts of serum to block the infection could 
be due to antibodies with reduced neutralization effect of the virus on the surface of 
BNL cells in comparison to the surface of HepG2 cells. 
 
 
Figure 1.1. Inhibition of GFP adenovirus (AdC63 cmvLP eGFP) infection of the 
liver cell lines HepG2 and BNL using post-vaccination mouse serum. 50000 
HepG2 [A] or BNL [B] cells per well were infected with 5•102 to 5•105 ifu of 
adenovirus which had been pre-incubated for 1 hour with serum concentrations 
ranging from 1:200 to 1:3200. Graphs represent the percentage of infected cells 
(GFP+) [A1 and B1] or the percentage of infection blocked [A2 and B2]. 
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1.2.2. Infection of liver cell lines with P. berghei GFP 
sporozoites  
 
HepG2 cells and BNL cells were infected with transgenic Plasmodium berghei 
sporozoites expressing GFP. 5000, 10000, 20000 or 40000 sporozoites were added to 
50000 cells seeded to each well of a 96 well-plate. Plates were incubated overnight 
with cells harvested and run on a flow cytometer the following day. An infectivity of 1% 
to 5% was found for HepG2 cells [Figure 1.2.A], while the percentage of GFP+ cells 
was always lower than 0.5% for BNL cells [Figure 1.2.B]. The differences in infectivity 
could be due to the distinctive repertoire of surface receptors expressed on the 
hepatoma cell line. In both cases, the percentage of infected cells increased 
proportionally to the amount of sporozoites added, which also indicates that the method 
used is a valid one to evaluate the amount of infected cells. Due to the low level of 
infectivity achieved with BNL cells, we decided not to use this cell line with the purpose 
of the ISI assay. 
 
 
Figure 1.2. Infection of the liver cell lines HepG2 and BNL with P. berghei GFP 
sporozoites. Percentage of infected cells when 50000 HepG2 [A] or BNL [B] were 
infected with different amounts of sporozoites (5000 to 40000). 
 
With the aim of increasing the percentage of infected cells, the effect of plating a 
different number of cells per well was assessed. Plating 30000 cells per well led to 
higher percentages of infected cells compared to wells with 50000 cells [Figure 1.3.A], 
this was true for any amount of sporozoites added. The same percentage of infected 
cells (over 3%) was achieved using 30000 sporozoites and 50000 cells than with 
20000 sporozoites and 30000 cells. When a smaller number of cells were seeded, the 
population of infected cells represented a larger proportion of the total population of 
cells. Nevertheless, the total numbers of positive GFP events [Figure 1.3.B] acquired 
on the flow cytometer were within a similar range regardless the number of cells plated 
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per well. Using fewer cells did not have a negative effect in the total number of positive 
events recorded. Interestingly, when using lower number of sporozoites to infect the 
cells the variability in the percentage of infected cells measured between replicates 
seemed to be smaller, which will be helpful for the ISI assay. 
 
Figure 1.3. Effect of the number of cells per well on the percentage of infected 
cells. 50000 or 30000 HepG2 cells were plated per well and infected with 10000, 
20000 or 30000 P. berghei GFP sporozoites. A) Percentage of infected cells for 
different amount of cells and sporozoites per well. B) Total number of GFP 
positive cells detected for each sample on the flow cytometer. 
 
 
The number of sporozoites obtained per mosquito varied between batches of 
infected mosquitoes, usually between 4000 and 30000. The typical yield of mosquitoes, 
produced at the insectary while this work was performed, was around 10000 
sporozoites per mosquito. Therefore, large numbers of mosquitoes need to be 
dissected for these in vitro studies, which could involve a long time of dissection, 
especially when the mosquitoes presented low yields. The limiting factor determining 
the size of each experiment (the number of conditions and samples to test) was the 
number of sporozoites obtained. For these reason, it is desirable to adjust the ISI assay 
to be performed using a low amount of sporozoites. This may involve a higher risk to 
find less positive events, but can be minimized through the use of replicate wells.  
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1.2.3. Effect of culture media on sporozoite infectivity 
 
The media used for cell culture was also regarded as a factor that could influence 
cell infectivity. Culture media could modulate sporozoite behaviour; for example, Hegge 
et al. showed that sporozoites transformed into exoerythrocytic forms in RPMI within 6 
hours, while in DMEM in only 1 hour (223). Sporozoite neutralizing assays described 
previously have been performed using a variety of cell culture media, mainly DMEM 
and RPMI. To test a potential influence of cell media on infection rates, cells were 
cultured using different media for several days prior to and during the infection. As the 
human liver cell line HepG2 showed previously a higher infectivity than the mouse 
derived cell line BNL, it was used in this experiment together with other two human liver 
cell lines (Huh7 and HC04). DMEM was the media used initially in the experiments 
described so far, and the two other media tested were DMEM* (DMEM supplemented 
with non-essential amino acids and pyruvate) and RPMI. All media contained 10% 
FCS, p/s and L-glutamine. While addition of NEAA and pyruvate to DMEM increased 
the infectivity by 20% in Huh7 and HepG2, and in 40% for HC04, culturing cells with 
RPMI gave the highest levels of infectivity [Figure 1.4].  
 
Figure 1.4. Effect of cell culture media on the percentage of infected cells. 30000 
cells (Huh7, HepG2 or HC04) cultured in DMEM, DMEM* or RPMI, were seeded 
per well and infected with 10000 P. berghei GFP sporozoites. Data was analysed 
with Kruskal-Wallis test, Dunn’s multiple comparisons test (p-values below 0.3 
are included in the graph). 
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When culturing with RPMI instead of DMEM an increase in the infectivity between 
40 to 50% was observed for all cell lines. RPMI was therefore chosen as the media to 
use in future experiments. The effect of culture media on the percentage of infected 
cells may be related with an effect on the host-parasite interactions that take place on 
the cell surface or with a modulation of sporozoite or cell metabolism. An effect of the 
culture media on the cell line growth may also influence the percentage of infected cells 
measured.  
With all different types of media, the highest level of infectivity was observed with 
Huh7 cells [Figure 1.4]. The following experiment was performed to directly compare 
the infectivity of these three cell lines with varying numbers of sporozoites [Figure 1.5]. 
Consistent with the previous experiment, Huh7 cells showed higher percentages of 
infected cells at all sporozoite numbers. In addition, Huh7 cells were easier to handle 
than HepG2 cells, as HepG2 cells have a greater tendency to clump together, which 
can cause problems when acquiring the samples on the flow cytometer. The 
differences found in infectivity among the three cell lines may be related with specific 
characteristics of their cell surface. Each cell line also have different speeds of division, 
which may influence in the percentage of infected cells measured. Carly Bliss (DPhil 
student) performed an experiment where she found that HC04 cell division rate was 
higher than the one of Huh7 cells. Non-infected cells may divide at a higher rate than 
infected cells and, as a result, the percentage of infected cells would become smaller in 
a faster dividing cell line at the time of readout. 
 
Figure 1.5. Infection of the liver cell lines Huh7, HepG2 and BNL with P. berghei 
GFP sporozoites. Percentage of infected cells when each cell line was infected 
with 5000 to 40000 sporozoites. 
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1.2.4. Pre-incubation and temperature during the first hour of 
incubation 
 
To determine the best conditions to test the effect of post-vaccination serum 
samples, initial experiments were performed with a monoclonal antibody against P. 
berghei CS (mAb-PbCS, 3D11 Fab fragment). Firstly, it was important to establish 
whether pre-incubation of sporozoites and antibodies was necessary to observe their 
inhibitory effect. Secondly, it was tested whether infectivity could be more efficient if the 
first hour of incubation was performed at 21ºC (room temperature) or at 37ºC 
(incubator). Sporozoites are very sensitive to temperature, when kept at room 
temperature for a long time they can become non-infectious, therefore sporozoites 
were kept on ice. Since infectivity decreases when sporozoites are maintained in vitro 
at 37ºC (224), it was important to determine whether maintaining cells at room 
temperature after addition of sporozoites could increase infectivity of the sporozoites. 
Addition of 1 µg/mL of mAb-PbCS antibody was shown to reduce the percentage 
of infected cells, however no difference was observed when pre-incubating the 
sporozoites for 15 or 30 minutes than when sporozoites and antibodies were 
simultaneously added to the cells [Figure 1.6.A]. This would suggest that antibody 
binding occurs rapidly, and waiting for longer does not increase the inhibitory effect. 
Consequently, pre-incubation of sporozoites with serum or monoclonal antibody was 
disregarded for future experiments.  
 
Figure 1.6. The effect of temperature on different steps of the ISI assay. 
A) Effect of the time of pre-incubation of 10000 P. berghei GFP sporozoites with 
1 µg/mL mAB-PbCS on ice prior to addition to 30000 Huh7 cells. B) Effect of the 
temperature during the first hour of incubation when infecting 30000 Huh7 cells 
with 20000 P. berghei GFP sporozoites. 
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Keeping plates at room temperature during the first hour of incubation did not 
increase the rate of infection [Figure 1.6.B] and while placing the plates at a 
temperature of 37ºC could have a detrimental effect, the data would suggest that 
sporozoites infect hepatocytes before losing infectivity capacity at 37ºC. Therefore, 
keeping the plates at room temperature for the first hour will not be necessary for future 
experiments.  
 
 
1.2.5. Time of readout  
 
The readout of the ISI assay by flow cytometry relies on the expression of GFP 
from the P. berghei parasite. Parasites used in this project expressed GFP only or the 
fused protein GFP-luciferase. In the experiments described above, parasites 
expressing GFP only were used and samples were run on the flow cytometer the 
following morning (16-18 hours incubation). When parasites expressing GFP-luciferase 
were initially used, almost no infected cells were detected when measuring at the same 
time post-infection. To find the best time to measure infectivity, two experiments were 
performed to establish the time course of GFP and GFP-luciferase expression [Figure 
1.7]. Cells infected with P. berghei expressing GFP only could be detected by flow 
cytometry as early as 4 hours after infection [Figure 1.7.A]. However, it was not 
possible to detect cells infected with P. berghei expressing GFP-luciferase before 20 
hours post-infection [Figure 1.7.B]. The presence of luciferase together with GFP could 
delay the expression of the protein, as the fused protein is a more complex product. 
The mean fluorescence intensity (MFI) of GFP+ cells (represented on the right Y axis) 
increased with the time of incubation, as the parasites developed within the cells and 
expressed a larger amount of protein. Although the MFI can not be compared between 
different experiments, the range of MFI recorded when using GFP is 1.5 log points 
while the range of MFI measured for GFP-luciferase is 0.6 log points [Figure 1.7]. The 
fact that the mean fluorescence intensity of the GFP is lower for GFP-luciferase 
infected cells, could be due to a fewer number of protein copies within the infected 
hepatocyte, or may indicate that fusion to luciferase could result in modifications of the 
GFP folding or quenching of the fluorescent emission. 
An increase in the time of incubation seems to be associated with a decrease in 
the percentage of infected cells, probably due to cell division of uninfected cells (208). 
The profile of the curves in [Figure 1.7] indicates that an increase in the MFI had an 
effect on the percentage of infected cells detected. Both ‘% Infected cells’ curves (GFP 
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and GFP: luciferase) follow similar kinetics with the main difference being that for GFP-
luciferase, the GFP signal was not detected before 20 hours.  
Based on these results, 24-28 hours after infection was chosen as the optimal 
time to measure cells infected with GFP-luciferase parasites. When cells are infected 
with GFP parasites, the rate of infectivity can be measured 3-4 hours after infection, but 
if it is measured after an overnight incubation (as it has been done in the experiments 
described so far) a large percentage of infected cells can still be detected.  
 
Figure 1.7. Effect of the incubation time on the percentage of infected cells 
detected. A) 30000 Huh7 cells per well were infected with 15000 P. berghei GFP 
sporozoites and the percentage of infected cells was measured between 4 and 
41 hours after incubation. B) 30000 Huh7 cells per well were infected with 20000 
P. berghei GFP-luciferase sporozoites and the percentage of infected cells was 
measured between 20 and 48 hours after incubation. In both graphs the log 
Mean Fluorescence Intensity (MFI) of the GFP+ events has been plotted on the Y 
right axis.  
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1.2.6 Blocking curve for mAb-PbCS: concentration effect and 
sensitivity 
 
mAb-PbCS concentrations from 0.1 to 5 μg/mL mixed with either 15000 or 30000 
sporozoites (GFP-luciferase) were added to each well (containing 30000 cells). mAb-
PbCS was found to inhibit the infection in a concentration-dependent manner, 
achieving a blocking of 50-60% with 1 μg/mL, 96% with 5 μg/mL and only 3% with 0.1 
μg/mL [Figure 1.8.A]. While cells infected with 30000 sporozoites showed almost a 
doubling in the percentage of infected cells [Figure 1.8.A]. When transforming the data 
to show percentage of infection blocked, similar inhibition curves were obtained with 
addition of 15000 sporozoites and 30000 [Figure 1.8.B].  
 
  
 
Figure 1.8. Effect of mAb-PbCS on sporozoite infection. 30000 or 15000 
sporozoites (P. berghei GFP-luciferase) were added to 30000 Huh7 cells per well 
in the presence of a range of mAb-PbCS concentrations (0-5 µg/mL). A) 
Percentage of infected cells. B) Percentage of infection blocked. The log MFI 
found for the infected cells (GFP+) is represented when infecting with 15000 
sporozoites (C1, black) and 30000 sporozoites (C2, blue). 
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The percentages of infection blocked were slightly higher when 15000 sporozoites 
were added, suggesting a limiting effect of antibody when more sporozoites were 
added into the well. Interestingly, doubling the amount of sporozoites did not effect the 
range of infection blocked by the monoclonal antibodies, which confirms that a smaller 
amount of sporozoites per well (15000) can be used without having a detrimental effect 
on assay sensitivity. This data would also suggest that fluctuations in the sporozoite 
infectivity or the error associated to the sporozoite count should not largely effect the 
ISI assay, as long as the data obtained is analysed with reference to infectivity in the 
control wells.  
Interestingly, higher concentrations of antibody were associated with lower MFI 
values [Figure 1.8.C1, 1.8.C2]. Although the effect observed is very small (a decrease 
of the MFI from 103.8 to 103.7) it could be related to an effect of the antibodies on growth 
of the parasite within the infected cell. 
 
 
1.2.7 Antibody effect on MFI 
 
In the previous experiment, a trend towards slightly lower values of GFP MFI was 
observed when using higher antibody concentrations [Figure 1.8.C1,C2], suggesting 
that the presence of antibody could have an effect on the GFP MFI. Prudencio et al. 
(208) found a positive correlation between the intensity of the GFP signal and the 
number of parasite copies (measured by qRT-PCR), describing that flow cytometry 
could be used to assess parasite development within hepatocytes. The presence of 
antibody could impair sporozoite development (114,200,225), which might be detected 
as lower GFP MFI values. 
An experiment was performed to find whether antibody could have a significant 
effect on GFP MFI when measuring at late time points (longer incubation times than 
26h, which was the readout time in Figure 1.8). GFP-luciferase sporozoites were added 
in the presence of mAb-PbCS at 0.25 and 0.5 μg/mL. These antibody concentrations 
blocked less than 50% of the infection, which enabled detection of an adequate 
number of infected cells where GFP MFI would be measured. No significant differences 
were observed when comparing GFP MFI from cells infected in the absence of 
antibody with those where monoclonal antibody was added together with the 
sporozoites (measuring at 26h and later time points after infection) [Figure 1.9]. 
In the experiment about the time of readout [Figure 1.7] it was described that 
GFP MFI increase with time of incubation was much more limited in GFP-luciferase 
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sporozoites (used in this experiment) than in GFP sporozoites. Antibody effects on 
parasite development might be measured using GFP sporozoites, or other kind of 
transgenic sporozoites, which count with a fluorochrome that can elicit a more intense 
fluorescent signal. In this work, the transgenic parasites of interest (P. berghei GFP-
luciferase) did not generate a fluorescent signal strong enough to enable the measuring 
of variations on development caused by the presence of antibodies. For this reason, it 
was decided not to continue with the study of GFP MFI. 
  
 
Figure 1.9. Effect of mAb-PbCS on GFP MFI. 15000 sporozoites (P. berghei GFP-
luciferase) were added to 30000 Huh7 cells per well in the presence of mAb-
PbCS (0.25 or 0.5 µg/mL). A) Percentage of infected cells over time. B) 
Percentage of infection blocked over time. C) log MFI found for infected cells 
(GFP+). log (MFI GFP+) data was analysed with a Friedman test and Dunn’s 
multiple comparisons test, confirming that means were not significantly different 
at any time point.  
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1.2.8. Non-specific effect of naive serum and heat inactivation  
 
In future experiments, serum from naive mice will be used as a negative control. 
One of the described limitations of the ISI assay is the detection of blocking with non-
specific serum (198,211,226). For this reason, an experiment was run to determine the 
effect of naive serum on sporozoite infectivity and to establish whether heat-inactivation 
could reduce the non-specific effect. Addition of non heat-inactivated (HI) serum up to 
10% of the total final volume was shown to have a blocking effect of less than 20%, 
while addition of 20% non HI serum resulted in blocking more than 40% of the infection 
[Figure 1.10.A1].  
 
Figure 1.10. Effect of addition of naive serum on sporozoite infection of liver 
cells. 15000 sporozoites (P. berghei GFP-luciferase) were used to infect 30000 
Huh7 cells per well in the presence of various concentrations (0-20%) of serum 
from naive BALB/c mice or 1 µg/mL mAB-PbCS. Heat inactivated (HI) serum and 
mAb-PbCS are shown in orange, and black is used for non HI samples. A) 
Percentage of infection blocked in the presence of HI/non HI BALB/c naive 
serum (A1) and HI/non HI mAb-PbCS (A2). B) Percentage of infected cells in the 
presence of HI/non HI BALB/c naive serum. 
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Low concentrations (≤ 2%) of HI serum did not have a blocking effect on the infection, 
while addition of 5%-20% HI serum had a greater effect on blocking the infection (more 
than 30% of blocking) than non HI serum [Figure 1.10.A1]. It is not clear why HI 
samples prevented the infection to a larger extent than non HI samples. In addition, 
heat inactivation of mAb-PbCS inhibited its blocking capacity [Figure 1.10.A2], which 
discouraged the use of heat inactivation of the samples in future assays. 
 
1.2.9. Monoclonal antibody against P. falciparum CSP         
(mAb-PfCS) 
 
Since an important number of serum samples to test in future experiments had 
been raised against P. falciparum CSP and there was an available monoclonal 
antibody (mAb-PfCS, 2A10) against this protein, some experiments were performed to 
explore the blocking capacity of this antibody with the objective of establishing it as a 
positive control.  
 
Figure 1.11. Effect of mAb-PfCS (2A10) on sporozoite infection. 15000 
sporozoites (P. berghei GFP-luciferase) were added to 30000 Huh7 cells per well. 
A) PfCS addition sporozoites (PfCS@UIS4) with mAb-PfCS (2A10) at 1 to 100 
μg/mL with (blue dots) or without (black dots) mAb-PbCS (3D11) at 1 μg/mL. B) 
PfCS replacement sporozoites (PfCS@PbCS) with mAb-PfCS at 0.05 to 10 μg/mL. 
 
mAb-PfCS used in concentrations up to 100 μg/mL did not block infectivity of P. 
berghei sporozoites expressing P. falciparum CSP and P. berghei CSP (PfCS@UIS4; 
PfCS addition sporozoites which express both P. falciparum and P. berghei CSP) 
[Figure 1.11.A]. It seems that the presence of P. berghei CSP maintains sporozoite 
functionality regardless that mAb-PfCS may bind to P. falciparum CSP. When testing 
mAb-PfCS at 1 to 100 μg/mL in combination with mAb-PbCS (3D11) at 1 μg/mL, about 
60% of the infection was blocked [Figure 1.11. A] which is the value observed for mAb-
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PbCS on its own at this concentration. However, when mAb-PfCS (0.05-10 μg/mL) was 
used to prevent invasion by P. berghei sporozoites expressing P. falciparum CSP in 
which P. berghei CSP had been deleted (PfCS@PbCS; PfCS replacement 
sporozoites), the infection was blocked in a concentration-dependent manner [Figure 
1.11.B].  
 
 
Figure 1. 12. mAb-PfCS (2A10) is detectable inside infected hepatocytes. 20000 
sporozoites per well were added with mAb-PfCS at 3 μg/mL, to 60000 Huh7 cells 
seeded on a P24 plate and incubated during 45h. Sporozoites develop in a 
parasite vacuole inside hepatocytes, which is detectable through the green 
signal of GFP (expressed by chimeric parasites) and blue signal from DAPI 
staining parasite DNA. DAPI also stains hepatocyte nuclei. mAb-PfCS 
was detected with goat anti-mouse IgG conjugated to Alexa Fluor 594 (red). A) 
PfCS@UIS4 GFP P. berghei sporozoites B) GFP P. berghei sporozoites (negative 
control). 
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With the purpose of better understanding the interaction between mAb-PfCS and 
PfCSP@UIS4 sporozoites, confocal microscopy images were taken of cultures of Huh7 
cells where addition sporozoites and mAb-PfCS were added. Parasite vacuoles within 
hepatocytes where recognized for their GFP signal (green) and parasite DNA stained 
with DAPI (blue). DAPI also stained hepatocyte nuclei. An anti-mouse antibody 
conjugated to Alexa Fluor 594 (red) was used to detect mAb-PfCS presence. Red 
signal (mAb-PfCS) was found within the hepatocyte and surrounding the parasite 
vacuole [Figure 1.12.A], which suggests that sporozoites may have entered into 
hepatocytes with mAb-PfCS attached to their surface and the antibody has been left on 
the surface of the parasite vacuole. As a negative control, when P. berghei sporozoites 
that did not express P. falciparum CSP, had mAb-PfCS added, no red signal was 
detected [Figure 1.12.B]. 
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1.3 Discussion 
 
The aim of the work described in this chapter was the optimisation of a protocol 
to measure post-vaccination serum capacity to inhibit sporozoite invasion of liver cells. 
The following parameters were evaluated: the optimal number of sporozoites and cells 
to use per assay, the infectivity rates of several liver cell lines cultured in various 
media, the effect of sporozoite pre-incubation with antibodies, the temperature of the 
first hour of incubation, the best time of readout, the range of serum concentration to 
test and whether it was necessary to heat inactivate the serum. 
The possibility of measuring changes in the number of infected cells (GFP+) 
caused by the presence of serum by flow cytometry was first tested by adding GFP 
expressing adenovirus to the liver cell lines HepG2 and BNL. Serum from mice that had 
been vaccinated with the same adenovirus was used in a range of concentrations to 
block virus entry into the cells [Figure 1.1]. As expected, the percentage of infected 
cells increased with the amount of virus added to the culture. In addition, the presence 
of serum blocked the virus infection in a concentration-dependent manner.  
After this preliminary experiment with GFP adenovirus, HepG2 and BNL were 
both infected with various concentrations of GFP expressing sporozoites [Figure 1.2]. 
The number of infected cells was dependent on the number of sporozoites added, 
confirming flow cytometry as an adequate method to determine the number of infected 
cells. A percentage of infected cells between 1% and 5% was observed when adding 
5000 to 40000 sporozoites to HepG2 cells. However, the percentage of infected cells 
for BNL was less than 0.5% in all cases tested. The discrepancy between infectivity 
rates found for each cell line could be due to the particular repertoire of surface 
receptors expressed on the hepatocytes.  
A series of experiments were then performed with the aim of maximizing 
infectivity rates, since in the sporozoite neutralization assay the percentage of infection 
blocked is calculated using the number of infected cells in the absence and presence of 
post-vaccination serum. Then, performing the assay in the conditions were a higher 
number of infected cells could be achieved would increase the flow cytometry events 
upon which the percentage of infection blocked is calculated, increasing the reliability 
of the data. 
Regarding the liver cell line to use in the assay, the BNL cell line was discarded 
due to the low infectivity rates observed, and HepG2 were compared with other human 
liver cell lines: Huh7 and HC04 [Figure 1.5]. In these experiments, the higher 
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percentages of infected cells were achieved when using Huh7 cells. One of the 
sources of variability when comparing infectivity rates is the growth rate of each cell 
line. Carly Bliss (DPhil student) performed an experiment where she found that HC04 
cell division rate was higher than the one of Huh7 cells. If infected cells do not divide as 
rapidly as non-infected cells, the percentage of infected cells would be found to be 
smaller in a more rapidly growing cell line (such as HC04 compared to Huh7). 
Prudencio et al. found 1.5-4.5% infected cells in cultures of Huh7 infected with P. 
berghei (208), Kaushansky et al. measured 0.6-2.5% infected cells using HC04 cells 
(209) and P. falciparum, and Sinnis et al. described that when quantifying sporozoite 
invasion by flow cytometry at least 1% of total cells should be infected (217). Although 
direct comparison is not possible due to the different kind of cell lines and sporozoite 
strains used, sporozoite:cell ratio and variations in the protocols such as the time of 
readout; the percentage of infected cells found in this work is within the range 
previously described in the literature. 
Sporozoite neutralizing assays described previously have been performed using 
a variety of cell culture media, mainly DMEM or RPMI. Huh7 cells and P. berghei 
sporozoites have been described to be cultured both in DMEM (217,227,228) and 
RPMI (208,229,230). Although successful infections can be achieved in both media, an 
experiment was performed to explore whether there could be differences on infectivity 
rates using DMEM, DMEM (supplemented with non-essential amino acids and 
pyruvate) and RPMI. Culture media could modulate sporozoite behaviour; for example, 
Hegge et al. showed that sporozoites transformed into exoerythrocytic forms in RPMI 
within 6 hours, while in DMEM in only 1 hour (223). RPMI has a higher concentration of 
glucose and phosphate, but lower of calcium than DMEM (231), which could have an 
effect on sporozoite metabolism. Host cell growth rates could also vary in different 
media, which could modify the infection rates. For Huh7 cells, superior infectivity rates 
were found using RPMI rather than DMEM [Figure 1.5]. As a result, RPMI was selected 
for future experiments. 
The number of sporozoites was the limiting factor encountered when performing 
these assays. Sporozoites were obtained by homogenizing salivary glands dissected 
from infected mosquitoes and the parasites yields per mosquito were highly variable, 
usually between 4000 and 30000. To ensure efficient use of the sporozoites available, 
the assays were optimised to be performed with a minimal number of sporozoites. The 
cell:sporozoite ratio to plate was evaluated measuring the percentage of infected cells 
obtained when plating 30000 and 50000 cells per well and adding 10000, 20000 or 
30000 sporozoites [Figure 1.3]. A higher percentage of infected cells was obtained 
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when platting fewer cells [Figure 1.3.A]. If a number of sporozoites would infect a 
certain number of hepatocytes, the number of infected cells would represent a larger 
percentage if the total number of cells was smaller. Nevertheless, the total number of 
positive events (100-200 total GFP+ cells) was in the same range regardless of the 
number of cells plated [Figure 1.3.B]. Therefore, 30000 cells and 15000 sporozoites 
were chosen as the standard number to plate per well (96-well plate) that would 
generate infectivity rates between 1-3%. 
In order to test whether using a higher number of sporozoites would be possible 
to detect blocking effect of smaller antibody concentrations, a experiment was 
performed infecting hepatocytes with 15000 or 30000 sporozoites per well, in the 
presence of mAb-PbCS concentrations from 0.1 to 5 μg/mL [Figure 1.8]. When plotting 
the percentage of infection blocked versus monoclonal antibody concentration [Figure 
1.8.B], similar curves were obtained with both amounts of sporozoites used. Doubling 
the amount of sporozoites did not effect the range of infection blocked by monoclonal 
antibodies. It was concluded that 15000 sporozoites per well could be used without 
having a detrimental effect on assay sensitivity. It is interesting to note that when using 
30000 sporozoites per well, the percentage of infected cells was twice as much than 
with 15000 sporozoites [Figure 1.8.A], but similar percentage of infection blocked was 
obtained in both cases. This result shows that in spite of obtaining differences in the 
percentage of infected cells, the values of percentage of infection blocked are 
consistent. This is especially relevant since the percentage of infected cells presented 
certain fluctuations in each experiment (probably due mainly to the quality of different 
batches of sporozoites and the error associated to the number of sporozoites added to 
each well). 
Temperature has been described to play a role in sporozoite infectivity and in the 
process of transformation towards liver stage parasites. Sporozoites maintained in vitro 
at 37ºC rapidly lose their infectivity capacity (224), while infectivity could be preserved 
for longer periods of time when sporozoites were kept at lower temperatures (4-20ºC) 
(217). On the other side, Siau. et al showed that infectivity loss was delayed in the 
presence of human cells (232). A temperature elevation to 37ºC is required for efficient 
infection (232), causes early and faster sporozoite transformation into EEF 
(exoerythrocytic forms) (223) and is required to complete this transformation (233). It 
was considered, that the temperature of the first hour of infection might have an 
influence in the rate of infectivity achieved. As sporozoites lose capacity to invade cells 
at 37ºC, maintaining the sporozoites during the first hour of infection at room 
temperature instead of at 37ºC could increase the number of liver cells infected. 
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However, keeping the plates at room temperature did not have a positive effect 
increasing the infectivity rates measured [Figure 1.6.B]. Consequently, plates with 
sporozoites were placed in the incubator just after sporozoite addition in the 
subsequent experiments. 
To determine whether pre-incubation of the parasites with antibodies had an 
influence on the blocking effect, sporozoites were pre-incubated on ice with monoclonal 
antibody against P. berghei CSP (mAb-PbCS) prior to the addition of the mixture to the 
hepatocytes culture. The antibody blocking capacity after pre-incubation during 15 or 
30 minutes, was the same as when there was no pre-incubation [Figure 1.6.A]. 
Therefore, sporozoites mixed with monoclonal antibody or serum were added to the 
cells without a pre-incubation in all the subsequent experiments. The interaction 
between antibodies and sporozoites appears to occur rapidly enough to disregard pre-
incubation in the ISI assay. 
Other factor explored when trying to maximize the number of infected cells 
measured, was the time of readout. In preliminary experiments with sporozoites 
expressing GFP, the percentage of infected cells was quantified by flow cytometry after 
16-18h (overnight incubation). However, when measuring the number of cells infected 
with sporozoites expressing GFP-luciferase, the infectivity rates were much lower than 
expected after the usual time of incubation. For this reason, a time course was 
performed to determine how the percentage of infected cells measured changes over 
time. The percentage of infected cells (using GFP-luciferase sporozoites) reached a 
peak at 25-28 hours after infection, time established to measure the GFP signal; and 
later decreased with time, most likely due to cell division. When GFP is fused to 
luciferase, the expression of the protein could be delayed due to its overall larger size 
compared to GFP expressed on its own, as a result, the infected cell may need more 
time to accumulate enough reporter protein to be detected by flow cytometry. The 
presence of luciferase in the chimeric parasites allows performing in vivo imaging, 
constituting an important advantage for vaccination studies. For this reason GFP-
luciferase was chosen as the reporter gene in chimeric sporozoites expressing P. 
falciparum antigens that would be used to test post-vaccination serum samples, and 
the assay needed to be optimised for these parasites. Traditionally, assays which 
measure antibody functionality preventing liver sporozoite infection have been divided 
in ISI, whose incubation time last from few hours up to a day, and ILSDA with 
incubations of one or several days (209,210). ISI measures neutralisation capacity of 
antibodies avoiding invasion of hepatocytes and ILSDA evaluates antibody capacity to 
prevent sporozoite development within the liver. The requirement of waiting at least 24h 
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when using GFP-luciferase sporozoites to allow enough time for the GFP signal to 
develop, situates the assay employed in this work in the limit between ISI and ILSDA 
(nevertheless, it is referred through out this text as ISI). If antibodies are able to act 
both avoiding invasion and preventing sporozoite development, measuring the 
percentage of infected cells at later time points may be a more realistic approach to 
evaluate the actual capacity of the antibody to avoid the progress of the liver stage. 
Antibodies have been described to play a role on inhibition of parasite 
development (114,200,225). On other side, Prudencio et al. (208) found that the 
intensity of flow cytometry GFP signal of infected hepatocytes correlated with parasite 
load (measured by qRT-PCR), suggesting flow cytometry as a tool to evaluate parasite 
development within hepatocytes. GFP MFI (Mean Fluorescence Intensity) could be an 
indicator of parasite development within the hepatocyte, since a higher expression of 
GFP may indicate a larger number of parasite copies or a larger growth. The presence 
of antibodies could impair sporozoite development and therefore effect GFP MFI. A 
trend was detected towards slightly lower values of GFP MFI when increasing the 
concentration of mAb-PbCS (3D11) [Figure 1.8. C1, C2]. For this reason it was decided 
to measure whether the presence of monoclonal antibody could decrease GFP MFI at 
later time points, when the antibody inhibition of parasite development might be more 
evident. However, no difference was detected on GFP MFI signal between hepatocytes 
infected in the absence or presence of mAb-PbCS, even when measuring after 61 
hours of incubation [Figure 1.9]. As it has been described in [Figure 1.7], the range of 
GFP MFI measured was larger using GFP only sporozoites rather than GFP-luciferase 
sporozoites. GFP-sporozoites were detected after 4h of incubation with a log(MFI 
GFP+) close to 3.5, which increased up to 5.0 after 41h of incubation. GFP-luciferase 
sporozoites presented a log(MFI GFP+) of 3.2, which only increased up to 
approximately 3.8 after 48h. GFP fused to luciferase produced a weaker signal at later 
time points. GFP-luciferase sporozoites may not generate a signal intense enough to 
allow evaluation of antibody effects on liver stage development by flow cytometry or the 
monoclonal antibodies employed may not have an effect on the development 
detectable by this technique. Consequently, it was decided not to continue with the 
study of GFP MFI in future experiments. 
One of the limitations of the ISI assay is the non-specific blocking of sporozoite 
infection that may generate the presence of serum, evidenced in the finding of up to 
30% of inhibition blocked using naive sera described in the literature (198,211,226). It 
was considered that heat inactivation of serum could be a way to reduce the non-
specific effect observed. However, the percentage of non-specific infection blocked 
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observed after heat inactivation was higher than without it using serum dilutions of 5-
20% [Figure 1.10.A1]. In addition, mAb-PbCS lost its blocking effect after heat 
inactivation [Figure 1.10.A2]. Although heat inactivation is supposed to affect only the 
proteins of the complement, heat inactivation might elicit the loss of an active 
conformation of antibodies or cause antibody aggregation. As a result, heat inactivation 
of serum samples was disregarded. 
In addition to mAb-PbCS, which has been used as a positive control in some of 
the experiments to optimise the protocol and in the assays with serum samples (that 
will be described in chapter 2), a monoclonal antibody against P. falciparum CSP 
(mAb-PfCS, 2A10) was also available. This monoclonal antibody could be an adequate 
positive control, when testing human, macaque and mouse anti-PfCS sera. However, it 
was found that mAb-PfCS was not able to block the sporozoite entry in hepatocytes 
when the parasites expressed PfCS as an additional copy (PbCS was also present in 
the sporozoites), even when using very high antibody concentrations [Figure 1.11.A]. 
mAb-PfCS only acted efficiently blocking sporozoites expressing PfCS as a 
replacement copy, which express PfCS, but no PbCS [Figure 1.11.B]. One possible 
explanation could be that, in the presence of functional PbCS, even if PfCS is blocked 
through antibody binding, the parasite can still enter into the cell. In fact, some confocal 
images were taken where mAb-PfCS was detected inside the cell, surrounding the 
parasite vacuole [Figure 1.12.A]. This effect observed with mAb-PfCS, seemed to also 
be happening with R21 serum (anti-PfCS serum), which did not block sporozoites 
expressing PfCS as an additional copy in the experiments that will be described in 
chapter 2. Consistent with these observations, Persson et al described that 2A10 
(mAb-PfCS) prevented in vitro and in vivo liver stage invasion of P. berghei sporozoites 
expressing P. falciparum CSP in the P. berghei CSP locus (equivalent to the 
‘replacement parasites’ used here). The absence of blocking described when P. 
berghei CSP is also present, may highlight that antibodies are preventing the 
hepatocyte invasion because they block the function of a protein, rather than, for 
example, have a neutralization effect avoiding the contact between sporozoites and 
hepatocytes. 
The experiments performed in this chapter established a protocol to test post-
vaccination serum samples. The main assay limitations were sporozoite availability and 
the non-specific blocking effect of naive-serum. The percentage of infected cells 
presented certain variability, however, the measure of the serum blocking capacity was 
found to be very reproducible regardless the infectivity rate of a particular assay. The 
most important advantage that flow cytometry provides as a readout is the possibility of 
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using ISI assay as a high-throughput method to test antibody capacity to prevent 
sporozoite invasion. 
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Chapter 2:  
Testing mouse, macaque and clinical samples 
with ISI assay 
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CHAPTER 2: Testing mouse, macaque and 
clinical samples with ISI assay 
 
2.1 Introduction 
This second chapter describes the results obtained when testing diverse serum 
samples with the Inhibition of Sporozoite Invasion assay, described in chapter 1. 
Serum samples tested were obtained from pre-clinical and clinical studies 
performed by researchers at the Jenner Institute. The experiments described here 
were performed with the objective of better characterising the functionality of humoral 
immune responses generated through vaccines targeting pre-erythrocytic P. falciparum 
antigens.  
In order to evaluate the capacity of the post-vaccination serum samples to reduce 
hepatocyte invasion, transgenic P. berghei parasites expressing the same P. 
falciparum antigen that was targeted through vaccination were used. These chimeric 
parasites, kindly provided by Ahmed Salman (DPhil student), were generated through 
GIMO (‘Gene insertion/marker out’) transfection (215). Chimeric parasites contain a 
construct, inserted in the genomic silent locus 230p, which includes a P. falciparum 
gene under Pb UIS4 promoter and a GFP-luciferase cassette under the control of Pb 
eef1α promoter.  
 
Figure 2.0. Schematic representation of the construct included in P. berghei 
chimeric parasites (additional copy). The graph represents the construct 
included in 230p (genomic silent locus) to generate P. berghei parasites which 
express a P. falciparum antigen (Pf CDS: falciparum coding sequence) under Pb 
uis4 promoter and GFP-luciferase under Pb eef1α promoter. Image provided by 
Ahmed Salman [DPhil Thesis, University of Oxford 2014]. 
 
UIS4 gene has been shown to be upregulated in salivary gland sporozoites, like 
other UIS (Upregulated in Infective Sporozoites) genes (234). Silvie et al. found high 
levels of UIS4 transcript in P. berghei sporozoites, but absence of UIS4 protein until 
one day after infection (235). However, in transgenic salivary gland sporozoites, they 
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observed mCherry expression under the control of UIS4 UTRs 5’ (including UIS4 
promoter) and UTRs 3’ regions and consequently, they described a post-translational 
repression of UIS4 due to elements present in the UIS4 coding sequence (235). 
Therefore, UIS4 promoter was chosen to express pre-erythrocytic P. falciparum 
antigens in P. berghei sporozoites. 
The P. falciparum antigens tested here were: CelTOS, LSA1, LSA3, LSAP1, 
LSAP2, UIS3, ETRAMP5, Falstatin, SPECT1, SPECT2, RP-L3, HT, CSP and TRAP.  
These antigens are pre-erythrocytic malaria vaccine candidates that are being currently 
evaluated at the Jenner Institute.  P. falciparum CelTOS, UIS3, Falstatin, SPECT1, 
SPECT2, RP-L3, HT, CSP and TRAP are present both in P. falciparum and P. berghei, 
while the rest of the P. falciparum antigens tested do not have a P. berghei homolog. In 
this work, some experiments were performed with CSP replacement parasites in which 
P. berghei CSP has been deleted and P. falciparum CSP is expressed under the 
control of the P. berghei CSP promoter. This chimeric parasite was generated through 
the GIMO method, but replacing the P. berghei CSP by the P. falciparum CSP. 
Consistent with the additional transgenic parasites, Pf CSP replacement parasites 
express GFP-luciferase under Pb eef1α promoter in 230p. The rest of the chimeric 
parasites employed express the P. falciparum antigen under UIS4 promoter as an 
additional copy. This strategy allows the generation of transgenic parasites even when 
a P. berghei homolog is not present. 
Both the genotype and phenotype analysis of the transgenic parasites were 
performed by Ahmed Salman [Ahmed Salman, DPhil thesis]. The correct integration of 
the construct in the chimeric parasites was demonstrated through southern analysis 
and PCR. The expression of the P. falciparum antigen was probed by IFAT 
(Immunofluorescence antibody test) using monoclonal antibodies whenever available 
or sera collected from vaccinated animals. 
A short summary of information available in the literature for each of the P. 
falciparum antigens targeted through vaccination and expressed by the chimeric P. 
berghei parasites are included in the table [table 2.1]. Function and localization of these 
proteins are likely to have an effect on the role that antibodies targeting them may play 
inhibiting the invasion of sporozoites into hepatoma cell line.  
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Pre-erythrocityc antigens 
 
Name 
Localization 
 
Function 
 
Details 
 
CelTOS 
 
 
Cell-Traversal 
protein for 
Ookinetes and 
Sporozoites 
 
Located in 
micronemes 
(sporozoites) 
CelTOS plays an 
important role in 
breaking through 
host cellular 
barriers. CelTOS is 
involved in cell-
traversal capacity 
of ookinetes and 
sporozoites (at 
mosquito midgut 
and liver infection, 
respectively). 
CelTOS-disrupted P. berghei: 
-infected HepG2 cells (hepatoma cell line) 
with a similar efficiency to WT. 
-showed damaged cell-passage activity in 
vitro. 
-showed reduced ookinete movement from 
the cytoplasm of the mosquito midgut 
epithelial cell to the basal lamina. 
-showed limited sporozoite movement 
through the liver sinusoidal cell layer (which 
includes Kupffer cells, hepatic 
macrophages), which was restored when 
using Kupffer cell-depleted rats.  
 
Immunisation with P. falciparum CelTOS 
has been shown to generate high 
immunogenicity and protection in mice 
(heterologous challenge with P. berghei 
sporozoites). 
(236) 
(187) 
LSA1 Liver-Stage 
Antigen 1
  
Expressed 
only in liver 
stages. 
Located in the 
PV space. 
LSA1 plays an 
important role in 
late liver-stage 
development. 
LSA1-disrupted P. falciparum: 
-infected HCO4 cells (hepatoma cell line), 
but liver stage development was reduced at 
later stages. 
-did not achieve exo-erythrocytic merozoite 
formation in mice with humanised liver. 
 
Immune response to LSA1 have been found 
in individuals living in endemic areas. 
(237) 
(188) 
(238) 
(122) 
LSAP1 
 
Liver-Stage-
Associated 
Protein-1 
 
Mainly 
expressed in 
liver stages. 
Located in the 
PV 
membrane. 
Unknown LSAP1 has been detected in primary human 
hepatocytes infected with P. falciparum and 
it might be expressed in small quantities in 
sporozoites. 
 
Anti-LSAP1 serum did not prevent 
sporozoite cell traversal (1% dilution), nor 
affected sporozoite invasion of primary 
hepatocytes (1 and 5% dilution). 
 
(232) 
LSAP2 Liver Stage-
Associated 
Protein-2 
 
Mainly 
expressed in 
liver stages. 
Located in the 
PV 
membrane. 
Unknown 
LSAP2 has been detected in primary human 
hepatocytes infected with P. falciparum, two 
days after the inoculation. 
(232) 
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Pre-erythrocityc antigens 
 
Name 
Localization 
 
Function 
 
Details 
 
UIS3 Infective 
Sporozoites 
gene 3 
Expressed in 
sporozoites 
and liver-
stages. 
Located in the 
PV 
membrane. 
Belongs to 
ETRAMP 
family. 
UIS3 is essential 
for early liver-stage 
development.  
UIS3 has been 
shown to interact 
with L-FABP (liver-
fatty acid binding 
protein), so it could 
be involved with 
fatty acid 
acquisition by the 
liver stage 
parasite. 
 
UIS3-disrupted P. berghei: 
-infected Huh7 cells (hepatoma cell line), 
but did not mature into liver schizonts. 
-were unable to establish blood-stage 
infection, in vivo. 
 
Mice immunised with P. berghei  uis3(-) 
parasites were shown to be protected 
against WT sporozoites. 
 
P. yoelii UIS3 used in combination with 
other two antigens (P.y. falstatin and 
PY03661) elicited protection in CD1 mice. 
(239) 
(240) 
(228) 
(241) 
ETRAMP5 Early 
TRAnscribed 
Membrane 
Protein 5 
 
Putative PV 
membrane 
protein. 
ETRAMP5 binds 
human 
apolipoproteins 
(ApoA1, ApoE and 
ApoB) 
Antibodies against ETRAMP5 have been 
found in sera of individuals from endemic 
areas. 
(242) 
(243) 
LSA3 Liver-Stage 
antigen 3 
 
Expressed on 
sporozoites 
and in liver-
stages. 
Unknown Immunisation with LSA3 peptides and 
lipopeptides elicited protection in 
chimpanzees challenged with P. falciparum. 
Humoral and cellular immune responses 
have been detected in individuals from 
endemic areas. 
Purified antibodies against LSA3 from 
volunteers living in endemic areas inhibited 
P. yoelii invasion of mouse hepatocytes and 
in vivo infection of BALB/c mice. 
(244) 
(245) 
(246) 
Falstatin Expressed in 
sporozoites 
(secretory 
vesicles). 
Expressed in 
liver-stages. 
Inhibition of 
cysteine proteases 
Mouse antibodies (20% dilution) against Pb 
Falstatin blocked about 40% of P. berghei 
invasion of HepG2 cells. 
P. yoelii falstatin used in combination with 
other two antigens (P.y. UIS3 and 
PY03661) elicited protection in CD1 mice. 
 
(247) 
(241) 
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Pre-erythrocityc antigens 
 
Name 
Localization 
 
Function 
 
Details 
 
SPECT1 Sporozoite 
microneme 
Protein 
Essential for 
Cell Traversal 
Located in 
micronemes 
(of salivary 
gland 
sporozoites) 
SPECT1 is 
essential in cell-
passage ability. 
SPECT1-disrupted P. berghei: 
-infected HepG2 (hepatoma cell line) 
cells in a similar way to WT P. berghei. 
-lost cell-traversal ability in vitro. 
-showed a reduced liver infectivity in 
rats, compared to WT P. berghei. 
Disrupted and WT parasites had the 
same capacity of infection in Kupffer-
cell depleted rats. 
(248) 
SPECT2 Sporozoite 
microneme 
Protein 
Essential for 
Cell Traversal 
2 
Located in 
micronemes 
(of salivary 
gland 
sporozoites) 
SPECT2 is 
essential for cell-
traversal activity. 
 
SPECT2 has 
been suggested 
to mediate host 
cell membrane 
rupture through 
the pore forming 
activity of a 
MACPF 
(membrane 
attack complex/ 
perforin) related 
domain. 
SPECT2-disrupted P. berghei, (like 
SPECT1): 
-infected HepG2 (hepatoma cell line) 
cells in a similar way to WT P. berghei. 
-lost cell-traversal ability in vitro. 
-showed a reduced liver infectivity in 
rats, compared to WT P. berghei. 
Disrupted and WT parasites had the 
same capacity of infection in Kupffer-
cell depleted rats. 
 
(249) 
RP-L3 Ribosomal 
Protein L3 
Expressed in 
liver stages 
Unknown In mice immunised with P. yoelii 
sporozoites (irradiated or in 
combination with chloroquine 
prophylaxis), CD8+ T cells targeted a 
peptide from RP-L3. 
(250) 
HT Hexose 
Transporter 
Expressed in 
sporozoites 
and liver-
stages (in the 
PVM). 
Uptake of host 
hexoses such as 
fructose or 
glucose by the 
parasite. 
-Liver development was inhibited using 
a D-glucose-derived specific inhibitor. 
-Sporozoites retained motility in the 
absence of D-glucose. 
 
(251) 
(252) 
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Pre-erythrocityc antigens 
 
Name 
Localization 
 
Function 
 
Details 
 
TRAP/ 
SSP2 
Thrombospon
din-related 
Anonymous 
Protein/ 
Sporozoite 
Surface 
Protein 2 
 
Located in 
micronemes 
and on the 
surface of 
sporozoites, 
and in liver 
stages. 
Involved in 
invasion of salivary 
glands and 
hepatocytes. 
 
Essential for in 
vitro gliding 
motility. 
 
TRAP binds 
HPSGs on 
hepatocyte surface 
(through adhesion 
domains) and is 
connected to 
parasite 
cytoskeleton 
(through a 
cytoplasmic 
domain which 
interacts with actin 
binding proteins). 
-Sera against TRAP reduce sporozoite 
invasion and development in primary 
human liver cells. 
-Immunisation with P. yoelii TRAP and CSP, 
elicited complete protection against P. 
yoelii. 
-Antibodies and T cell responses against 
TRAP have been detected in volunteers 
protected through immunisation with 
irradiated sporozoites. 
-TRAP has been included in a leading 
malaria vaccine: ChAd63 MVA ME-TRAP, 
which has been shown to generate high 
levels of T-cell responses, delay to the 
development of clinical disease and 
protection. 
 
TRAP-disrupted P. berghei sporozoites: 
-showed reduced infectivity of mosquito 
salivary glands. 
-generated blood infection in rats, but with a 
delay compared to WT. 
-lost in vitro gliding motility 
(253) 
(225) 
(34) 
(254) 
(255) 
(256) 
(257) 
(258) 
CSP Circum- 
sporozoite 
protein 
Located in 
micronemes 
and on the 
surface of 
sporozoites 
CSP is involved in 
sporozoite 
formation within 
oocyst and 
mediates 
sporozoite 
attachment to 
hepatocytes and 
invasion. 
 
 
 
In CS-disrupted P. berghei oocysts, 
sporozoite formation showed 
a drastically reduction compared to WT. 
 
Monoclonal antibodies against CSP 
prevented P. berghei infection in mice and 
in vitro invasion (WI38 cells). 
 
CSP is the target of the most advanced 
malaria vaccine (RTS,S / AS01), which has 
shown a protection of 30-50% and induces 
high antibody titers and moderate cellular 
responses. 
 
CS-disrupted P. berghei sporozoites: 
-showed a drastically reduced capacity to 
egress from oocyts. 
-decrease on the attachment to HepG2 
surface*. 
-lost the capacity to infect rats*. 
(*using midgut sporozoites) 
(259) 
(260) 
(261)  
(262) 
(192) 
(191) 
(263) 
(264) 
 
 
Table 2.1. Pre-erythrocytic antigens tested with ISI assay in this chapter. 
Each row includes available information of each antigen about 
localization, function and other data related to immune response. 
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2.2 Results 
 
2.2.1 Mouse samples 
 
2.2.1.1 CS and TRAP 
 
The first samples tested with the flow cytometry optimised ISI protocol were sera 
obtained from mice vaccinated with CS and TRAP expressing vaccines. Samples from 
three different studies were tested, where mice had been immunised with 107 or 108 iu 
AdCh63 followed at least 6 weeks later by 106 or 107 pfu of MVA. Serum samples were 
tested at a final concentration of 10, 5 or 2%.  
 
 
Figure 2.1. BALB/c mice were immunised with 107  AdCh63 CS and 106 MVA CS 8 
weeks apart and serum collected 4 weeks after MVA vaccination. Serum 
samples were tested at 2 and 10% serum dilution and Huh7 cells infected with P. 
falciparum CSP P. berghei sporozoites in the presence of serum samples (A: 
black dots) or naive sera (A: grey bars). Results are expressed as the % 
Infection blocked, taking infectivity in the absence of serum as a reference. The 
line at 30% (A) indicates the threshold level for positive responses. Correlation 
between % Infection blocked and ELISA-CS is shown at 2% (B1) and 10% (B2) 
serum dilution. Data (B1, B2) was analysed with: nonparametric Spearman 
correlation test (r); linear regression (R2; p-value from F test: is the slope 
significantly different than zero?). 
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Chimeric P. berghei parasites expressing the P. falciparum protein (CSP or 
TRAP) were mixed with each serum sample and added to hepatoma cell line Huh7, 
which had been plated approximately 8 hours prior to infection. Tests were performed 
in duplicate or triplicate. Cultures were incubated at 37ºC for 24-28 hours prior to 
sample acquisition on the flow cytometer to determine the percentage of infected cells. 
Results are shown in the three figures: Figure 2.1 (BALB/c - CS), Figure 2.2 (C57BL/6 
and CD1 -TRAP) and Figure 2.3 (BALB/c - CS and TRAP). The percentage of infection 
blocked (percentage of infection avoided in the presence of serum) has been plotted for 
each serum dilution used. CS samples showed a positive concentration-dependent 
blocking response [Figure 2.1.A, Figure 2.3.A]. BALB/c mice vaccinated against CS 
with a higher dose of ChAd63 and MVA [Figure 2.3.A] showed higher blocking 
responses (82% Infection blocked, with 2% serum dilution), than those that received 
the lower doses of vaccine [Figure 2.1.A] (50% Infection blocked, with 2% serum 
dilution). 
 
 
Figure 2.2. C57BL/6 and CD1 mice, CS samples. Mice were immunised with 108  
AdCh63 and 106 MVA, both vectors encoding ME-TRAP and administered 7 
(C57BL/6) or 8 (CD1) weeks apart. Serum was collected one week after MVA 
vaccination. Each serum sample was tested in triplicates and at two 
concentrations, 2 and 10% (final serum volume). P. falciparum TRAP P. berghei 
sporozoites were employed to infect Huh7 cells. The % Infection blocked has 
been plotted in A), where each dot (black-C57BL/6, blue-CD1) represents an 
individual mouse. The line at 30% indicates the threshold above which blocking 
is considered positive. B) The graph shows the correlation between % Infection 
blocked and LIPS data, data was analysed with a nonparametric Spearman 
correlation test (r); linear regression (R2; p-value from F test: is the slope 
significantly different than zero?). 
 
C57BL/6 and CD1 mouse strains were tested for blocking capacity of antibodies 
after ME-TRAP vaccination. It was possible to detect positive responses at 10% 
dilution for CD1 mice, but not for C57BL/6 [Figure 2.2.A].  
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Figure 2.3 shows the blocking obtained with serum from BALB/c mice vaccinated 
against CS [Figure 2.3.A] or TRAP [Figure 2.3.B]. Both antigens elicited strong blocking 
responses, higher in the case of CS (at 2% serum dilution: CS generated 82% of 
blocking and TRAP, 69%). 
 
 
Figure 2.3. BALB/c mice were immunised with 108 iu AdCh63 followed 8 weeks 
later by 107 pfu MVA, expressing either CS (A) or TRAP (B). Serum samples were 
taken 8 to 14 days after the last vaccination and each sample tested in 
duplicates and at three dilutions: 2, 5 and 10% serum. Transgenic P. berghei 
sporozoites (PfCS Pb in A and PfTRAP Pb in B) and serum were added to Huh7 
cells. In both graphs, each dot represents an individual mouse and the blocking 
effect (non-specific background effect) of naive serum is shown as bars. 
 
 
To determine whether the level of infection blocked is due to the amount of 
antigen specific antibodies, the level of % Infection blocked was compared to LIPS 
(Luminescence ImmunoPrecipitation System) or ELISA values. While ISI assay is a 
measurement of antibody functionality, LIPS and ELISA give information about 
antibody concentration. Comparing ISI assays with other studies may give an idea of 
the relative effect of antibody concentration on the blocking of sporozoite infection and 
allow appreciation of the different information obtained by each assay. In Figure 2.1, 
%Infection blocked at 2% (B1) and 10% (B2) serum dilution was plotted against ELISA 
values. Although samples with lower ELISA titres tend to have a smaller blocking 
effect, there was not a strong correlation between the two values, most likely due to the 
small number of samples tested. In Figure 2.2, the regression line for %Infection 
blocked against LIPS values had a slope significantly different than zero (linear 
regression), but the correlation between the two parameters was not statistically 
  
 79 
significant (Spearman test). Unfortunately, LIPS / ELISA data was not available for 
samples used in Figure 2.3 to enable a correlation analysis on a larger data set. 
The experiments described confirmed that, using the optimised flow cytometry 
based ISI assay, it is possible to detect a reduction on the rate of infection with the 
addition of post-vaccination serum samples. These first results emphasise the 
importance of the serum dilution employed in the ISI assay, the effect of the vaccination 
dose on the antibody responses, the influence of using a particular mouse strain on the 
antibody responses, and support (with the trends found between LIPS and ELISA 
assays and % Infection blocked) the search for possible correlations between ISI and 
other antibody assays in future studies.  
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2.2.1.2 Comparing candidates: CelTOS, LSA1, LSA3, LSAP1, LSAP2, UIS3, 
ETRAMP5 and Falstatin. 
 
Eight pre-erythrocytic P. falciparum antigens (CeLTOS, LSA1, LSA3, LSAP1, 
LSAP2, ETRAMP5 and Falstatin) were studied as potential candidates to be included 
in a malaria vaccine. Immunogenicity and protective efficacy for each candidate were 
evaluated in BALB/c mice after vaccination with ChAd63 and MVA vaccines expressing 
each antigen (190). The humoral immune responses were analyzed with LIPS assay 
and used in this study to determine the capacity to inhibit sporozoite invasion of liver 
cells.  
Mice were immunised against a P. falciparum candidate with 108 iu ChAd63, 
followed by 106 or 107 pfu MVA eight weeks later, with serum collected two weeks after 
the last vaccination. Independent experiments testing serum samples from mice 
vaccinated against each candidate in combination with the correspondent transgenic 
parasite were performed in the standard experimental set-up. Monoclonal antibody 
against P. berghei CS (3D11) was utilised as a positive control in each experiment 
(data not shown in this chapter, but chapter 1 includes Figure 1.8 showing the 
%Infection blocked with different concentrations of this monoclonal antibody). BALB/c 
naive mouse serum was used as a negative control, to determine the effect of non-
specific blocking. Due to the high non-specific blocking observed with naive sera, a 
threshold was established where only blocking effect was considered positive when at 
least 30% of the sporozoite infectivity was blocked. 
Serum samples from two different MVA vaccination doses (106  or 107 MVA) were 
tested and each sample was analysed at 2% and 10% serum dilution. Results are 
shown in Figure 2.4. Almost no blocking effect was detected at 2% serum dilution 
[Figure 2.4. A1, A2], therefore the serum concentration was increased to 10% [Figure 
2.4. B1, B2] to detect positive blocking effects and find differences between antigens. 
The MVA dose, had an effect on the antibody responses detected by ISI, which were 
higher when mice were vaccinated with 107 MVA instead of 106 MVA [Figure 2.4. B1, 
B2]. The candidate antigen which showed the highest blocking effect was CelTOS, with 
an inhibition of almost 70% [Figure 2.4. B2] in mice vaccinated with 107 MVA and at 
10% serum dilution. In the same conditions, LSAP1 reached a percentage of infection 
blocked of 50%, but the rest of the candidates showed mean blocking values below the 
30% threshold [Figure 2.4. B2]. CelTOS showed a slightly higher blocking response 
than the other candidates at 2% serum dilution and 107 MVA vaccination dose [Figure 
2.4. A2] and at 10% for 106 MVA [Figure 2.4. B1], supporting the idea that antibodies 
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generated against this antigen seem to have a higher capacity to block the sporozoite 
infection compared to the other antigens. 
 
Figure 2.4. Percentage of infection blocked by serum samples against different 
P. falciparum antigens. Each antigen (LSAP2, Falstatin, LSAP1, LSA2, CelTOS, 
LSA1 and UIS3) was tested independently using P. berghei sporozoites 
expressing the P. falciparum antigen of interest. BALB/c mice were vaccinated 
with prime-boost viral vector regimes, 108 iu ChAd63 followed by 106 pfu MVA 
(A1, B1) or 107 pfu MVA (A2, B2). Serum samples were taken two weeks after 
MVA vaccination and added at 2% (A1, A2) or 10% (B1, B2) serum dilution, with 
the appropriate transgenic parasite, to Huh7 cells. The results from the ISI assay 
are presented as percentage of infection blocked (referred to the infectivity in 
the absence of serum), each dot is the average value of duplicates or triplicates 
and represents an individual mouse, horizontal lines show the mean value 
response of each group and grey bars represent naive serum mean response. 
Data was analysed with Kruskal-Wallis test, Dunn’s multiple comparisons test 
(p-values below 0.3 are included in the graph). 
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In Figure 2.4, each antigen was assessed in an independent experiments (one 
per antigen) with data combined for presentation and statistical analysis (Kruskal-
Wallis test, Dunn’s multiple comparisons test) to compare mean blocking values 
between different antigens. It is essential to bear in mind that the values obtained in 
each column have been obtained using different P. berghei chimeric parasites, which 
raises concerns about the ability to compare antigens, so it is important to be cautious 
considering the p-values obtained. The data showed for each candidate was obtained 
using the serum samples of mice vaccinated against a P. falciparum antigen but tested 
against a P. berghei chimeric parasite expressing both the P. berghei and P. 
falciparum protein (where a homolog exists in both species). The percentage of 
infection blocked by each sample is referred to the infectivity achieved in the absence 
of serum. The presence of a P. falciparum protein on the P. berghei parasite could 
cause differences in parasite infectivity. Nevertheless, each transgenic P. berghei 
should conserve all of its functional capabilities, as no protein has been removed from 
the parasite. The additional P. falciparum protein could support the function of an 
ortholog P. berghei protein or add a new function if no equivalent protein was present 
in P. berghei. The percentage of infected Huh7 cells (in the absence of serum), 
measured in the different experiments, varied between 1.5 to 4.5% (data not shown). 
However, this variability is probably more related to the number of sporozoites added, 
to the time of readout or to the health and viability of the sporozoites at the moment of 
infection, rather than to the kind of transgenic parasite used. In all experiments, 1 μ
g/mL of monoclonal antibody against P. berghei CSP (3D11) was used as a positive 
control and showed a consistent percentage of infection blocked (about 60%) and 
would therefore suggest all parasites had similar rates of infectivity and ability to be 
blocked were all behaving similarly and there is a true difference between the blocking 
effect on different P. falciparum antigens. 
 
IFAT (Immunofluorescence antibody test) 
To gain a better understanding of the antibody responses in terms of the ability of 
serum Ab to bind to sporozoites surface proteins, IFAT (Immunofluorescence antibody 
test) was performed for each antigen with the different vaccination doses and dilutions 
employed in ISI assay. IFAT is an assay based on the same principle as an ELISA, 
with the advantages of presenting the antigens in their native conformation and not 
needing to purify the antigen; but with some disadvantages, like the difficulty in 
quantifying the antigen-antibody interaction. P. berghei sporozoites expressing the 
relevant P. falciparum antigen were stained with the corresponding post-vaccination 
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serum (2% or 10% dilution) and bound antibody detected using a secondary antibody 
(goat anti-mouse Ig-G Alexa Fluor 488, green). Sporozoite nuclear DNA was stained 
with Hoechst-33342. In an attempt to compare the levels of antibody binding, green 
signal was recorded for 7 seconds and blue signal for 3-4 seconds with adjusting 
brightness and contrast occurring in the same proportion, to allow comparison between 
different images. Maximum signal was also always modified in the same proportion, but 
the minimum signal (background signal) was modified differently in a few images. If it 
was not possible to detect sporozoites in the image, the minimum signal was slightly 
reduced (removing less background than in the rest of the images), which has been 
stated in the figures as *bl [Figure.2.6]. If the image had a very high minimum signal 
(very high background), the minimum signal was increased to achieve a better contrast 
between the sporozoite signal and the background (stated as *br [Figure 2.5, Figure 
2.6]). Blue images were modified to obtain the best image possible for each case, as 
the purpose of the nuclear stain was primarily to indicate location of sporozoites on the 
slide. Merged images (which combine signals from green and blue channels) and 
bright field images are shown in Figure 2.5 (sera from vaccination dose: 108 ChAd63, 
107 MVA) and Figure 2.6 (sera from vaccination dose: 108 ChAd63, 106 MVA).  
With this technique it was possible to collect interesting qualitative information, 
but it is essential to take into account its limitations and be cautious when comparing 
antigens. Sporozoites were obtained from the mosquito salivary glands, and even 
when careful dissections were performed, it was extremely hard to avoid contamination 
with other small particles from the mosquito. In addition, the sporozoites were fixed on 
a slide on the day of dissection and were kept on PBS (at 4ºC), in some cases for 
months. It is understandable that contamination and possible deterioration, could have 
affected each slide differently and had an effect on the image acquired (possibly 
affecting the amount of background signal or sporozoite quality). However, in spite of 
these drawbacks, it is still possible to obtain valuable information with IFAT.  
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Figure 2.5. IFAT: post-vaccination serum 108 ChAd63, 107 MVA with corresponding (Pf 
antigen) Pb. Sporozoites fixed on slides were prepared for each strain and stained with 
2% (2nd column) and 10% (4th column) serum dilution. Bright field images (3rd and 5th 
columns) and composite images (merged of green and blue colour, 2nd and third 
columns) are presented. Green signal was collected during 7 seconds, and all images 
were adjusted for brightness and contrast in the same proportion. Maximum signal was 
always modified in the same proportion, but when it is stated (*br) minimum signal was 
decreased because the image presented a high green background. *br: higher amount 
of background removed than in the rest of the images.  
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Figure 2.6. IFAT: post-vaccination serum 108 ChAd63, 106 MVA with corresponding (Pf 
antigen) Pb. Sporozoites fixed on slides were prepared for each candidate and stained 
with 2% (2nd column) and 10% (4th column) serum dilution. Bright field images (3rd and 
5th columns) and composite images (merged of green and blue colour, 2nd and third 
columns) are presented. Green signal was collected during 7 seconds and blue signal 
for 2-3 seconds. All green images were adjusted for brightness and contrast in the same 
proportion. Maximum signal was always modified in the same proportion except, 
whenever is stated the background signal was either increased (if it was not possible to 
detect stained sporozoites) or decreased (if the image presented a high green 
background). *br: higher amount of background removed than in the rest of the images, 
*bl: less background removed than in other images. Green exposition was reduced in 
LSAP2 and UIS3 (4th column) because the background signal was so high, that the 
image obtained after 7 seconds was saturated. g1: green signal collected during 1 
second, g4: green signal recorded during 4 seconds. 
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In general terms, the staining produced by post-vaccination serum with the 
smaller MVA dose [Figure 2.6] was less intense than observed with the higher MVA 
dose [Figure 2.5]. This supports what has been also observed with ISI assay: a higher 
MVA dose generates a higher antibody response. Interestingly, Pf CelTOS Pb 
sporozoites were weakly stained by post-vaccination serum, even when serum from 
the highest vaccination dose was used at 10% dilution [Figure 2.5. First row, 3rd 
column], while serum against CelTOS showed the larger inhibition capacity in ISI 
assay. In contrast, UIS3, showed one of the best staining (high signal recorded and 
sporozoites uniformly stained) for the two sera and both concentrations tested [Figure 
2.5 and 2.6, 7th row]. LSA1, LSAP1 and Falstatin also showed a high signal at 10% 
serum dilution and higher MVA dose [Figure 2.5]. LSA1 was not expected to present 
IFAT staining since it is only expressed in liver stages. The signal detected here [Figure 
2.5] could be due to cross-reaction with other sporozoite proteins, or to a different 
pattern of LSA1 expression in the transgenic parasite where LSA1 is expressed under 
Pb UIS4 promoter. 
The additional P. falciparum protein may present different levels in the P. berghei 
chimeric parasite (all the falciparum antigens are expressed under the same promoter, 
but the complexity of the protein could influence the levels of expression and protein 
stability would also have an effect on the frequency of degradation), and also, a higher 
presence of the protein could generate more opportunities for interaction with 
antibodies. Nevertheless, this could also have an effect on the inhibition of the 
sporozoite invasion, because there would be a higher number of interactions antigen-
antibody preventing the normal function of the falciparum protein. One alternative 
explanation is that not all the P. falciparum proteins may be equally accessible to 
specific antibodies in the serum, but as the sporozoites are fixed, internal proteins 
become available to Ab binding.  
ISI assay has proved to be concentration dependent. Therefore, we could expect 
that CelTOS (the antigen that elicited the highest blocking response) would show an 
intense IFAT signal, indicating high antibody titer. However, according to that IFAT, 
there was a higher antigen-antibody interaction with other candidates that did not 
shown a blocking effect. There could be two possible explanations for this finding. On 
one side, proteins that are accessible to antibodies on fixed sporozoites (which present 
holes on their membranes), may not be accessible in live sporozoites. On the other 
side, it is possible that only antibodies against a protein which has a role on hepatocyte 
infectivity may play a role on the inhibition of sporozoite invasion. All the candidates 
tested are pre-erythrocytic antigens expressed in sporozoite and/or liver stages. 
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Information about their function is only available for some of the candidates. As it has 
been described in the introduction, UIS3 and LSA1 function has been related with 
development within the hepatocyte, while CelTOS is a protein involved in the 
sporozoite motility. Diverse protein functions could explain differences seen in the ISI 
assay. This assay evaluates antibody capacity to avoid a particular step of the malaria 
infection: sporozoite invasion. Functionality of antibodies targeting proteins whose 
function is related to other malaria stage, would require an alternative assays. 
Nevertheless, antigens that have not been associated with a function in the ISI assay 
may act as negative controls and help to understand how the assay works. It is 
important to bear in mind that no definitive conclusions can be stated about protein 
functionality using P. berghei chimeric sporozoites expressing P. falciparum antigens, 
since P. falciparum proteins are not being expressed under their normal promoter to 
their usual levels or in their normal context. P. falciparum sporozoites would be the 
appropriate model to use in order to gain a better understanding on how protein 
functionality may be interfered by antibodies. 
 
LIPS (Luminescence Immunoprecipitation System)  
In the absence of purified protein, it is possible to measure antigen specific 
antibodies by the LIPS assay (265) where antibodies are measured based on the 
ability to bind antigen fused to a reporter gene (Ruc, renilla luciferase). Cell lysates 
from HEK 293 transfected cells (human embryonic kidney cells) are used in the assay, 
avoiding the need to purify soluble antigen. Figure 2.7 has been plotted from data 
provided by R. Longley. It is not possible to compare between antigens because there 
is no way to normalise for the difference between constructs, and, for this reason a 
statistical analysis comparing between groups has not been included. Nevertheless, it 
is interesting to have a rough idea of the response elicited by the different antigens. 
UIS3 generated one of the highest LIPS signals [Figure 2.7. A, B] which corresponds 
with the IFAT response found. LSA3 and CelTOS which did not show a good IFAT 
signal, have LIPS responses at the lower end of the spectrum [Figure 2.7. A,B]. 
Falstatin, LSAP2, and LSA1 with high and medium LIPS values [Figure 2.7. A,B], gave 
better than average IFAT signals [Figure 2.5 and 2.6]. Possibly the highest discrepancy 
between IFAT and LIPS is for LSAP1 which showed low LIPS signal [Figure 2.7. A,B] 
although it showed one of the best IFAT signal [Figure 2.5 and 2.6]. Different antibody 
assays emphasise diverse aspects of the antibody response, like concentration, avidity 
or functionality. The varied information obtained with ISI, IFAT and LIPS supports the 
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importance of not limiting the analysis of antibody responses to only one type of 
experiment. 
 
 
Figure 2.7. LIPS assay. These graphs have been plotted with LIPS data 
generated by Rhea Longley [Rhea Londgley, DPhil thesis]. LIPS (Luminescence 
immunoprecipitation system) allows the detection of antigen-specific antibodies 
without the need to purify the antigen. A cellular lysate is obtained from cultures 
of mammalian cells expressing the antigen of interest fused to a reporter gene 
(Ruc, Renilla luciferase). This lysate is mixed with the serum samples and added 
to a plate coated with A/G beads. Fused protein bound to antibody is retained on 
the beads, while non-bound antigen is washed away. Adding luciferase 
substrate, a light signal proportional to the amount of antigen bound to antibody 
can be recorded. Results are expressed as the log of luminescence (light units). 
Data for sera obtained with 108 ChAd63, 106 MVA is presented in A and with 108 
ChAd63, 107 MVA in B. 
 
 
P. berghei effect 
 
To determine the effect of cross-reactive Plasmodium berghei proteins present 
on the sporozoites the ISI assay was performed with P. berghei sporozoites expressing 
only GFP-luciferase and each post-vaccination sample from mice vaccinated with 108 
ChAd63, 107 MVA (high MVA dose) and 10% dilution. The results, shown in Figure 2.8, 
indicate a blocking effect of 54% of CelTOS and 67% of LSAP1. There is a high degree 
of homology between P. berghei and P. falciparum CelTOS ortholog (187), so it is not 
surprising that antibodies against falciparum CelTOS may elicit a blocking effect 
against P. berghei. On the contrary, a LSAP1 homolog has not been identified in P. 
berghei. One possible explanation for this result could be the presence of factors in the 
serum responsible of an antibody-independent blocking response. Alternatively, 
antibodies elicited through vaccination against P. falciparum LSAP1 may cross-react 
with other P. berghei proteins with similar epitopes.  
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In Figure 2.8, the spread of the data seems to be higher than in the equivalent 
figure where each serum was tested with the corresponding chimeric parasite [Figure 
2.4. B2]. A possible way to justify this is that serum against vaccination is polyclonal 
and generated differently in each mouse. The serum from a particular mouse targets a 
particular set of epitopes, generating different cross-reactivity with diverse P. berghei 
proteins that may be especially noticeable in the absence of the targeted falciparum 
protein. 
 
Figure 2.8. P. berghei effect. ISI assay was performed employing P. berghei 
parasites that do not express a P. falciparum protein. The % Infection blocked 
measured for each mouse sample is represented with dots and horizontal lines 
indicate the mean value of the group. The horizontal line at 30% indicates a 
positive cut-off with responses under this level considered a non-specific 
background effect. All serum samples were tested at 10% serum dilution and are 
from mice vaccinated with 108 ChAd63, 107 MVA. Data was analysed with 
Kruskal-Wallis test, Dunn’s multiple comparisons test. 
 
 
IFAT (Immunofluorescence antibody test) 
IFAT staining was also performed with P. berghei sporozoites (that did not 
express P. falciparum proteins), for each post-vaccination serum. Sporozoites stained 
with anti-LSAP1 serum showed high green signal [Figure 2.9], supporting the 
mentioned suggestion that post-vaccination serum against LSAP1 (which does not 
have a berghei ortholog) could cross-react with other P. berghei proteins. anti-Falstatin 
and anti-LSA1 serum stained sporozoites also showed strong IFAT signal [Figure 2.9] 
(but these sera did not had a significant blocking response [Figure 2.8]). P. berghei has 
a Falstatin ortholog, which justifies the observed strong IFAT signal, but no ortholog 
has been identified for LSA1. Anti-UIS3 serum presented a high IFAT signal for PfUIS3 
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Pb sporozoites [Figure 2.5, Figure 2.6] and a medium-high IFAT signal with Pb 
sporozoites [Figure 2.9], consistently with the fact that UIS3 has a P. berghei ortholog. 
Low green signals were recorded for sporozoites stained with serum from mice 
vaccinated LSA3, LSAP2 and ETRAMP5 [Figure 2.9], but none of them have P. 
berghei homologs. CelTOS, in spite of having a P. berghei ortholog, also showed weak 
staining [Figure 2.9], as happened when Pf CelTOS Pb was employed [Figure 2.5, 2.6] 
(probably due to a low antibody titer or poor protein stability). 
 
Figure 2.9. IFAT: post-
vaccination serum 108 ChAd63, 
107 MVA and P. berghei. 
Sporozoites were stained with 
10% serum dilution. Bright field 
images (3rd column) and 
composite images (merged of 
green and blue colour, 2nd 
column) are presented. Green 
signal was recorded during 7 
seconds and blue signal for 2-3 
seconds. All green images were 
adjusted for brightness and 
contrast in the same proportion. 
Maximum signal was always 
modified in the same 
proportion, but whenever is 
stated (*br) the background 
signal was decreased (because 
the image presented a high 
green background). *br: higher 
amount of background removed 
than in the rest of the images. 
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2.2.1.3 Comparing candidates: SPECT1, SPECT2, RP-L3 and HT 
 
A second group of pre-erythrocytic P. falciparum candidate malaria antigens and 
corresponding chimeric P. berghei parasites were generated and evaluated by Ahmed 
Salman. BALB/c and CD1 mice were vaccinated with 108 ChAd63 and 107 MVA (with 
an interval of 8 weeks), both vectors expressing one of the pre-erythrocytic candidates: 
SPECT1, SPECT2, RP-L3 or HT. Serum samples were collected between 8 to 14 days 
after MVA boost and tested in the ISI assay at 2 and 10% serum dilution. 
The ISI assay was the first experiment performed to evaluate antibody responses 
generated by these candidate vaccines and it took place on the same day of challenge. 
Sporozoite availability is the limiting factor for the ISI assay. Each mouse is typically 
challenged with 1000 sporozoites, while to analyse each single serum sample at least 
30000 sporozoites (duplicates, 15000x2) are required per sample. Performing the 
assay on the same day of the challenged proved to be a good way to optimise the 
insectary resources and enabled the use of left-over sporozoites. This particular 
screening study of four candidates was the only occasion when ISI assay took place on 
the same day of challenge (as the rest of the serum samples tested in this thesis 
belonged to studies that were carried out months before the ISI assay was optimised). 
Nevertheless, it proved to be an efficient way of performing both experiments in the 
future, provided that two researchers are available on the day. 
 
Figure 2.10. Vaccination, challenge and ISI assay. Mice were vaccinated with a 
prime-boost viral vector regimen. Serum was collected and frozen one or two 
weeks after the last vaccination dose. Sporozoites were obtained and used to 
both challenge vaccinated mice and for the ISI assay. 
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The percentages of infection blocked by serum against each of the four antigens 
from the screening study and CS are presented in Figure.2.11. CS was included to 
compare its blocking effect with the other candidates, since it was obtained by the 
same researcher in the same period of time as the other samples. In the previous set 
of P. falciparum candidates tested (2.2.2) very little blocking was detected with 2% 
dilution [Figure 2.4.A2], but here it was necessary to use this dilution to observe 
differences between antigens [Figure 2.11.A] (at 10% serum dilution, all samples 
inhibited almost 100% of the infection [Figure 2.11.B]). The fact that with this second 
group of antigens a much higher blocking response was observed, may be due to 
antibody levels or to the particular function of the antigens tested. However, the large 
difference between both groups could be more likely related with the fact that the 
serum samples employed for the first study of P. falciparum antigens (2.2.2) had been 
stored for about two years and frozen and thawed a number of times, which could 
decrease the blocking capacity (due to degradation or lost of functional conformation of 
the antibodies). 
 
 Figure 2.11. Percentage of infection blocked by post-vaccination serum 
samples against different P. falciparum antigens. Each serum was tested 
independently using P. berghei parasite expressing the corresponding P. 
falciparum protein. BALB/c (black in the graph) and CD1 (blue) mice were 
vaccinated with 108 ChAd63 followed by 107 MVA. Serum samples were collected 
8-14 days after MVA vaccination and were added to Huh7 cells at 2% (A) or 10% 
(B) serum dilution, with the appropriate transgenic parasite. The results from the 
ISI assay are presented as percentage of infection blocked (referred to the 
infectivity in the absence of serum): each point (average of duplicate tests) 
represents an individual mouse, horizontal lines show the mean per group and 
grey bars represent naive serum mean response. Horizontal line at 30% 
Infection blocked indicate the threshold to consider a positive blocking effect. 
Data was analysed (BALB/c and CD1, separately) with a Kruskal-Wallis test, 
Dunn’s multiple comparisons test (p-values below 0.3 are included in the graph). 
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At 10% serum dilution all candidates blocked almost 100% of the sporozoite 
invasion [Figure 2.11.B]. At 2% serum dilution, blocking ranged from approximately 
20% to 100% [Figure 2.11.A]. The highest responses observed were with serum from 
SPECT1 (SP1, BALB/c mean: 87%) or CS (BALB/c mean: 82%) vaccinated mice, 
followed by moderately positive response from HT (BALB/c mean: 56%) and RP-L3 
(BALB/c mean: 43%) vaccinated mice.  SPECT2 did not show a positive response at 
2% dilution [Figure 2.11.A]. 
SPECT1 and SPECT2 are expressed in sporozoites and have been associated 
with cell-traversal ability (248,249). Interestingly, serum from SPECT1 vaccinated mice 
displayed inhibition of a similar magnitude to CS serum samples. HT, expressed on 
sporozoites and during the liver-stage, is involved in the uptake of D-glucose, and sera 
against this protein produced a positive blocking response (251,252).  RP-L3 is mainly 
expressed in liver-stages (250) and its function is unknown. RP-L3 blocking response 
is not as good as CS or SPECT1, but having a detectable antibody response at 2% 
serum dilution could be an indicator of good antibody function.  
Samples from CD1 mice were tested for SPECT1, SPECT2 and HT antigens. 
CD1 mean blocking responses were nearly the same level as obtained with serum from 
BALB/c against each antigen [Figure 2.11.A]. CD1 are outbred mice, what could effect 
the overall magnitude of immune responses or the variability between mice, however 
vaccination elicited antibodies with similar functionalities in CD1 and BALB/c mice. 
 
IFAT (Immunofluorescence antibody test) 
 
As in the previous study (2.2.2), IFAT test was performed to gain more 
information about antibody responses.  At 2% [Figure 2.12. 2nd column] serum dilution, 
SPECT2 showed the highest signal, RP-L3 and SPECT1 had moderate binding and HT 
binding was not detected.  
SPECT2 seems to have a higher antibody titre than SPECT1 as determined by 
IFAT, but only SPECT1 showed a positive blocking capacity at 2% serum dilution. 
Antibodies generated against SPECT1 might be more functionally efficient, even at a 
lower antibody concentration, than those against SPECT2. It is possible that although 
both proteins have been associated with the same function (cell-traversal), they do not 
have the same relative importance in the process and antibodies bound to these 
antigens limit sporozoite motility to differing extents. 
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Figure 2.12. IFAT: post-vaccination serum 108 ChAd63, 107 MVA with 
corresponding (Pf antigen) Pb. Sporozoites were stained with 2% (2nd column) 
and 10% (4th column) serum dilution. Bright field images (3rd and 5th columns) 
and composite images (merged of green and blue color, 2nd and third columns) 
are presented. Green signal was collected during 7 seconds and blue signal for 
1 to 4 seconds. All green images were adjusted for brightness and contrast in 
the same proportion. 
 
 
P. berghei effect  
ISI assay was also performed with each serum (2% dilution) with P. berghei 
sporozoites that did not express any P. falciparum protein. A positive effect (69% 
Infection blocked) was only detected for SPECT1 [Figure 2.13]. P. berghei and P. 
falciparum orthologs of SPECT1 share 45.6% of sequence identity (248). This data 
would suggest that antibodies generated against P. falciparum SPECT1 were able to 
bind P. berghei SPECT1 and reduce sporozoite infectivity. When using Pf SPECT1 Pb 
it was possible to detect an increase in blocking by about 20% [Figure 2.11], 
suggesting that although there is some cross-reactivity there is still an effect of anti-Pf 
SPECT1 vaccinated serum. 
SPECT2, HT and RP-L3 P. falciparum proteins all have P. berghei homologs. HT 
and RP-L3 had a blocking effect on sporozoite invasion with P. berghei parasite 
expressing the corresponding P. falciparum proteins [Figure 2.11. A], but not with 
control P. berghei parasites, indicating the blocking effect is through interaction with the 
transgenic P. falciparum proteins. 
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Figure 2.13. P. berghei effect. P. berghei parasites expressing GFP-luciferase 
were treated with different ChAd63-MVA P. falciparum post-vaccination serum 
(2% dilution). Serum samples were taken from mice immunised with 108 ChAd63, 
107 MVA. Due to the limited number of sporozoites available, serum samples 
from 4-6 mice vaccinated against the same P. falciparum antigen were mixed 
together and tested in triplicates (each dot represents one of this single 
triplicates and horizontal lines the mean value). Horizontal line at 30% indicates 
the positive threshold level. Data was analysed with a Kruskal-Wallis test, Dunn’s 
multiple comparisons test. 
 
To further analyse the effect of 
the cross-reactivity with P. berghei 
proteins, P. berghei sporozoites not 
expressing any P. falciparum protein 
were stained with 2% dilution of 
serum from each of the four P. 
falciparum antigen vaccinated mice. 
The staining observed was not strong 
for any antigen [Figure 2.14], although 
all of them have P. berghei orthologs. 
SPECT2 appeared to give a higher 
signal, supporting the idea that there 
is cross-reactivity between orthologs 
which could be influencing the ISI 
assay. Antibodies against P. 
falciparum SPECT1 may cross-react 
with P. berghei SPECT1 and impair 
sporozoite infectivity to a greater 
extent than a higher titre of SPECT2. 
 
  
Figure 2.14. IFAT: post-vaccination 
serum 108 ChAd63, 107 MVA and P. 
berghei. Sporozoites were stained with 
2% serum dilution. Bright field images 
(3rd column) and composite images 
(merged of green and blue colour, 2nd 
column) are presented. The green signal 
was recorded for 7 seconds and blue 
signal for 2-3 seconds. All green images 
were adjusted for brightness and 
contrast to the same proportion. 
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2.2.1.4 R21 study 
 
RTS,S, which is expected to be licensed in 2015 (currently in a phase III trial 
involving 16000 children), is the most advanced malaria candidate vaccine and has 
shown efficacy of 30-50% (266), (267).  RTS,S targets CSP (circumsporozoite protein, 
an abundant protein on the sporozoite surface) using a VLP (Virus Like Particle) 
comprised by two proteins (RTS and S). RTS,S , which is produced in S. cerevisiae, 
contains 189 amino acids from the CSP protein (including B and T cell epitopes) fused 
to HBsAg (Hepatitis B surface antigen) and HBsAg on its own (268). R21 has been 
designed to improve RTS,S immunogenicity and efficacy through increasing the ratio 
CSP:HBsAg present in the vaccine. R21 contains the same CSP regions as RTS 
(minus 14 aa which do not play a role in RTS) fused to HBsAg. R21 is produced in 
Picha pastoris without HBsAg co-expression, therefore the VLP is formed from only the 
CSP-HBsAg fusion protein and is composed of larger percentage of CSP compared to 
RTS,S . R21 was developed by Katharine Collins as part of her DPhil research project 
[Katharine Collins, DPhil thesis, University of Oxford, 2014] and provided serum 
samples for assessment with the ISI assay. 
Three experiments were performed using R21 post-vaccination serum samples. 
First, an experiment measuring the inhibition of sporozoite invasion detected using the 
P. falciparum CSP addition chimeric parasite (P. berghei parasite expressing P. 
berghei CSP and P. falciparum CSP) compared to the CSP replacement transgenic 
parasite (P. berghei parasite expressing P. falciparum CSP under the control of the P. 
berghei CSP promoter). In the second experiment, the effect on inhibition of sporozoite 
invasion of administering R21 with different adjuvants was determined and the third 
experiment compared the effect of vaccination with RTS,S and R21 formulated with 
AS01B . 
Experiments were carried out, as described previously, at final serum 
concentrations of 0.2, 2 and 10%.  0.2% serum dilution was selected, because these 
samples had shown antibody levels much higher (log ELISA endpoint titer: 4-7) than 
those found in prime-boost viral vector vaccinated mice (ELISA μg/mL: 0-100). Plates 
were centrifuged (6min, 1600rpm) to improve sporozoite infection and incubated at 37º 
for 24-28 hours. Samples were acquired on a flow cytometer, detecting infected cells 
with the GFP-luciferase expressed by the transgenic parasites. The data is presented 
as the percentage of infection blocked, the reduction in % of infected cells compared to 
when no serum was added. In %Infection blocked graphs, each dot represents an 
individual mouse and is the average of duplicate wells, while bars indicate the infection 
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blocked by BALB/c naive serum. Pre-vaccination data is not available for each mouse, 
but as they are genetically identical, naive serum has been used to have an idea of the 
non-specific background effect. Although in the three experiments, the percentage of 
infection blocked by the naive serum is very low or even negative (when the sporozoite 
infectivity was found to be higher in the presence of naive serum than in absence of 
serum), due to the variability of this effect and the fact that higher background values 
have been found in previous experiments, only values over 30% were considered 
positive.  
 
a) CS addition vs CS replacement  
 
In a pilot experiments with R21 samples and CS addition parasites, the 
percentage of infection blocked was lower than observed with ChAd-MVA vaccinated 
serum, in spite that R21 serum is known to have higher Ab titres. As this finding was in 
total contrast to the expected results, we wondered whether the presence of very high 
Ab titers cause the parasite to change its behaviour. With the aim of finding whether 
using the CS replacement parasite with R21 samples could overcome this different 
behaviour, serum dilutions of 0.2%, 2% and 10% were added with CS addition or 
replacement parasite to Huh7 cells. Sera samples were obtained from BALB/c mice 
immunised with 0.5 μg R21 given with Abisco adjuvant (12 μg). Mice received 2 
vaccinations with an interval of 8 weeks and serum was collected 3 weeks after the 
final vaccination. 
A higher percentage of infection blocked was achieved at every serum dilution 
when using the CS replacement parasite instead of CS addition [Figure 2.15]. A 
concentration dependent blocking of sporozoite invasion was observed using the 
replacement parasite [Figure 2.15.A1]. The blocking effect found with the addition 
parasite was lower, supposedly due to the presence of P. berghei CSP [Figure 
2.15.A2] which could still carry out the CSP function.  
For the CS replacement parasite, there was a trend to increased blocking with 
increased NANP IgG ELISA titer, with 2% and 0.2% serum dilution [Figure 2.15.B1]. 
With a serum dilution of 10% the ISI assay seems to be saturated and no differences in 
blocking capacities were observed between the different samples [Figure 2.15.B1]. For 
the CS addition parasite, no correlation was found with ELISA data [Figure 2.15.B2].   
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Figure 2.15. R21 samples: addition vs replacement CS transgenic. Serum 
samples from BALB/c mice vaccinated with two doses of 0.5 μg R21 formulated 
with Abisco adjuvant administered 8 weeks apart with serum collected 3 weeks 
after the last dose. Huh7 cells were infected with Pf CS replacement P. berghei 
(A1) or Pf CS addition P. berghei (A2) in the presence of 0.2, 2 or 10% post-
vaccination R21 serum (dots) or 0.2, 2 or 10% BALB/c naive serum (bars). The 
percentage of infection blocked by each serum is represented in A1 and A2.  B1 
and B2 show the correlation between the percentage of infection blocked and the 
ELISA (IgG NANP) endpoint titer for each sample. Data was analysed with a 
nonparametric Spearman correlation test (r); linear regression (R2; p-value from 
F test: is the slope significantly different than zero?). 
 
It is not clear why R21 samples failed to show a blocking effect as high as 
samples from prime-boost viral vector regimens when used in combination with the CS 
addition parasite. CS viral vector vaccines (CS ChAd63 and CS MVA), RTS,S and R21 
target P. falciparum CS protein. All these vaccines contain NANP repeats (tandem 
repeats of 4 aa located in the CSP central region), which constitute an 
immunodominant epitope for B cells. However, certain differences in the specific CSP 
regions included in the protein (viral vectors include the whole CSP protein except for 
some of the NANP repeats, while RTS,S and R21 contain 189 aa from the C terminalT 
region) could elicit antibodies against different CSP epitopes that might behave 
differently on blocking sporozoite invasion. The absence of a high blocking effect with 
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addition parasites could also be related to a high antibody concentration or avidity 
which could cause the release of CSP or an increase of the host-pathogen interactions.  
R21 vaccinated mice were challenged with CS addition parasites. Inhibition of 
sporozoite invasion in vivo should be easier to achieve than in vitro, as the serum is not 
diluted and the sporozoite need to travel through different tissues and cellular barriers 
before reaching the hepatocytes. Nevertheless, the same low blocking capacity 
observed in vitro with the addition parasite, could be happening in vivo. If this was the 
case, higher efficacy might be observed in mice challenged with the replacement 
parasite. 
 
b) R21 administered with different adjuvants 
 
To evaluate whether the adjuvant used in combination with R21 could have an 
effect on the sporozoite blocking capacity, post-vaccination serum from BALB/c mice 
vaccinated with 0.5 μg R21 without adjuvant or with one of the following adjuvants: 
Alhydrogel (85 μg), Abisco (12 μg), AddaVax (50 μL) or AddaVax and Abisco (50 μL 
and 12 μg, respectively) was assessed by ISI. Mice received 3 immunisations with a 3 
week interval and serum was collected 3 weeks after the last vaccination. 
R21 with Alhydrogel sera showed the lowest blocking activity: significantly less 
than Abisco at 0.2% and 2% serum volume and significantly less than AddaVax and 
AddaVax and Abisco at 10% [Figure 2.16. A1, A2, A3]. Abisco and AddaVax (together 
or on its own), or R21 in the absence of adjuvant were found to have similar capacity to 
block the sporozoite invasion [Figure 2.16. A1, A2, A3]. A significant correlation 
(Spearman test) was observed between the percentage of infection blocked values and 
the ELISA endpoint titer at all the serum dilutions tested [Figure 2.16. B1, B2, B3]. 
When these mice were challenged, mice vaccinated with R21 AddaVax showed a 
delay in time to 1% parasitaemia (compared to naive mice), while mice which received 
R21 Abisco were sterilely protected [Katharine Collins, DPhil Thesis]. Both groups of 
mice had similar antibody titres measured with ELISA. One possible explanation for the 
differences observed in protection between these two groups, could be that vaccination 
with Abisco elicited antibodies with a greater capacity to block the sporozoite invasion 
of hepatocytes (more functional antibodies). However, no significant differences were 
detected between Abisco and AddaVax with the ISI assay.  It was also found that R21 
+ Abisco vaccinated mice have a higher T cell response by ELISPOT (R21 Abisco 
generated a median group response of 211 SFC/106 splenocytes, while R21 AddaVax, 
only the half (96.5 SFC/106 splenocytes) [Katharine Collins, DPhil Thesis]. 
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Figure 2.16. R21 with different adjuvants. BALB/c mice were vaccinated with 3 
doses (3 weeks apart) of 0.5 μg R21 and serum was taken three weeks after the 
last dose. 5 groups of mice were tested according to the adjuvant given with 
R21: no adjuvant, Alhydrogel, Abisco, AddaVax or AddaVax and Abisco. Huh7 
cells were infected with Pf CS replacement P. berghei in a final serum 
concentration of 0.2, 2 or 10%. The results from the ISI assay are presented in 
A1, A2 and A3 (each dot represents a different mouse, and the bars represent 
naive serum) and its correlation with ELISA (IgG NANP) data on B1, B2 and B3. 
Serum samples and ELISA endpoint titres were provided by Katharine Collins, 
DPhil student. A1, A2 and A3 were analysed with Kruskal-Wallis test and Dunn’s 
multiple comparisons test. B1, B2 and B3 were analysed with nonparametric 
Spearman correlation test (r) and linear regression (R2; p-value from F test: is 
the slope significantly different than zero?). 
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The fact that no functional differences were found with the ISI assay, suggests 
that the differences in protection between these two adjuvants may be due to the 
different T cell responses. This example supports the importance of ISI assay for 
gaining a better understanding of the immune mechanisms working on a pre-
erythrocytic malaria vaccine. 
 
 
c) RTS,S vs R21 
 
To compare the ability of antibodies generated by R21 to inhibit sporozoite 
invasion with the blocking ability of antibodies generated by the most advanced malaria 
vaccine in development, RTS,S, BALB/c mice were vaccinated with 0.5, 1.6 or 5 μg of 
either RTS,S or R21 and serum tested in the ISI assay. Both vaccines were 
administered in combination with AS01B (50 μL) with two doses given with an interval 
of 8 weeks and serum taken 11 days after the last vaccination. 
There was no significant difference in the percentage of infection blocked 
achieved with the various groups of vaccinated mice, suggesting that R21 is as good 
as RTS,S at preventing infection of liver cells in this model. Antibodies from mice 
immunised with either vaccine (RTS,S or R21) were able to inhibit almost 100% of 
sporozoite invasion at very low serum concentrations (serum dilution of 2%) [Figure 
2.17.A2]. This is the highest level of blocking seen at this serum dilution compared to 
the other vaccines assessed in this model. It is possible that by diluting the serum 
below 0.2%, larger differences between doses or vaccines might be detected. 
However, it is probably not needed to dilute the serum more than 0.2%, as with this 
concentration was already possible to register a range of percentage infection blocked 
from 40 to 90% [Figure 2.17.A1]. Diluting the serum further would also increase the 
spread of the data. Probably, the most interesting information would be to know which 
antibodies continue to be more functional over time, collecting sera at later time points 
and testing them with the ISI assay. 
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Figure 2.17. R21 vs RTS,S. BALB/c mice were immunised with 0.5, 1.6 or 5 μg of 
either RTS,S or R21, with AS01B (50μL). Two doses were given with an interval of 8 
weeks and serum was collected 11 days after the last vaccination. Huh7 cells were 
infected with Pf CS replacement P. berghei in the presence of 0.2 or 2 % serum. A1 and 
A2 show ISI assay results for each vaccination group (dots represent each mouse 
sample and bars represent naive serum). B1 and B2 show the correlation of these data 
with ELISA (IgG NANP) values. C1 and C2 represent the correlation between the 
percentage of infection blocked and the time to develop 1% parasitaemia for each 
mouse. Serum samples, ELISA endpoint titer and time to develop 1% parasitaemia were 
provided by Katharine Collins (DPhil student). Data was analysed with Kruskal-Wallis 
test, Dunn’s multiple comparisons test (A1, A2); and nonparametric Spearman 
correlation test (r), linear regression (R2; p-value from F test: is the slope significantly 
different than zero?) (B1, B2, C1, C2). 
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There was a trend in the correlation with ELISA data, although not statistically 
significant (p=0.06, Spearman test) with 0.2% serum [Figure 2.17.B1]. The correlation 
was weaker in this experiment compared to the previous one (R21 with different 
adjuvants). One possible explanation may be that in the other experiment, the values of 
ELISA endpoint titres were more evenly spread along a range of two logs, while in the 
present experiment a high number of the samples had ELISA values spread within less 
than one log. The ELISA data only included the isotype IgG. Possibly, a stronger 
correlation between the ISI assay and antibody titres could be found if the ELISA 
antibody titres included all antibody isotypes. 
Percentage of infection blocked data were also plotted against the time that took 
to each mouse to develop 1% parasitaemia. Mice that did not develop parasitaemia by 
day 14 were considered to be protected, they appear in the graph at day 14, although 
no parasite infection was detected in these mice. The percentage of infection blocked 
correlated with the time to develop 1% parasitaemia excluding protected mice. A 
significant correlation was found for 2% samples [Figure 2.17.C2]. Nevertheless, this 
correlation must be considered with caution as the percentages of infection blocked 
measured are very close to each other and ISI assay is unlikely to be able to 
discriminate blocking effect differences of less than 10%. In these graphs including the 
time to 1% parasitaemia [Figure 2.17.C1, C2], it is interesting to note that some mice 
whose antibodies have a high capacity to inhibit sporozoite invasion developed 
parasitaemia, while mice with lower inhibition activity did not develop parasitaemia. 
These data would support that antibody-mediated inhibition of sporozoite invasion is 
not the only mechanism operating to provide protection in RTS,S or R21 vaccines. 
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2.2.2 Macaque samples 
 
2.2.2.1 TRAP 
 
Rhesus macaques were immunised with 5•107 iu/animal AdCh63 ME-TRAP 
followed 8 weeks later by 8•107 pfu/animal MVA ME-TRAP, and serum samples were 
collected three week after the MVA vaccination. ME is a construct fused to TRAP that 
includes CD4+ and CD8+ epitopes that belong to six pre-erythrocytic antigens: LSA1, 
CSP, STARP, LSA3, Exp1 and TRAP. These samples, kindly provided by Dr. 
Alexandra Spencer, were tested with the ISI assay to determine antibody-mediated 
inhibition of malaria infection. First, a group of 5 samples was tested at 2% and 10% 
serum dilution, both with and without prior heat inactivation (56ºC, 30min). The best 
results were observed for non-heat inactivated samples, at 10% dilution, therefore, an 
additional group of samples were tested in this condition. Figure 2.18 shows the results 
obtained for these experiments, including the percentage of infection blocked 
measured for pre-vaccination and post-vaccination serum from each subject.  
At 10% serum dilution, post-vaccination sera achieved a statistically significant 
higher prevention of sporozoite entry in hepatocytes (Infection blocked mean: 53%) 
than pre-vaccination sera (Infection blocked mean: 37%) [Figure 2.18.A2]. No 
significant increase of the blocking capacity of antibodies was observed at 2% serum 
dilution [Figure 2.18. A1] or whenever the serum samples were heat inactivated [Figure 
2.18.B1,B2]. 
Macaque humoral responses were expected to show more complexity and 
present higher background responses than genetically identical mice like BALB/c. In 
fact, with 10% serum dilution, pre-vaccination sera avoided about 40% of the 
sporozoite invasion [Figure 2.18.A2].  
In this context, heat inactivation of the serum was considered again as a possible 
solution to obtain values with lower background signal. Nevertheless, it has been 
shown already that heat inactivation [Figure 1.10.A2] was found to prevent the blocking 
effect of a monoclonal antibody. Similarly, the significant increase of blocking effect 
after vaccination found at 10% serum dilution was not detected when the samples had 
been heat inactivated previously.  
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Figure 2.18. Rhesus macaques were vaccinated with ME-TRAP. Each animal 
received 5•107 iu AdCh63 ME-TRAP, 8•107 pfu/animal MVA ME-TRAP (8 weeks 
apart) and serum taken three weeks after MVA vaccination. A1 and A2 show 
%Infection blocked at ISI assay by serum samples at 2% and 10% dilution, 
respectively. The same experiment was performed with heat inactivated 
samples (56ºC, 30min) and results obtained are included in B1 (2%) and B2 
(10%). Data was analysed with Wilcoxon matched-pairs signed rank test (two-
tailed). 
 
%Infection blocked data obtained with ISI assay were plotted against LIPS and 
ELISA data obtained by Dr. Alexandra Spencer. Figure 2.19 (A1 and B1) contains the 
LIPS (A1) and ELISA values (B1) available for both pre- and post-vaccination serum 
samples. A significant correlation was found between LIPS signal and %Infection 
blocked [Figure 2.19.A1] and between ELISA endpoint titre and %Infection blocked 
[Figure 2.19.B1]. The analysis was also performed representing ISI data as Blocking 
increase (% Infection blocked with post-vaccination serum - % Infection blocked with 
pre-vaccination serum) against the fold increase found after vaccination with ELISA 
and LIPS assays [Figure 2.19.A2,B2]. Although the data analysed is the same, 
significant correlations were not found with this last approach. This observation is 
probably due to the reduction of the number of samples to the half (instead of 
considering each sample on its own, each post-vaccination figure is related to its pre-
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vaccination value) and to the accumulation of variability associated with each 
experiment when values from post-vaccination samples are related to values from pre-
vaccination ones. In the next section of this chapter, experiments performed with 
human samples from clinical trials are described. Correlations with ISI results were 
presented with Blocking increase (%) for normalisation purposes, in an attempt to 
remove the non-specific blocking effect from each volunteer. For macaque serum 
samples, both analysis approaches have been included [Figure 2.19] to stress the 
effect of the number of samples included in the correlation and the increase on 
variability that may be associated to a result obtained from two different serum samples 
in the ISI assay. 
 
 
 
Figure 2.19. ISI assay data vs LIPS/ELISA data. Rhesus macaques were 
immunised with ME-TRAP AdCh63 and MVA (8 weeks apart) and serum collected 
three week after MVA. %Infection blocked obtained for each pre- and post-
vaccination sample at 10% serum dilution has been plotted against LIPS values 
(A1) or ELISA values(B1) obtained for each sample. Blocking increase (which is 
obtained as %Infection blocked (post-vaccination serum) minus % Infection 
blocked (pre-vaccination serum) has been represented against fold increase of 
LIPS values (A2) or ELISA values (B2). Data was analysed with nonparametric 
Spearman correlation test (r); linear regression (R2; p-value from F test: is the 
slope significantly different than zero?).  
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2.2.3 Clinical trial samples 
 
2.2.3.1 CS clinical trial 
 
UK adults were immunised with 5•1010 vp ChAd63-CS followed 8 weeks later by 
2•108 pfu MVA-CS and serum samples were taken 2 weeks after the last vaccination. 
On the same date, volunteers were challenged with P. falciparum sporozoites 
administered through mosquito bite. Serum samples were tested using P. berghei 
chimeric sporozoites expressing P. falciparum CSP either as an additional copy (Pf CS 
P. berghei addition), or replacing P. berghei CSP (Pf CS P. berghei replacement). The 
use of both kinds of parasites was due to the results obtained for R21 samples [Figure 
2.15], where serum samples showed a greater capacity to inhibit the sporozoite 
invasion of Pf CS P. berghei replacement than of Pf CS P. berghei addition. 
First, six serum samples were tested with Pf CS P. berghei addition sporozoites 
and using 2% and 10% serum dilutions [Figure 2.20]. Secondly, the ISI assay was 
performed for five samples (some of them were already tested in the first experiment, 
some of them were not) with Pf CS P. berghei replacement sporozoites [Figure 2.21]. A 
higher difference between pre- and post-vaccination blocking response was detected at 
10% serum dilution, rather than at 2% [Figure 2.20. A1, A2]. In an attempt to increase 
the difference observed at 10% serum dilution, in the second experiment serum 
samples were tested at 10% and 20% serum dilution. ISI assay results from both 
experiments have been presented with other graphs were ISI values are plotted 
against ELISA data available for these samples (this data and the serum samples were 
provided by Georgina Bowyer and Dr. Katie Ewer) [Figure 2.20, Figure 2.21]. A 
statistically significant (p<0.05, Wilcoxon test) increase of the blocking capacity of post-
vaccination sera compared to pre-vaccination was not found [Figure 2.20. A1, A2; 
Figure 2.21 A1,A2]. Nevertheless, at 10% serum dilution the p-values obtained were 
low: p=0.09 with addition parasites [Figure 2.20.A2] and p=0.13 with replacement 
parasites [Figure 2.21.A1], indicating that the detected increase of the blocking effect 
after vaccination could be due to a real effect with a probability of at least 87%. When 
using the replacement parasites the mean %Infection blocked for post-vaccination sera 
was 56% [Figure 2.21.A1], while with addition parasites was 26% [Figure 2.20.A2]. Pre-
vaccination blocking effect was also higher with replacement parasites, with a 
%Infection blocked mean of 44% [Figure 2.21.A1], while the mean response with 
addition was 5% [Figure 2.20.A2].  
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Figure 2.20. UK adults were immunised intramuscularly with 5•1010 vp ChAd63-
CS, followed 8 weeks later by 2•108 pfu MVA-CS and serum samples were 
collected 2 weeks after MVA vaccination. In addition, 2 weeks after MVA 
vaccination, volunteers were challenged with P. falciparum sporozoites. Results 
from ISI assay using Pf CS P. berghei addition sporozoites are shown for pre- 
and post-vaccination samples, at 2% serum dilution (A1) and 10% serum dilution 
(A2). Blocking increase (%Infection blocked by post-vaccination serum - 
%Infection blocked by pre-vaccination serum) for each sample at 10% dilution 
was plotted against ELISA units (obtained for post-vaccination samples) (B), 
isotype OD (C), day of diagnosis (D) and parasitaemia at day 7.5 (E). Serum 
samples and values for ELISA, isotype OD, day of diagnosis and parasitaemia 
were provided by Georgina Bowyer and Dr. Katie Ewer. Data was analysed with 
Wilcoxon matched-pairs signed rank test (two-tailed) (A1,A2); nonparametric 
Spearman correlation test (r) (B,C,D,E) and linear regression (R2; p-value from F 
test: is the slope significantly different than zero?) (B,D,E). 
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The higher blocking values observed with chimeric replacement sporozoites could be 
related to a lower amount of CS protein on the surface of the sporozoite, which would 
become more vulnerable in the presence of anti-CS antibodies from the serum sample. 
At 20% serum dilution with replacement parasites, rather than achieving a better 
differentiation of the pre- and post-vaccination blocking effect, the blocking responses 
were more similar, probably due to an elevated non-specific effect in the presence of 
high protein concentration. Replacement parasites did not provide a better system than 
addition parasites to evaluate the anti-CS clinical sera, differently to what occurred in 
the R21 study. Already in previous experiments, addition parasites also allowed the 
detection of high %Infection blocked values for serum samples from mice vaccinated 
with viral vector prime-boost strategies [Figure 2.1.A; Figure 2.3.A]. 
Interestingly, a statistically significant correlation (Spearman test) was found 
between the increase of %Infection blocked (obtained with Pf CS P. berghei addition, at 
10% serum dilution) with ELISA units, day of diagnosis and level of parasitaemia 7.5 
days after challenge [Figure 2.20. B,D,E]. Although significance was not achieved for 
these correlations when the sporozoites employed were Pf CS P. berghei replacement, 
low p-values (Spearman test) reflected the same effect [Figure 2.21. B,D,E]. Blocking 
increase% values were obtained as: (%Infection blocked by post-vaccination sample) - 
(%Infection blocked by pre-vaccination sample), with the objective of normalising 
background responses among volunteers. Presumably, the blocking increase should 
be a measure of the functionality of antibodies to avoid sporozoite invasion gained 
through vaccination (due to the generation of specific antibodies against the antigen 
included in the vaccine). ELISA units included in the correlation were the values 
obtained for each post-vaccination sample. Pre-vaccination ELISA data was not 
obtained for all the clinical data and when it was available, no differences were 
detected among pre-vaccination sera. For these reasons, it was decided to analyse the 
correlation using post-vaccination ELISA values in all clinical trials. A significant 
correlation between Blocking increase (10% dilution) and ELISA Units [Figure 2.20.B], 
indicates the determinant influence of antibody titre in the prevention of the sporozoite 
invasion. A significant correlation between Blocking increase (at 10% serum dilution) 
and the level of a particular antibody isotype (IgA, IgM, IgG1, IgG2 or IgG3) was not 
detected, but a trend was found for IgM (p=0.06) with addition sporozoites, and IgA 
(p=0.08) with replacement [Figure 2.20.C, Figure 2.21.C]. In the replacement 
experiment, it is interesting to observe that the two samples with higher ELISA units 
and higher Blocking increase (10% dilution) were probably achieving these effects 
through the production of either IgM or IgA.   
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Figure 2.21. UK adults were immunised intramuscularly with 5•1010 vp ChAd63-
CS followed 8 weeks later by 2•108 pfu MVA-CS and serum samples were 
collected 2 weeks after MVA vaccination. In addition, 2 weeks after MVA 
vaccination, volunteers were challenged with P. falciparum sporozoites. Results 
from ISI assay using Pf CS P. berghei replacement sporozoites are shown for 
pre- and post-vaccination samples, at 10% serum dilution (A1) and 20% serum 
dilution (A2). Blocking increase (%Infection blocked by post-vaccination serum - 
%Infection blocked by pre-vaccination serum) for each sample at 10% serum 
dilution was plotted against ELISA units (obtained for post-vaccination samples) 
(B), isotype OD (C), day of diagnosis (D) and parasitaemia at day 7.5 (E). Serum 
samples and values for ELISA, isotype OD, day of diagnosis and parasitaemia 
were provided by Georgina Bowyer and Dr. Katie Ewer. Data was analysed with 
Wilcoxon matched-pairs signed rank test (two-tailed) (A1,A2); nonparametric 
Spearman correlation test (r) (B,C,D,E); linear regression (R2; p-value from F 
test: is the slope significantly different than zero?) (B,D,E). 
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Since the individuals were challenged with P. falciparum, data about the day of 
diagnosis and the levels of parasites on blood at day 7.5 was available. Higher levels of 
Blocking increase at 10% serum dilution were associated with a delay of the clinical 
day of diagnosis [Figure 2.20.D]. A greater functional capacity of serum to block the 
sporozoite invasion would play an essential role delaying the establishment of the 
malaria infection and consequently: the greater the capacity of the sera to prevent 
sporozoite invasion was, the smaller the quantity of parasites/mL detected in blood at 
day 7.5 [Figure 2.20.E]. The correlations between ISI and day of diagnosis and 
parasitaemia were statistically significant in the experiment performed with addition 
sporozoites. 
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2.2.3.2 TRAP clinical trial 
	  
Serum samples from volunteers vaccinated with ME-TRAP were tested in the ISI 
assay and results were contrasted with other data obtained previously. These serum 
samples and data were provided by Georgina Bowyer and Dr. Katie Ewer. UK adults 
were vaccinated with 5•1010 vp ChAd63-ME-TRAP and 2•108 pfu MVA-ME-TRAP, 8 
weeks apart, and serum samples were collected 2-3 weeks after MVA. Volunteers 
were challenged with P. falciparum 2-3 weeks after MVA vaccination. Two experiments 
were performed, each one with samples from a different clinical trial: one had been 
conducted on July 2012 [Figure 2.22] and the other took place on June 2009 [Figure 
2.23].  
ISI assay was performed, as previously described, at 10% serum dilution (20%, 
also in the first experiment) and Pf TRAP P. berghei addition parasite (no replacement 
parasite was available for Pf TRAP). Contrary to what was expected, post-vaccination 
serum samples presented an inferior capacity to avoid sporozoite invasion than pre-
vaccination serum samples. This decrease after vaccination was statistically significant 
in the second experiment [Figure 2.23.A], where pre-vaccination samples showed a 
mean blocking response of 25% and post-vaccination samples, only 12%; and a trend 
to lower post-vaccination %Infection blocked values was observed in the first 
experiment at 10% (p=0.08) and 20%(p=0.08) serum dilution [Figure 2.22. A1, A2]. 
Using 20% serum dilution in the first experiment did not help to measure a higher 
difference between pre-vaccination and post-vaccination values compared to 10% 
serum dilution and increased the background responses: pre-vaccination %Infection 
blocked mean at 20% dilution was 62% [Figure 2.22. A2], while with 10% dilution was 
46% [Figure 2.22. A1]. 
In previous experiments (with macaque serum samples) heat inactivation (30min, 
56ºC) did not help to get rid of background responses and decreased the differences 
between blocking values measured. To confirm that it was not advisable to heat 
inactivate samples prior to ISI assay, a small group of samples was tested in the ISI at 
20% dilution after being heat inactivated. Once again, the difference in blocking 
responses between groups at the same serum dilution [Figure 2.22. A2] disappeared 
upon heat inactivation treatment [Figure 2.22.A3]. 
Significant correlations were not found between Blocking increase% at 10% 
serum dilution and ELISA units, Isotype OD, IgG avidity, Day of diagnosis or 
Parasitaemia at day 7.5. The strongest correlation was found in the first experiment 
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between Blocking increase% and IgG2 OD (p=0.07) and IgM OD (p=0.12) [Figure 
2.22.C]. 
In the first experiment, the largest blocking decrease value was obtained for the 
sample with the highest value of ELISA units [Figure 2.22.B]. Similarly, in the second 
experiment, the samples which lost more blocking capacity after vaccination had better 
than average ELISA units [Figure 2.23.B]. The described trends between Blocking 
increase% and IgM or IgG2 [Figure 2.22.C] also suggest that higher levels of the 
isotype decreased the blocking capacity. These results contradict what was found for 
macaque samples, where vaccination with ME-TRAP increased the blocking capacity 
of the serum [Figure 2.18.A2]. One possible explanation for the surprising effect 
observed in humans vaccinated with ME-TRAP, could be that higher levels of 
antibodies (generated after vaccination) may promote sporozoite invasion of 
hepatocytes, possibly by increasing pathogen-host contacts. The ISI assay is 
performed with a human liver cell line, and human antibodies bound to TRAP on the 
parasite surface could be recognised by Fc receptors on the surface of the hepatocyte. 
If the antibody did not prevent sporozoite invasion through its binding to TRAP, it could 
have just helped the anchoring of the parasite to the hepatocyte surface. Also, the P. 
berghei parasite used here is expressing P. falciparum TRAP as an additional protein, 
so P. berghei TRAP is also present on the surface. This could have as a consequence 
that, even if the antibody could achieve a good ‘blocking’ through binding to P. 
falciparum TRAP, the parasite may still conserve the functionality of P. berghei TRAP 
in the presence of specific antibodies against falciparum TRAP.  
Finally, samples from ME-TRAP clinical trial (July 2012) used in the first 
experiment were the only samples with available IgG avidity data. Like antibody 
concentration has been regarded as an important factor contributing to the level of 
infection blocked, the avidity of antibodies may be playing also an important effect on 
the interaction between a specific antibody and its target antigen. Here, no correlation  
or trend was found between Blocking increase% and IgG avidity [Figure 2.22 D]. 
Nevertheless, this result can not be generalised, specially as serum samples had an 
effect on sporozoite invasion opposite to what had been found in previous experiments.  
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Figure 2.22. UK adults received intramuscularly 5•1010 vp ChAd63-ME-TRAP and 
2•108 pfu MVA-ME-TRAP, 8 weeks apart. Serum samples were taken 2 weeks after 
the last vaccination, the following day volunteers were challenged with P. 
falciparum. ISI assay was performed using Pf TRAP P. berghei with 8 samples at 
serum dilution of 10% (A1), 20%(A2), and four samples were tested also at 20% 
serum dilution after being heat inactivated (30min, 56ºC) (A3). Blocking increase 
(%Infection blocked by post-vaccination serum - %Infection blocked by pre-
vaccination serum) for each sample (at 10% dilution) was plotted against ELISA 
units (obtained for post-vaccination samples) (B), isotype OD (C), IgG avidity (D), 
day of diagnosis (E) and parasitaemia at day 7.5 (F). Serum samples and values 
for ELISA, isotype OD, IgG avidity, day of diagnosis and parasitaemia were 
provided by Georgina Bowyer and Dr. Katie Ewer. Data was analysed with 
Wilcoxon matched-pairs signed rank test (two-tailed) (A1,A2,A3); nonparametric 
Spearman correlation test (r) (B,C,D,E,F); linear regression (R2; p-value from F 
test: is the slope significantly different than zero?) (B,D,E,F). Green colour in A1, 
A2, A3, B, D and F indicates that the samples belong to volunteers who were 
protected upon challenge.  
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Figure 2.23. UK adults received intramuscularly 5•1010 vp ChAd63-ME-TRAP and 
2•108 pfu MVA-ME-TRAP, 8 weeks apart. Serum samples were taken 2 or 3 weeks 
after the last vaccination, volunteers were challenged with P. falciparum the 
following day. ISI assay was performed using Pf TRAP P. berghei with 10 
samples at 10% serum dilution (A). Blocking increase (%Infection blocked by 
post-vaccination serum - %Infection blocked by pre-vaccination serum) for each 
sample (at 10% dilution) was plotted against ELISA units (obtained for post-
vaccination samples) (B), isotype OD (C), day of diagnosis (D) and parasitaemia 
at day 7.5 (E). Serum samples and values for ELISA, isotype OD, IgG avidity, day 
of diagnosis and parasitaemia were provided by Georgina Bowyer and Dr. Katie 
Ewer. Data was analysed with Wilcoxon matched-pairs signed rank test (two-
tailed) (A); nonparametric Spearman correlation test (r) (B,C,D,E); linear 
regression (R2; p-value from F test: is the slope significantly different than zero?) 
(B,D,E). Green colour in A, B and E indicates that the samples belong to 
volunteers who were protected upon challenge. 
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2.3 Discussion 
 
 
Once the flow cytometry based ISI assay was optimised (process described in 
chapter 1), the developed protocol was used to test a number of serum samples from 
mouse, macaque and human clinical trials. In studies with mouse samples, the assay 
proved to be useful comparing the functional capacity of antibodies generated against 
different antigens and with different vaccination strategies, such as the adjuvant or 
vaccination dose. A positive increase of antibody functionality after vaccination was 
shown for some macaque and volunteer samples, and interesting correlations were 
found for ISI assay data and other antibody assays and clinical data. In all cases, 
samples tested were sera obtained after vaccination against a pre-erythrocytic P. 
falciparum antigen, and the sera was tested for its capacity to avoid the invasion of 
Huh7 cells by a P. berghei sporozoite expressing the same P. falciparum antigen 
targeted through vaccination. 
There are limitations with the ISI assay, the most important is the difficulty to 
obtain live sporozoites, since mosquito yields can be variable and the number of 
sporozoite needed for the assay may require several hours of salivary gland dissection. 
The assay is also affected by significant levels of inhibition observed with non-specific 
sera, as it has been reported in the literature (198,211,226) and could be observed in 
the experiments described. For this reason, a threshold level of 30% was set above 
which blocking was considered positive. In addition, the high variability in the assay can 
result in differences between samples within 10-15% blocking not considered relevant. 
Some sources of this variability could be error in the amount of cells, sporozoite and 
serum plated in each well or variations on the viability of the sporozoites. Variability 
could be compensated by including a higher number of replicates and a greater 
number of samples per group, but it would require also a higher number of sporozoites. 
Despite these limitations, the flow cytometry based protocol optimised in this work 
proved to be a reliable and efficient approach to test antibody capacity to avoid 
sporozoite invasion. It is particularly important to highlight the high throughput capacity 
achieved with this method, which enabled to test a large number of samples. The flow 
cytometry readout makes it possible to routinely use the ISI assay with clinical and pre-
clinical studies and overcomes the subjectivity of the traditional microscopy readout.  
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CSP and TRAP 
The first experiments with mouse samples tested the capacity of CS and TRAP 
post-vaccination serum to inhibit sporozoite invasion. A range of positive blocking 
responses were observed for CS and TRAP, which are consistent with previous 
studies, helped to validate the assay and confirmed that 2% and 10% serum dilutions 
were appropriated concentrations to test samples. Some serum samples were tested at 
20% serum dilution but resulted in a high non-specific effect and when using 2% serum 
dilution, sometimes no positive blocking responses were detected. For other serum 
samples (anti-CS serum from mice vaccinated with R21) positive blocking was 
detected even at 0.2% serum dilution. Following these results in mice, serum samples 
from humans vaccinated against CS were tested, obtaining a trend towards an 
increase in blocking responses after vaccination. With regard to TRAP, a statistically 
significant increase on the blocking response after vaccination was detected at 10% 
serum dilution with serum samples from macaques but, surprisingly, the human anti-
TRAP serum samples behaved differently: a trend towards a decrease in the blocking 
response was observed after vaccination which was statistically significant in one of 
the clinical studies. There is not a clear explanation for an increase of sporozoite 
invasion in the presence of post-vaccination serum. It could be suggested that human 
anti-TRAP antibodies may be facilitating host-cell contact through the interaction 
between their Fc region and the Fc receptors on the human hepatocyte surface. 
Antibodies against CSP have been largely described to have the capacity to 
inhibit sporozoite invasion. Serum and monoclonal antibodies, both from mouse and 
human origin, targeting CSP have been shown to block sporozoite invasion in vitro and 
in vivo. Mouse monoclonal antibodies against P. berghei CSP injected into mice 
protected them from challenge with P. berghei (192,269) and also blocked the 
sporozoite entry into WI38 cells and HepG2 cells (191,199,270). Sera from mice or 
rabbits immunised with peptides or recombinant protein containing a P. falciparum CSP 
epitope (tandem repeats) inhibited P. falciparum entry in HepG2 cells (271,272) and in 
primary human hepatocytes (200). The same effect was observed with P. berghei 
sporozoites expressing P. falciparum CSP treated with mouse post-vaccination sera 
(against CSP repeats) and added to HepG2 cells (273). Monoclonal antibodies from a 
volunteer vaccinated with RTS,S protected mice with humanised liver against P. 
falciparum challenge and avoided sporozoite entry in HepG2 and Huh7 cells (264). 
Post-vaccination sera from some volunteers vaccinated with recombinant protein 
R32tet (containing a repeating region from CSP) blocked P. falciparum entry in HepG2 
cells (274,275). With regard to TRAP, post-vaccination sera from mice immunised with 
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recombinant proteins of P. falciparum TRAP fragments inhibited P. falciparum 
sporozoites invasion in cultures of primary human hepatocytes (225) and in HepG2 
cells (276). Charoenvit et al. found that sera from mice immunised with peptides from 
TRAP partially inhibited P. falciparum invasion of HepG2 cells (277). In other study, 
immunisation or passive transfer of monoclonal or polyclonal antibodies against certain 
TRAP epitopes did not protected mice from P. yoelii infection (278). 
CSP and TRAP are the antigens which have been more extensively studied as 
pre-erythrocytic malaria antigens. Therefore, is not surprising that previous studies on 
the capacity of antibodies to prevent hepatocyte invasion focus mainly on CSP and 
TRAP. It is extremely complicated to compare inhibition results obtained by different 
studies. Apart from the variability that could be associated to the researcher performing 
the experiment, the assay used in different laboratories present many variations: cell 
type, strain of sporozoites, times of incubation, use of purified antibodies or whole sera 
or method of readout. In addition, serum against a particular antigen is obtained in 
each study following different vaccination strategies (delivery method, epitopes 
targeted, adjuvants, dose…), which is likely to affect the concentration of specific 
antibodies in sera and their functionality. Therefore, it has not been attempted to make 
any quantitative comparison between results described here and those reported in 
other studies. 
 
Mouse samples: screening studies 
In this work, serum samples from mice vaccinated against a number of candidate 
pre-erythrocytic antigens were tested following the same ISI protocol, which provided 
some suggestions of which antigens may had a greater capacity of generating 
antibodies with better functionality to inhibit sporozoite invasion. Two sets of mouse 
samples obtained in two screening studies were assessed, one included eight 
antigens: CeLTOS, LSA1, LSA3, LSAP1, LSAP2, ETRAMP5 and Falstatin; and the 
other, four candidates: SPECT1, SPECT2, RP-L3 and HT. In the first group of 
antigens, CelTOS elicited the highest blocking response, inhibiting almost 70% of 
sporozoite invasion. anti-LSAP1 serum blocked about 50% of the infection, but the rest 
of the samples did not show inhibition over the threshold of 30%. Consistent with these 
results, sera from mice immunised with recombinant CelTOS has previously been 
described to block P. falciparum sporozoite entry in HepG2 cells (187). In contrast to 
these current results, Siau et al. found that anti-LSAP1 mice serum did not block P. 
falciparum invasion of primary hepatocytes (232), but this effect was described using a 
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lower serum dilution (1% and 5%) and in any case, the inhibition observed here for this 
antigen was not strong. It has also been described that mouse sera against Pb ICP (P. 
berghei Falstatin homolog, which share 40% amino acid sequence identity) blocked 
about 40% of P. berghei invasion of HepG2 cells at 20% dilution (247). 
In the second screening study, almost 100% blocking was obtained for all the 
serum samples at 10% serum dilution, potentially because these samples have only 
been thawed once and were stored for less than one month at -20oC before performing 
the ISI assay. In contrast the samples used in the first screening study had been frozen 
and thawed a number of times and stored for about two years at -20oC (which could 
have affected protein degradation or favoured the lost of functional antibody 
conformation). Therefore, the best concentration to use in the assay may be dependent 
on the particular characteristics and quality of the serum samples, in fact, for the 
samples from the first screening positive blocking responses where only observed at 
10% serum dilution, while for the second study at the same concentration the blocking 
responses were close to saturation and it was not possible to compare between 
antigens. The most significant finding of this experiment, was the high blocking 
response obtained by anti-SPECT1 serum at 2% serum dilution (87% mean infection 
blocked), which was equivalent to the blocking response observed for anti-CS serum 
(82% mean infection blocked). CS is the target of the most advanced malaria vaccine 
in clinical trials: RTS,S, which induces an antibody response associated with protection 
(140,264,279). Pre-erythrocytic antigens, such as SPECT1, that could elicit strong 
humoral responses could be included with CS in a vaccine to achieve higher levels of 
sterile efficacy. 
Using chimeric sporozoites in the ISI assay enabled the testing of P. falciparum 
antigens in a P. berghei model, regardless whether the protein was or was not 
originally present in P. berghei sporozoites (all the antigens tested in this work have a 
P. berghei homolog except: LSA1, LSA3, LSAP1, LSAP2 and ETRAMP5). To evaluate 
the role of the P. berghei protein on the observed inhibition, serum samples were 
tested with P. berghei sporozoites that did not express any P. falciparum antigen. In 
this system, anti-CelTOS serum samples also elicited high blocking responses, which 
is not surprising since there is a high degree of homology between P. falciparum 
CelTOS and P. berghei CelTOS (187). However, it was not expected to find a high 
blocking response to LSAP1 that does not have a P. berghei homolog (232). It is 
possible that the serum contained factors that caused a non-specific inhibition 
response or the anti-LSAP1 antibodies cross-reacted with other P. berghei protein. In 
the second screening study, where all the four antigens tested had P. berghei 
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homologs, a higher blocking capacity was detected with chimeric sporozoites 
expressing P. falciparum antigens than with WT P. berghei, likely due to a better 
interaction between the specific antibodies and the actual proteins they are targeting.  
IFAT staining was performed to gain a better understanding of the ability of 
antibodies to bind to sporozoites. Surprisingly, the best IFAT signals were not obtained 
with the candidates that presented the best blocking effect within each group: CelTOS 
and SPECT1. UIS3 showed one of the best IFAT staining in the first study, together 
with high signals from LSA1, LSAP1 and Falstatin. In a similar way, SPECT2 showed 
better staining than SPECT1. Therefore, the lack or low concentration of antibodies is 
not the only cause of absent or low blocking responses found for some antigens. These 
discrepancies between IFAT and ISI, may be due to protein accessibility and/or protein 
function. P. falciparum proteins not exposed on the surface of live sporozoites may not 
be accessible to specific antibodies in ISI assay, while in IFAT staining, these internal 
proteins become accessible since the sporozoites are fixed to the slide. Serum 
samples from mice vaccinated against antigens whose function has been mainly 
related with parasite development within the hepatocyte such as LSA1, LSAP1, LSAP2, 
UIS3, RP-L3 and HT showed reduced or absent blocking response. Apart from 
antibody accessibility to antigen, a low blocking response could be due to a non-
sufficient antibody level or to a weak interaction, but also, to a lack of function of the 
target protein in the process of hepatocyte invasion.  It could be hypothesised that 
antibodies that bind proteins which play a role on hepatocyte invasion may be more 
likely to have an effect on the blocking of sporozoite entry in liver cells. Nevertheless, it 
is important to bear in mind that the ISI has been performed using chimeric P. berghei 
sporozoites expressing P. falciparum antigens and no definitive statements regarding 
functionality of proteins can be made, using P. falciparum sporozoites would be a more 
appropriate model.  
It is interesting to point out that outstanding blocking responses compared with 
other antigens were observed for serum samples obtained from mice vaccinated 
against TRAP, CS, CelTOS and SPECT1. As it has been mentioned in the introduction 
to this chapter, these antigens can be found on the sporozoite surface and micronemes 
(secretory organelles that contain proteins released upon host cell contact to the 
sporozoite surface). Microneme proteins, move on the sporozoite surface from the 
apical end of the parasite to the posterior end supporting sporozoite motility, therefore, 
these proteins would be exposed to specific antibodies present in the serum samples 
tested. TRAP, CS, CelTOS and SPECT1 have been associated with functions such as 
sporozoite motility, cell traversal, hepatocyte attachment and invasion, which could 
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presumably be interfered by bound antibodies, impairing the process of sporozoite 
entry into the hepatocyte. For example, CelTOS and SPECT1 are involved in breaking 
through host barriers, but they do not seem to play a role on hepatocyte invasion since 
P. berghei parasites which had these proteins disrupted infected HepG2 cells 
(236,248). However, even though the protein targeted by specific antibodies do not 
play a role at the moment of invasion, the binding of specific antibodies could 
immobilise the sporozoite, preventing further steps even in an in vitro assay where the 
sporozoites are added directly on the hepatocytes. In fact Bergmann-Leitner et al. 
showed that CelTOS antibodies interfered with sporozoite motility (187), Stewart et al. 
reported that anti-CSP antibodies immobilised sporozoites (270) and Okitsu et al. 
described a positive correlation between migration inhibition and invasion inhibition 
(280). 
 
Mouse samples: R21 vaccine 
Following the screening studies experiments with the ISI assay, a set of 
experiments were performed with serum samples from mice that had been vaccinated 
with R21, a virus like particle vaccine which targets P. falciparum CSP. Two 
experiments were conducted: one to know whether the adjuvant employed in R21 
vaccine delivery had an effect on antibody functionality to prevent infection of 
hepatocytes and the other, to compare the functionality between antibodies elicited by 
R21 vaccine and RTS,S vaccine. In the adjuvants experiment, serum samples from 
mice vaccinated with R21 administered with Alhydrogel showed a lower blocking 
response than other adjuvants at 0.2% serum dilution, this difference was statistically 
significant between Alhydrogel and Abisco. Vaccination with R21 in two other 
adjuvants, AddaVax and Abisco, demonstrated similar ELISA antibody titres, but 
Abisco vaccinated mice were sterilely protected while AddaVax only elicited a delay to 
parasitaemia [Katharine Collins, DPhil Thesis]. ISI assay did not detect differences in 
antibody responses after vaccination with AddaVax or Abisco, which is consistent with 
the ELISA results. Abisco vaccinated mice showed higher T cell response by ELISPOT 
than AddaVax mice, and as the humoral responses were similar in terms of titre and 
functionality evaluated with ISI assay, it seems that the protection achieved by 
R21+Abisco may be enhanced with a cellular immune response. This example shows 
how ISI assay can help to gain a better understanding of the immune mechanisms 
working on a pre-erythrocytic malaria vaccine.  
In the second experiment, there was no significant difference between the 
capacity to inhibit sporozoite invasion by the serum samples from mice vaccinated with 
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RTS,S  and those vaccinated with R21, showing that R21 elicited an antibody response 
with an invasion blocking capacity as good as RTS,S, measured by ISI. It would be 
interesting to measure with ISI serum samples from later time points, to determine 
whether either vaccine is capable of maintaining antibody functionality and preventing 
hepatocyte invasion. 
Interestingly, high levels of inhibition were only achieved with these R21 samples 
when the chimeric P. berghei sporozoites used in the assay expressed only P. 
falciparum CSP (replacement parasite), not as an additional copy to P. berghei CSP 
(addition parasite). This observation was surprising since serum samples obtained 
from mice vaccinated with viral vectors targeting Pf CSP showed a high blocking effect 
with chimeric addition CS parasites, and clinical trial samples did not show a better 
blocking when using replacement CS parasites. It seemed that the use of replacement 
sporozoites with ISI could provide an advantage only for certain anti-CSP serum 
samples. According to ELISA, R21 serum samples had a high CS antibody titer, and, in 
fact, positive blocking responses were observed even at 0.2% serum dilution. The 
cause of the differential behaviour observed with replacement and addition chimeric 
parasites is not clear, but could be related to the high specific antibody concentration in 
R21 samples or the avidity of these antibodies. A very strong antibody binding to 
PfCSP could cause shedding of the protein (known to occur naturally on sporozoite 
invasion), while the chimeric addition sporozoite would still conserve CSP functionality 
from the P. berghei protein.  
 
Addition and replacement sporozoites 
CSP was the only antigen with a chimeric replacement parasite available, so for 
all the other antigens tested, chimeric addition parasites were always employed. The 
presence of the P. berghei protein could reduce the blocking effect, if antibodies could 
bind the P. falciparum antigen but leaving free the P. berghei homolog to perform its 
normal function. The decrease of the blocking effect observed with human post-
vaccination anti-TRAP serum samples could be related to the use of the chimeric 
TRAP addition parasite. It would be interesting to evaluate these samples again with 
ISI assay using a TRAP replacement chimeric sporozoite, when it becomes available. 
Replacement sporozoites would constitute a cleaner model to study antibody 
function of sporozoite invasion, since antibodies are targeting a single sporozoite 
protein. When both the P. falciparum and P. berghei versions of the protein are 
available, the specific antibodies may be targeting both proteins or only one of then, 
and the amount of expression of the protein of interest may be overrepresented. 
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ISI compared with other antibody assays 
To evaluate the effect of antigen specific antibody concentration on the inhibition 
of sporozoite invasion, the values obtained with the ISI assay were compared with 
ELISA or LIPS data, both of which provide a measure antibody concentration. ELISA is 
an assay commonly used to obtain the titre of antigen specific antibodies present in a 
serum sample and LIPS, which also evaluates antibody concentration, was used when 
purified protein was not available. For some of the experiments, particularly those with 
large numbers of samples, a statistically significant correlation was found between ISI 
and ELISA or LIPS values, such as the study of anti-CS serum from R21 vaccinated 
mice, anti-TRAP macaque pre- and post-vaccination serum samples or one of the 
experiments testing CS clinical samples. Although not significant, a trend towards a 
larger blocking effect was observed with serum samples with higher ELISA values. 
Previous studies have usually sought a correlation between ISI and ELISA, rather 
than ISI and LIPS, which is an assay that has been introduced later and it has been 
less used. While no definitive answer can be given about ELISA correlation with ISI 
assay from this current study, this is consistent with previously published data where 
both significant correlation (280–282) and the absence of correlation (206,274) have 
been described. 
Taking all the data together in this study, ISI assay has been shown to be 
concentration dependent, with higher blocking of sporozoite invasion observed when 
using a higher concentration of monoclonal antibody or a higher percentage of serum 
dilution. Therefore, it is not surprising to find a correlation for ISI and ELISA values. 
Nevertheless, several factors could cause discrepancies between an assay focused on 
evaluating antibody concentration, measuring antigen-antibody interaction, and an 
assay like ISI. For example, there could be differences in the conformation of the 
antigen expressed in the sporozoite compared to purified antigen used in ELISA, or 
antigen obtained from transfected cell lysates used in LIPS. In the ISI assay, antigens 
targeted by specific antibodies may not be exposed on the sporozoites or may not play 
a role on sporozoite invasion, and therefore, even if antigen specific antibodies are 
present in the serum sample, they will not be detected. It is likely that correlation of ISI 
with ELISA or LIPS will be dependent on the characteristics of the antigen (expression, 
localisation and function) targeted by the antibody evaluated, the vaccination strategy 
which may enhance a certain kind of immune response, the range of serum dilution 
employed in the ISI assay and other factors dependent on the specific antibody like its 
fine specificity and isotype.  
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With regard to the antibody isotype, the relationship between the blocking 
response and the isotype was studied for CS and TRAP clinical trials samples. No 
statistically significant correlation was found for any isotype, probably due in part to the 
low number of samples (5-10 per experiment). In the literature, positive correlations 
have been described between sporozoite inhibition capacity and IgG levels (100,199), 
and both IgG and IgA (283). 
It could be considered that ISI assay may offer a better model to evaluate 
humoral responses than ELISA or LIPS, due to its higher degree of similarity with an in 
vivo system. On the other side, ISI assay is focused only on one step of the malaria 
cycle, and measures antibody functionality to block this specific stage, but not the 
effect that antibodies could have on a different site of the cycle. 
 
ISI correlation with protection 
In the first screening study on mice whose samples were analysed with ISI, the 
highest protection for BALB/c mice had been observed when mice were vaccinated 
against LSA1 or LSAP2 (in both cases of 87.5% mice were protected) and was shown 
to be mediated primarily through CD8+ T cells (190). CelTOS vaccination did not induce 
sterile protection or even a delay in parasitaemia, even though it was the antigen that 
generated a higher blocking response in the ISI assay. Antibodies against CelTOS may 
had not reached a minimum level to generate in vivo protection with this vaccination 
regimen.  
In the second screening study, vaccination with SPECT1 vaccines conferred both 
sterile protection (37.5% BALB/c and 70% CD1) and a significant delay to 1% 
parasitaemia, no protection or delay was described for HT, nor RP-L3, and 
unfortunately, protection data for SPECT2 was not available  [Ahmed Salman, DPhil 
Thesis]. The protection achieved by SPECT1 was even higher than conferred by CSP 
vaccination (31.25 BALB/c and 33.3% CD1), and both candidates showed high 
blocking responses in the ISI assay. 
Serum samples from mice vaccinated with either R21 or RTS,S (both vaccines 
targeting CSP),  were tested in the ISI assay where some protected mice showed lower 
inhibition levels than unprotected animals. The percentage of infection blocked 
significantly correlated with a delay in developing parasitaemia at 2% serum dilution, 
but not at 0.2% where the differences between samples were better distinguished (at 
2% serum dilution the assay was probably working on the saturation limit). 
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The most interesting finding regarding the relation between ISI assay and 
protection was a statistically significant correlation between the increase of the blocking 
response in UK adults vaccinated against CS with the day of diagnosis and with the 
parasitaemia at day 7.5 [Figure 2.20]. Samples from the same study were evaluated 
using addition and replacement Pf CSP chimeric parasites and statistically significance 
was only observed with addition sporozoites, although the same trend was also 
detected with replacement parasites, probably due to the low number of samples. 
Although the immune response elicited after vaccination was not sufficient to confer 
protection, it seemed that a higher level of functional antibodies reduced the liver 
burden and resulted in a pre-patent blood-stage period and later day of diagnosis. 
However, no correlation was found with serum samples from TRAP clinical trials with 
protection, day of diagnosis or parasitaemia. 
Previous studies that have tested human or animal serum samples with a 
functional antibody assays have in some cases supported a correlation with protection 
(100,187,198,275,284,285), but in others no correlation in terms of resistance to 
malaria or delay has been found (226,268,274,286,287). The small number of samples 
studied has limited the statistical significance of the results found. However, the cellular 
immune response not evaluated in the ISI assay and may be playing a key role in 
protection. In addition, the humoral response may carry out its functions in a way that is 
not evaluated by this kind of assays, such as opsonising activity (110) or it may even 
take place before reaching the liver, for example retaining the sporozoites in the skin 
(288). On other hand, targeting a particular antigen, or the particularities of vaccine 
delivery such as dose or adjuvant, can also have an effect on the immune response 
generated, making it difficult to compare between different studies.  
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SUMMARY AND CONCLUSIONS 
 
Chapter 1 described the process to optimise a protocol for a flow cytometry 
based Inhibition of Sporozoite Invasion assay. The main criteria observed was 
maximising the infectivity rates, in order to increase the number of positive events 
acquired. The “percentage of infection blocked” was calculated using the percentage of 
infected cells, which if it was based in a higher number of events, would increase the 
reliability and reproducibility of the data. When comparing several cell lines and culture 
media, HuH7 cell line cultured in RPMI were selected since higher infectivity rates were 
observed with this combination.  
Other parameters were evaluated, such as pre-incubation of sporozoites with 
antibodies which appeared to be unnecessary; and the temperature of the first hour of 
incubation (room temperature or 37º) where no differences were observed and it was 
decided to place the plate containing the co-culture in the incubator after infection and 
centrifugation.  With the objective of testing as many samples as possible with the 
number of sporozoite available, several cell:sporozoite ratios were tested, finally 
deciding to plate 30000 cells and 15000 sporozoites per well in 96-well plates. These 
numbers did not have a detrimental effect on sensitivity, generated an acceptable 
number of positive events and allowed the use of replicates (duplicates or triplicates).  
A time course was performed to determine the best time of sample acquisition on 
the flow cytometer. Hepatocytes infected with transgenic parasites expressing GFP 
were detectable by flow cytometry much earlier (4 hours and less after infection) than 
those whose reporter was GFP fused to luciferase which were better detected between 
24 and 28 hours post-infection. It is essential to perform a time course every time a 
different reporter protein is being used in a transgenic parasite, because infected cells 
may not been detected at a certain time point due to low levels of reporter protein 
expression. 
Since non-specific sera inhibition contributed to a significant background effect, it 
was set a threshold level of 30% above which blocking was considered positive. This 
value was chosen after observing the behaviour of naive serum samples at 2% and 
10% serum concentration. For human and macaque samples, due to the important 
effect of background immune responses in each subject, pre and post-vaccination sera 
was tested for each individual. In addition, due to the high variability in the assay 
(caused by error in the amount of cells, sporozoites and serum plated and by variations 
in sporozoite viability and infectivity), differences between blocking values within 10-
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15% were not considered relevant. With regard to normalisation of variations due to 
changes in infectivity rates in each particular experiment, the percentage of infected 
cells achieved in wells without serum (calculated as the average of three or more 
replicates) was used to calculate the “percentage of infection blocked”, which was 
considerably consistent between experiments. 
In Chapter 2, the optimised protocol proved to be useful to test mouse, macaque 
and human serum samples using P. berghei transgenic parasites expressing P. 
falciparum antigens. It is specially relevant the high throughput capacity of the assay: 
performing the assay for all the samples in a vaccination group would take usually one 
day (depending on the size of the group of samples, usually 6-8) and the time to 
acquire samples on the flow cytometer the following day.  
The transgenic parasites expressing P. falciparum antigens and a reporter 
protein (GFP fused to luciferase) were first developed in order to establish a challenge 
system to test protection elicited after vaccination with viral vector vaccines including 
the P. falciparum antigens. Without the need of purified protein to perform ELISA, this 
same transgenic parasites already available in the laboratory, provide also a tool to 
evaluate humoral responses.  
In studies with mouse samples, the assay proved to be useful comparing the 
functional capacity of antibodies generated against different antigens and with different 
vaccination strategies, such as the adjuvant or vaccination dose. A positive increase of 
antibody functionality after vaccination was shown for some macaque and volunteer 
samples, and interesting correlations were found for ISI assay data and other antibody 
assays and clinical data.  
With regard to the results obtained with mouse samples, high blocking responses 
were detected for the antigens: CeLTOS, CSP, TRAP, SP1, SP2, RP-L3 and HT. The 
inhibition of sporozoite invasion was particularly higher in CSP and SP1, with more 
than 80% of sporozoite infection blocked only at 2% serum concentration. The finding 
that SP1 could generate antibody blocking responses similar to CSP, which is the 
antigen included in RTS,S, together with the protection elicited upon challenge, 
supports the further progress of a vaccine including SP1. 
In other study, higher blocking responses were elicited when R21 (virus like 
particle vaccine which targets P. falciparum CSP) was administered with the adjuvant 
Abisco compared to Alhydrogel (a result consistent with previous ELISA data). R21 
vaccine induced an antibody response with an invasion blocking capacity as good as 
RTS,S. An important concern raised when evaluating R21 serum samples, was that 
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high blocking responses were only achieved when the transgenic P. berghei 
sporozoites used in the assay expressed P. falciparum CSP instead of P. berghei CSP 
(replacement parasites), and not with those expressing P. falciparum CSP as an 
additional copy (addition parasites). Although the cause of these differences is not 
clear, it is relevant to point that the design of transgenic parasites can have important 
consequences when evaluating antibody functionality with ISI assay. 
Significant correlation was found between ISI and ELISA values with: R21 
samples, serum samples from macaques vaccinated against TRAP and with human 
anti-CSP serum samples (blocking responses were significantly increased after 
vaccination in all these studies). Although this association was not always found, and 
no definitive statement can be made, it is not surprising that correlations can be 
established with data obtained by ELISA since ISI assay is also concentration 
dependent.  
ISI assay data for UK adults vaccinated against CSP significantly correlated with 
the day of diagnosis and parasitaemia at day 7.5. In the same way, SP1 vaccinated 
mice, which were sterile protected or presented a delay to 1% parasitaemia, showed 
high blocking capacity measured by ISI. However, for instance, in RTS,S and R21 
study some protected mice showed lower inhibition levels than unprotected animals. 
Similarly, from the potential candidates evaluated in mice studies, the highest 
protection in BALB/c mice was shown for LSA1 or LSAP2, which did not present 
outstanding blocking data. Discrepancies between ISI assay and other immunological 
and clinical data can be related to the presence of various immune mechanisms 
involved in protection, for example, LSA1 and LSAP2 vaccines primarily induced 
protection through CD8+ T cells. In fact, ISI assay would only be an important indicator 
of in vitro protection in vaccines which elicit high antibody responses that prevent 
sporozoite invasion. Nevertheless, other vaccines, even those mainly targeting cellular 
responses, also induce humoral responses whose role in host immunity to malaria is 
important to characterise. 
 
Future directions: 
 
The most important limitation for the ISI assay is to obtain live sporozoites, since 
if mosquito yields (which vary between mosquito batches) are low, to collect the 
required amount of sporozoites can be time-consuming or not enough sporozoites may 
be available to perform the assay. For this reason, any technical improvement 
facilitating mosquito salivary gland dissection (which needs specialised training and 
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practice) and research towards achieving higher sporozoite yields in mosquito salivary 
glands would greatly benefit the assay. Testing a larger number of samples would 
provide more relevant statistic information on potential correlations between ISI assay 
and other antibody assays and clinical data. In addition, establishing a standardised 
protocol for the assay, would allow data comparison between studies and research 
centres. 
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